Gene Detail

Gene Symbol ERBB2
Synonyms CD340 | HER-2 | HER-2/neu | HER2 | MLN 19 | NEU | NGL | TKR1
Gene Description ERBB2 (HER2), erb-b2 receptor tyrosine kinase 2, is an EGFR receptor tyrosine kinase that activates PI3K-AKT-mTOR and RAS-RAF-MEK-ERK pathways, therefore regulating growth and transformation (PMID: 17471238). ERBB2 (HER2) amplification, overexpression, and activation has been implicated in several tumor types (PMID: 17471238).
Entrez Id 2064
Chromosome 17
Map Location 17q12
Canonical Transcript NM_004448

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Variant Impact Protein Effect Variant Description Associated with drug Resistance
L720V missense unknown ERBB2 (HER2) L720V lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L720V has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Sep 2018).
E717K missense unknown ERBB2 (HER2) E717K lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). E717K is associated with resistance to Tykerb (lapatinib) in cell culture (PMID: 18413839), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2018). Y
P122Q missense no effect - predicted ERBB2 (HER2) P122Q lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). P122Q has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
P230L missense unknown ERBB2 (HER2) P230L lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). P230L has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
L755P missense gain of function ERBB2 (HER2) L755P lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L755P results in increased phosphorylation of Erbb2 (Her2), activation of downstream signaling, and is transforming in cell culture (PMID: 22046346, PMID: 29967253).
M916I missense unknown ERBB2 (HER2) M916I lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). M916I has not been biochemically characterized, but demonstrated decreased transformation ability in one of two different cell lines as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
S305F missense no effect - predicted ERBB2 (HER2) S305F lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). S305F has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
P1170A missense no effect - predicted ERBB2 (HER2) P1170A lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). P1170A is a common polymorphism (PMID: 15743501) that has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
R966C missense loss of function ERBB2 (HER2) R966C lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). R966C results in decreased Erbb2 (Her2) and Mapk phosphorylation in cell culture (PMID: 28743916).
L726F missense gain of function ERBB2 (HER2) L726F lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L726F confers a gain of function to the Erbb2 (Her2) protein as indicated by increased cell proliferation in culture, increased tumor growth in vivo, and localization to the perinuclear cytoplasm (PMID: 25435280).
D821N missense gain of function - predicted ERBB2 (HER2) D821N lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). D821N is weakly transforming and confers resistance to the Erbb2 (Her2) inhibitor Tykerb (lapatinib) in cell culture (PMID: 18413839) and therefore, is predicted to result in a gain of Erbb2 (Her2) protein function. Y
G776delinsVV indel unknown ERBB2 (HER2) G776delinsVV results in a deletion of a glycine (G) at amino acid 776 within the protein kinase domain of the Erbb2 (Her2) protein, combined with the insertion of two valines (V) at the same site (UniProt.org). G776delinsVV results in IL-3-independent growth in cell culture (PMID: 29686424), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown.
R678Q missense no effect ERBB2 (HER2) R678Q lies within the Kpnb1 and Eea1-interacting region of the Erbb2 (Her2) protein (UniProt.org). R678Q demonstrates phosphorylation levels and transformation potential comparable to wild-type Erbb2 (Her2) protein in cell culture (PMID: 29533785) and xenograft models (PMID: 23220880).
T733I missense no effect - predicted ERBB2 (HER2) T733I lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). T733I has not been biochemically characterized, but has weak transformation activity (PMID: 18413839) and induces similar cell proliferation and cell viability as wild-type Erbb2 (Her2), in two different cell lines (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
E1244Q missense no effect - predicted ERBB2 (HER2) E1244Q lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). E1244Q has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
G660R missense gain of function - predicted ERBB2 (HER2) G660R lies within the transmembrane domain of the Erbb2 (Her2) protein (PMID: 30449325). G660R results in increased cell survival as compared wild-type Erbb2 (Her2) in culture (PMID: 30449325), and therefore, is predicted to result in a gain of Erbb2 (Her2) protein function.
G660D missense gain of function ERBB2 (HER2) G660D lies within the transmembrane domain of the Erbb2 (Her2) protein (UniProt.org). G660D leads to constitutive activation of Erbb2 (Her2) and increased downstream signaling in cell culture (PMID: 26545934) and results in increased cell survival and the formation of multi-acinar bodies in the absence of ligand (PMID: 30449325).
A775_G776insSVMA insertion gain of function - predicted ERBB2 (HER2) A775_G776insSVMA results in the insertion of four amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 775 and 776 (UniProt.org). A775_G776insSVMA has not been characterized however, because similar exon 20 insertion mutations are activating (PMID: 17311002), A775_G776insSVMA is predicted to lead to activation of Erbb2 (Her2).
S250F missense unknown ERBB2 (HER2) S250F lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). S250F has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
V773A missense gain of function ERBB2 (HER2) V773A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V773A results in constitutive phosphorylation of Erbb2 (Her2) and is transforming in cell culture (PMID: 22046346).
D251N missense unknown ERBB2 (HER2) D251N lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). D251N has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2018).
C311R missense gain of function ERBB2 (HER2) C311R lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). C311R results in disulfide bond-mediated Erbb2 (Her2) dimerization and is transforming in cell culture (PMID: 22908275).
G776delinsLC indel gain of function ERBB2 (HER2) G776delinsLC results in a deletion of a glycine (G) at amino acid 776 within the protein kinase domain of the Erbb2 (Her2) protein, combined with the insertion of a leucine (L) and a cystine (C) at the same site (UniProt.org). G776delinsLC leads to constitutive activation of Erbb2 (Her2), increased downstream signaling (PMID: 26545934) and is transforming in cell culture (PMID: 29967253).
Y835F missense unknown ERBB2 Y835F lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). Y835F results in decreased Erbb2 (Her2) kinase activity, reduced cell proliferation, is not transforming in culture (PMID: 23220880), and in another study, Y835F results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2), in two different cell lines (PMID: 29533785).
E930K missense no effect - predicted ERBB2 (HER2) E930K lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). E930K has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
R1153* nonsense unknown ERBB2 (HER2) R1153* results in a premature truncation of the Erbb2 (Her2) protein at amino acid 1229 of 1255 (UniProt.org). R1153* has been identified in the scientific literature (PMID: 29420467), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
D582N missense no effect - predicted ERBB2 (HER2) D582N lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). D582N has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, is predicted to have no effect on Erbb2 (Her2) protein function.
exon 20 ins insertion gain of function - predicted ERBB2 (HER2) exon 20 insertions are in-frame insertions within the kinase domain of Erbb2 (Her2) (PMID: 16843263). Exon 20 insertions result in increased Erbb2 (Her2) kinase activity, and are associated with low sensitivity to Egfr tyrosine kinase inhibitors (PMID: 16843263) and therefore, is predict to result in a gain of Erbb2 (Her2) protein function.
D277Y missense no effect - predicted ERBB2 (HER2) D277Y lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). D277Y did not demonstrate Erbb2 (Her2) gain of function activity in a cell culture assay (J Clin Oncol 35, 2017 (suppl; abstr e23150)) and therefore, is predicted to have no effect on Erbb2 (Her2) protein function.
I767M missense unknown ERBB2 (HER2) I767M lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). I767M results in increased Erbb2 (Her2) kinase activity, sustained Akt phosphorylation, and is transforming in cell culture (PMID: 25994018, PMID: 29967253), however in another study, I767M resulted in similar cell proliferation and viability levels as wild-type Erbb2 (Her2), in two different cell lines (PMID: 29533785).
D277H missense unknown ERBB2 (HER2) D277H lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). D277H results in minor changes in Erbb2 (Her2) activity alone, but enhanced phosphorylation of Erbb2 (Her2), Shc and Erk when in combination with S310F in cell culture (PMID: 24971884).
G778_S779insG insertion gain of function - predicted ERBB2 (HER2) G778_S779insG results in the insertion of a glycine (G) in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 778 and 779 (UniProt.org). G778_S779insG has not been characterized, however other exon 20 insertions are activating thus, G778_S779insG is predicted to lead to gain of Erbb2 (Her2) function (PMID: 16843263, PMID: 17311002, PMID: 23220880) and has been demonstrated to be transforming in cell culture (PMID: 29967253).
M953I missense no effect - predicted ERBB2 (HER2) M953I lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). M953I has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
P489L missense no effect - predicted ERBB2 (HER2) P489L lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). P489L has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
E280K missense no effect - predicted ERBB2 (HER2) E280K lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). E280K has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785)and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
R1053M missense no effect - predicted ERBB2 (HER2) R1053M lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). R1053M has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
ERBB2 - TMEM98 fusion unknown ERBB2 (HER2)-TMEM98 results from the fusion of ERBB2 (HER2) and TMEM98. ERBB2 (HER2)-TMEM98 has not been characterized in the scientific literature and therefore, its effect on protein function is unknown (PubMed, Aug 2018).
R217C missense unknown ERBB2 (HER2) R217C lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). R217C has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Sep 2018).
G778A missense unknown ERBB2 (HER2) G778A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). G778A has been identified in the scientific literature (PMID: 29420467), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
R487W missense no effect - predicted ERBB2 (HER2) R487W lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). R487W has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
amp none no effect ERBB2 (HER2) amplification indicates an increased number of copies of the ERBB2 (HER2) gene. However, the mechanism causing the increase is unspecified.
P761del deletion unknown ERBB2 (HER2) P761del results in the deletion of one amino acid in the protein kinase domain of the Erbb2 (Her2) protein at amino acid 761 (UniProt.org). P761del has been identified in the scientific literature (PMID: 29420467), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
V777_G778insG insertion gain of function - predicted ERBB2 (HER2) V777_G778insG results in the insertion of a glycine (G) in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 777 and 778 (UniProt.org). V777_G778insG has not been characterized, however other exon 20 insertions are activating thus, G778_S779insG is predicted to lead to gain of Erbb2 (Her2) function (PMID: 16843263, PMID: 17311002, PMID: 23220880).
S760A missense no effect ERBB2 (HER2) S760A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). S760A did not demonstrate an independent functional effect, however, has been shown to occur with other ERBB2 (HER2) activating mutations, including L755_T759del (PMID: 23220880).
R677L missense gain of function - predicted ERBB2 (HER2) R677L lies within the juxtamembrane domain of the Erbb2 (Her2) protein (PMID: 30449325). R677L results in increased cell survival as compared wild-type Erbb2 (Her2) in culture (PMID: 30449325), and therefore, is predicted to result in a gain of Erbb2 (Her2) protein function.
C334S missense gain of function ERBB2 (HER2) C334S lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). C334S results in disulfide bond-mediated Erbb2 (Her2) dimerization and is transforming in cell culture (PMID: 22908275).
C805S missense unknown ERBB2 (HER2) C805S lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). C805S is associated with resistance to Erbb2 (Her2)-targeted drugs in cell culture (PMID: 28363995), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2018). Y
S310Y missense gain of function - predicted ERBB2 (HER2) S310Y lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). S310Y has not been biochemically characterized, but results in increased transformation potential in cell culture (PMID: 22908275, PMID: 29967253) and in one of two cell lines, S310Y increased cell proliferation and cell viability as compared to wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, is predicted to result in a gain of Erbb2 (Her2) protein function.
G1015W missense no effect - predicted ERBB2 (HER2) G1015W lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). G1015W has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
K228N missense no effect - predicted ERBB2 (HER2) K228N lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). K228N has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
T182I missense no effect - predicted ERBB2 (HER2) T182I lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). T182I has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, is predicted to have no effect on Erbb2 (Her2) protein function.
G776V missense unknown ERBB2 (HER2) G776V lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). G776V has not been biochemically characterized, but in one of two cell lines, G776V increased cell proliferation and cell viability as compared to wild-type Erbb2 (Her2) (PMID: 29533785) and is transforming in cell culture (PMID: 29967253).
V697L missense unknown ERBB2 (HER2) V697L lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). V697L has been identified in the scientific literature (PMID: 29247016, PMID: 28679771), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
W825* nonsense loss of function - predicted ERBB2 (HER2) W825* results in a premature truncation within the protein kinase domain of the Erbb2 (Her2) protein at amino acid 825 of 1255 (UniProt.org). Due to the disruption of the protein kinase domain (UniProt.org), W825* is predicted to lead to a loss of Erbb2 (Her2) protein function.
L869Q missense unknown ERBB2 (HER2) L869Q lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L869Q has been identified in the scientific literature (PMID: 26487584, PMID: 27602491, PMID: 28274957), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Sep 2018).
V842E missense unknown ERBB2 (HER2) V842E lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V842E has not been biochemically characterized, but demonstrated decreased transformation ability in one of two different cell lines as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
S653C missense gain of function ERBB2 (HER2) S653C lies within the transmembrane domain of the Erbb2 (Her2) protein (UniProt.org). S653C results in constitutive activation of Erbb2 (Her2) and phosphorylation of Shc and Erk in cell culture (PMID: 24971884) and leads to increased cell survival as compared to wild-type Erbb2 (Her2) in culture (PMID: 30449325).
K753E missense unknown ERBB2 (HER2) K753E lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). K753E does not result in increased phosphorylation of Erbb2 (Her2) or downstream PLC-gamma, and results in similar tumor formation to wild-type Erbb2 (Her2) in mouse models, however, results in increased Egfr phosphorylation and is associated with resistance to some Erbb2 (Her2) inhibitors (PMID: 27697991). Y
G804S missense unknown ERBB2 (HER2) G804S lies within the protein kinase domain of the Erbb2 protein (UniProt.org). G804S has not been characterized, but is predicted to activate the kinase activity of Erbb2 (Her2) by structural modeling (PMID: 24817905).
mutant unknown unknown ERBB2 (HER2) mutant indicates an unspecified mutation in the ERBB2 (HER2) gene.
K716Q missense unknown ERBB2 (HER2) K716Q lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). K716Q has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
H473N missense no effect - predicted ERBB2 (HER2) H473N lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). H473N has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
S974F missense unknown ERBB2 (HER2) S974F lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). S974F has not been biochemically characterized, but demonstrated decreased transformation ability in one of two different cell lines as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
V773L missense gain of function ERBB2 (HER2) V773L lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V773L confers a gain of function to the Erbb2 (Her2) protein as demonstrated by increased tyrosine kinase activity and phosphorylation compared to wild-type, and abnormal cellular morphology in culture (PMID: 27697991).
G776_V777insYVMA insertion gain of function ERBB2 (HER2) G776_V777insYVMA results in the insertion of four amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 776 and 777 (UniProt.org). G776_V777insYVMA results in constitutive phosphorylation of Erbb2 (Her2), activation of downstream signaling, and is transforming in cell culture (PMID: 16843263).
P489Q missense unknown ERBB2 (HER2) P489Q lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). P489Q has not been biochemically characterized, but demonstrated decreased transformation ability in one of two different cell lines as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
A1216D missense no effect - predicted ERBB2 (HER2) A1216D lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). A1216D has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, is predicted to have no effect on Erbb2 (Her2) protein function.
K831N missense unknown ERBB2 (HER2) K831N lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). K831N has been identified in the scientific literature (PMID: 29420467), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
G1041fs frameshift unknown ERBB2 (HER2) G1041fs results in a change in the amino acid sequence of the Erbb2 (Her2) protein beginning at aa 1041 of 1255, likely resulting in premature truncation of the functional protein (UniProt.org). G1041fs has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Sep 2018).
G776S missense gain of function ERBB2 (HER2) G776S lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). G776S results in increased Erbb2 (Her2) kinase activity, activation of the Mapk pathway (PMID: 18039657), is transforming in cell culture (PMID: 29967253), and in one of two cell lines, G776S increased cell proliferation and cell viability as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
A293T missense no effect - predicted ERBB2 (HER2) A293T lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). A293T has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, is predicted to have no effect on Erbb2 (Her2) protein function.
A771_Y772insAYVM insertion gain of function - predicted ERBB2 (HER2) A771_Y772insAYVM results in the insertion of a four amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 771 and 772 (UniProt.org). A771_Y772insAYVM has not been characterized, however other exon 20 insertions are activating thus, A771_Y772insAYVM is predicted to lead to gain of Erbb2 (Her2) function (PMID: 16843263, PMID: 17311002, PMID: 23220880).
A890V missense unknown ERBB2 (HER2) A890V lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). A890V has been identified in sequencing studies (PMID: 22722839), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
D1058A missense no effect - predicted ERBB2 (HER2) D1058A lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). D1058A has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, is predicted to have no effect on Erbb2 (Her2) protein function.
E1244D missense no effect - predicted ERBB2 (HER2) E1244D lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). E1244D has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, is predicted to have no effect on Erbb2 (Her2) protein function.
G222C missense unknown ERBB2 (HER2) G222C lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). G222C has not been biochemically characterized, but demonstrated increased transformation ability in one of two different cell lines as compared to wild-type Erbb2 (Her2) in culture (PMID: 29533785).
R896C missense gain of function ERBB2 (HER2) R896C lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). R896C results in constitutive phosphorylation of Erbb2 (Her2), increased downstream signaling, and is transforming in cell culture (PMID: 23220880).
P1234S missense no effect - predicted ERBB2 (HER2) P1234S lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). P1234S has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
V308M missense unknown ERBB2 (HER2) V308M lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). V308M has not been biochemically characterized, but in one of two cell lines, V308M decreased cell proliferation and cell viability as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
Y1248F missense loss of function - predicted ERBB2 (HER2) Y1248F lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). Y1248F results in constitutive dephosphorylation of Erbb2 (Her2), which leads to endosomal internalization and lysosomal degradation of Erbb2 (Her2) in cell lines (PMID: 27345410) and therefore, is predicted to result in a loss of Erbb2 (Her2) protein function.
G804D missense unknown ERBB2 (HER2) G804D lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). G804D has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
D769N missense no effect - predicted ERBB2 (HER2) D769N lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). D769N has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, is predicted to have no effect on Erbb2 (Her2) protein function.
L755M missense no effect - predicted ERBB2 (HER2) L755M lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L755M has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
E719K missense unknown ERBB2 (HER2) E719K lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). E719K is associated with resistance to Tykerb (lapatinib) in cell culture (PMID: 18413839), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2018). Y
T862A missense gain of function ERBB2 (HER2) T862A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). T862A results in constitutive phosphorylation of Erbb2 (Her2) and is transforming in cell culture (PMID: 22046346, PMID: 29533785, PMID: 29967253).
V777A missense loss of function ERBB2 (HER2) V777A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V777A results in decreased Erbb2 (Her2) activity and a decreased ability to transform cells in culture (PMID: 22908275).
P416L missense no effect - predicted ERBB2 (HER2) P416L lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). P416L has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
G1015E missense unknown ERBB2 (HER2) G1015E lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). G1015E has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Sep 2018).
D326G missense no effect ERBB2 (HER2) D326G lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). D326G does not result in increased Erbb2 (Her2) phosphorylation or the ability to transform cells in culture (PMID: 22908275).
P1210S missense no effect - predicted ERBB2 (HER2) P1210S lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). P1210S has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
S974A missense unknown ERBB2 (HER2) S974A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). S974A has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Sep 2018).
E1229* nonsense unknown ERBB2 (HER2) E1229* results in a premature truncation of the Erbb2 (Her2) protein at amino acid 1229 of 1255 (UniProt.org). E1229* has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) function is unknown (PubMed, Oct 2018).
C630Y missense unknown ERBB2 (HER2) C630Y lies within the extracellular domain of the Erbb2 protein (UniProt.org). C630Y has been identified in the scientific literature (PMID: 18413839), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Sep 2018).
R678L missense unknown ERBB2 (HER2) R678L lies within the KPNB1 and EEA1-interacting region of the Erbb2 (Her2) protein (UniProt.org). R678L has been identified in the scientific literature (PMID: 25636205), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
G778_P780dup duplication gain of function ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP and V777_G778insGSP) indicates the insertion of 3 amino acids, glycine (G)-778 through proline (P)-781, in the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). G778_P780dup results in constitutive activation of Erbb2 (Her2), increased downstream signaling, and is transforming in cell culture (PMID: 23220880).
R868W missense loss of function ERBB2 (HER2) R868W lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). R868W results in decreased Erbb2 (Her2) and Mapk phosphorylation in cell culture (PMID: 28743916), and in one of two cell lines, R868W decreased cell proliferation and cell viability as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
T496I missense unknown ERBB2 (HER2) T496I lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). T496I has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
P1207A missense unknown ERBB2 (HER2) P1207A lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). P1207A has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Sep 2018).
G919W missense unknown ERBB2 (HER2) G919W lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). G919W has not been biochemically characterized, but demonstrated decreased transformation ability in one of two different cell lines compared to wild-type Erbb2 (Her2) in culture (PMID: 29533785).
A775_G776insYVMA insertion gain of function ERBB2 (HER2) A775_G776insYVMA results in the insertion of four amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 775 and 776 (UniProt.org). A775_G776insYVMA results in the same amino acid change as M774_A775insAYVM, which leads to constitutive phosphorylation of Erbb2 (Her2) and is transforming in cell culture (PMID: 17311002, PMID: 29967253).
T216S missense gain of function - predicted ERBB2 (HER2) T216S lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). T216S is predicted to confer a gain of function to the Erbb2 (Her2) protein as demonstrated by increased kinase activity (PMID: 22908275).
L49H missense no effect ERBB2 (HER2) L49H lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). L49H demonstrates phosphorylation level and transformation potential comparable to wild-type Erbb2 (Her2) protein in cell culture (PMID: 22908275).
R1006C missense no effect - predicted ERBB2 (HER2) R1006C lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). R1006C has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
T306M missense no effect - predicted ERBB2 (HER2) T306M lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). T306M has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
G776C missense unknown ERBB2 (HER2) G776C lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). G776C has been identified in the scientific literature (PMID: 22761469), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
K716E missense unknown ERBB2 (HER2) K716E does not lie within any known functional domains of the Erbb2 (Her2) protein (UniProt.org). K716E has not been biochemically characterized, but demonstrated decreased transformation ability in one of two different cell lines as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
K753A missense loss of function - predicted ERBB2 (HER2) K753A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). K753A has been described as a kinase deficient mutation and is predicted to confer a loss of function to the Erbb2 (Her2) protein as demonstrated by loss of protein kinase activity (PMID: 22393464).
P247S missense no effect - predicted ERBB2 (HER2) P247S lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). P247S has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
S779_P780insVGS insertion gain of function - predicted ERBB2 (HER2) S779_P780insVGS results in the insertion of three amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 779 and 780 (UniProt.org). S779_P780insVGS has not been characterized, however other exon 20 insertions are activating thus, S779_P780insVGS is predicted to lead to gain of Erbb2 (Her2) function (PMID: 16843263, PMID: 17311002, PMID: 23220880).
Q680R missense no effect ERBB2 (HER2) Q680R lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). Q680R confers no effect to the Erbb2 (Her2) protein, resulting in kinase activity, phosphorylation, and cell morphology in culture similar to wild-type (PMID: 27697991).
Y803N missense unknown ERBB2 (HER2) Y803N lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). Y803N is associated with Tykerb (lapatinib)-resistance in cell culture (PMID: 18413839), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2018). Y
L755_E757del deletion unknown ERBB2 (HER2) L755_E757del results in the deletion of three amino acids in the protein kinase domain of the Erbb2 (Her2) protein from amino acids 755 to 757 (UniProt.org). L755_E757del has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Sep 2018).
L869R missense gain of function ERBB2 (HER2) L869R lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L869R results in increased Erbb2 (Her2) phosphorylation, promotes growth in cell culture, and enhances tumor formation and metastasis in animal models (PMID: 27900369).
A775_G776insIRDG insertion no effect - predicted ERBB2 (HER2) A775_G776insIRDG results in the insertion of four amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 775 and 776 (UniProt.org). A775_G776insIRDG has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, is predicted to have no effect on Erbb2 (Her2) protein function.
G776_V777insVGC insertion gain of function - predicted ERBB2 (HER2) G776_V777insVGC results in the insertion of three amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 776 and 777 (UniProt.org). G776_V777insVGC has not been characterized, however other exon 20 insertions are activating thus, G776_V777insVGC is predicted to lead to gain of Erbb2 (Her2) function (PMID: 16843263, PMID: 17311002, PMID: 23220880).
V777M missense unknown ERBB2 (HER2) V777M lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V777M has been identified in the scientific literature (PMID: 22761469, PMID: 28481359, PMID: 27284958), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Sep 2018).
Q943* nonsense unknown ERBB2 (HER2) Q943* results in a premature truncation of the Erbb2 (Her2) protein at amino acid 943 of 1255 (UniProt.org). Q943* has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Sep 2018).
M774delinsWLV indel gain of function ERBB2 (HER2) M774delinsWLV results in a deletion of methionine (M) at amino acid 774 within the protein kinase domain of the Erbb2 (Her2) protein, combined with the insertion of a tryptophan (W), lysine (L), and a valine (V) at the same site (UniProt.org). M774delinsWLV results in activation of Erbb2 (Her2) and transformation of cultured cells (PMID: 28363995).
D880N missense no effect - predicted ERBB2 (HER2) D880N lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). D880N has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, is predicted to have no effect on Erbb2 (Her2) protein function.
V842I missense unknown ERBB2 (HER2) V842I lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V842I results in increased Erbb2 (Her2) activity, downstream Mapk pathway activation, and the ability to transform cells in culture (PMID: 23220880), however in another study, V842I results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2), in two different cell lines (PMID: 29533785).
I655V missense unknown ERBB2 (HER2) I655V lies within the transmembrane domain of the Erbb2 (Her2) protein (PMID: 18178548). I655V has not been characterized, but is predicted to stabilize Erbb2 (Her2) dimerization resulting in receptor activation and oncogenic transformation (PMID: 18178548, PMID: 12461170), however in another study, I655V results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2), in two different cell lines (PMID: 29533785).
L768S missense gain of function ERBB2 (HER2) L768S lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L768S confers a gain of function to the Erbb2 (Her2) protein as demonstrated by increased tyrosine kinase activity and phosphorylation compared to wild-type, and abnormal cellular morphology in culture (PMID: 27697991).
R970W missense unknown ERBB2 (HER2) R970W lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). R970W has been identified in the scientific literature (PMID: 21347793), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
Q711H missense no effect - predicted ERBB2 (HER2) Q711H lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). Q711H has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
V659E missense gain of function ERBB2 (HER2) V659E lies within the transmembrane domain of the Erbb2 (Her2) protein (UniProt.org). V659E results in constitutive phosphorylation of Erbb2 (Her2), activation of Src and Akt signaling in cell culture, and increased tumor metastasis in animal models (PMID: 16489002, PMID: 15753384), and leads to increased cell survival as compared to wild-type Erbb2 (Her2) in culture (PMID: 30449325), and in one of two cell lines, V659E increased cell proliferation and cell viability as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
E265K missense unknown ERBB2 (HER2) E265K lies within the extracellular domain of the Erbb2 protein (UniProt.org). E265K has been identified in sequencing studies (PMID: 24997986, PMID: 29338072), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
negative none no effect ERBB2 (HER2) negative indicates a lack of the ERBB2 (HER2) gene, mRNA, or protein.
D769A missense loss of function - predicted ERBB2 (HER2) D769A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). D769A is predicted to confer a loss of function to the Erbb2 (Her2) protein as indicated by loss of Erbb2 (Her2) kinase activity (PMID: 23843458).
G383E missense no effect - predicted ERBB2 (HER2) G383E lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). G383E has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
T686M missense no effect - predicted ERBB2 (HER2) T686M lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). T686M has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
L726I missense unknown ERBB2 (HER2) L726I lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L726I is associated with resistance to Iressa (gefitinib) and Tykerb (lapatinib) in cell culture (PMID: 17638894, PMID: 18413839), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2018). Y
C544F missense unknown ERBB2 (HER2) C544F lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). C544F has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Sep 2018).
L755_T759del deletion gain of function ERBB2 (HER2) L755_T759del results in the deletion of five amino acids in the protein kinase domain of the Erbb2 (Her2) protein from amino acids 755 to 759 (UniProt.org). L755_T759del confers a gain of function to the Erbb2 (Her2) protein as demonstrated by increased phosphorylation of Egfr and Erbb3 (Her3), tumor growth (PMID: 23220880), and is transforming in cell culture (PMID: 29533785).
R545* nonsense loss of function - predicted ERBB2 (HER2) R545* results in a premature truncation of the Erbb2 (Her2) protein at amino acid 545 of 1255 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), R545* is predicted to lead to a loss of Erbb2 (Her2) protein function.
A440T missense unknown ERBB2 (HER2) A440T lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). A440T has not been biochemically characterized, but in one of two different cell lines, A440T induced increased cell proliferation and cell viability as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
dec exp none no effect ERBB2 (HER2) dec exp indicates decreased expression of the Erbb3 (Her3) protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
S783P missense unknown ERBB2 (HER2) S783P lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). S783P is not associated with Erbb2 (Her2) activation (PMID: 28164408), but confers Tykerb (lapatinib)-resistance in cell culture (PMID: 18413839). Y
L313V missense unknown ERBB2 (HER2) L313V lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). L313V has not been biochemically characterized, but demonstrated decreased transformation ability in one of two different cell lines as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
E971G missense unknown ERBB2 (HER2) E971G lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). E971G has been identified in the scientific literature (PMID: 21347793, PMID: 29312610), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
L145F missense no effect - predicted ERBB2 (HER2) L145F lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). L145F has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
D277G missense unknown ERBB2 (HER2) D277G lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). D277G has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
R138W missense no effect - predicted ERBB2 (HER2) R138W lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). R138W has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
R432W missense unknown ERBB2 (HER2) R432W lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). R432W has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Sep 2018).
V782I missense no effect - predicted ERBB2 (HER2) V782I lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V782I has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
G776_V777insVC insertion gain of function - predicted ERBB2(HER2) G776_V777insVC results in the insertion of two amino acids in the protein kinase domain of the Erbb2(Her2) protein between amino acids 776 and 777 (UniProt.org). G776_V777insVC has not been biochemically characterized, however, other ERBB2 (HER2) exon 20 insertions are activating (PMID: 16843263, PMID: 17311002, PMID: 23220880), and therefore, G776_V777insVC is predicted to lead to gain of Erbb2 (Her2) function.
P551L missense unknown ERBB2 (HER2) P551L lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). P551L has not been biochemically characterized, but demonstrated increased transformation ability in one of two different cell lines as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
K937R missense unknown ERBB2 (HER2) K937R lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). K937R has not been biochemically characterized, but demonstrated decreased transformation ability in one of two different cell lines as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
S656C missense gain of function - predicted ERBB2 (HER2) S656C lies within the transmembrane domain of the Erbb2 (Her2) protein (PMID: 30449325). S656C results in increased cell survival as compared to wild-type Erbb2 (Her2) in cell culture (PMID: 30449325), and therefore, is predicted to result in a gain of Erbb2 (Her2) protein function.
E757A missense unknown ERBB2 (HER2) E757A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). E757A has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
L755S missense gain of function ERBB2 (HER2) L755S lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L755S results in increased phosphorylation of Erbb2 (Her2), activation of downstream signaling, is transforming in cell culture (PMID: 29967253), and is associated with resistance to Erbb2 (Her2)-targeted therapies (PMID: 22046346, PMID: 28487443). Y
N1219S missense no effect - predicted ERBB2 (HER2) N1219S lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). N1219S has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
T652R missense no effect - predicted ERBB2 (HER2) T652R lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). T652R has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
Y772_A775dup duplication gain of function ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA, M774_A775insAYVM, and E770delinsEAYVM) indicates the insertion of 4 duplicate amino acids, tyrosine (Y)-772 through alanine (A)-775, in the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). Y772_A775dup results in the constitutive phosphorylation of Erbb2 (Her2) and is transforming in cell culture (PMID: 17311002).
E930D missense no effect - predicted ERBB2 (HER2) E930D lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). E930D has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
P780L missense unknown ERBB2 (HER2) P780L lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). P780L confers resistance to Tykerb (lapatinib) in cell culture (PMID: 18413839), but has not been biochemically characterized and therefore its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2018). Y
P780_Y781insGSP insertion gain of function ERBB2 (HER2) P780_Y781insGSP (also referred to as G778_P780dup) results in the insertion of three amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 780 and 781 (UniProt.org). P780_Y781insGSP results in constitutive activation of Erbb2 (Her2), increased downstream signaling, and is transforming in cell culture (PMID: 23220880, PMID: 28363995, PMID: 29967253).
F616L missense unknown ERBB2 (HER2) F616L lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). F616L has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
L841V missense gain of function - predicted ERBB2 (HER2) L841V lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L841V has not been biochemically characterized, but in two different cell lines, L841V induced increased cell proliferation and cell viability as compared to wild-type Erbb2 (Her2) (PMID: 29533785) and demonstrated transformation in cell culture (PMID: 29967253) and therefore, is predicted to result in a gain of Erbb2 protein function.
P391Q missense no effect - predicted ERBB2 (HER2) P391Q lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). P391Q has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
S310F missense gain of function ERBB2 (HER2) S310F lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). S310F results in increased phosphorylation of Erbb2 and is transforming in cell culture (PMID: 22908275, PMID: 29533785, PMID: 29967253).
D417Y missense unknown ERBB2 (HER2) D417Y lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). D417Y has not been biochemically characterized, but in one of two cell lines, D417Y decreased cell proliferation and cell viability as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
K676R missense no effect ERBB2 (HER2) K676R lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). K676R confers no effect to the Erbb2 (Her2) protein, resulting in kinase activity, phosphorylation, and cell morphology in culture similar to wild-type (PMID: 27697991).
Y803H missense no effect - predicted ERBB2 (HER2) Y803H lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). Y803H has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
E1064Q missense no effect - predicted ERBB2 (HER2) E1064Q lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). E1064Q has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, is predicted to have no effect on Erbb2 (Her2) protein function.
D742H missense no effect - predicted ERBB2 (HER2) D742H lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). D742H has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, is predicted to have no effect on Erbb2 (Her2) protein function.
V777L missense gain of function ERBB2 (HER2) V777L lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V777L results in increased Erbb2 (Her2) activity, increased downstream Mapk pathway activation, increased ability to transform cells in culture (PMID: 29967253), and increased tumor growth in xenograft models (PMID: 23220880)
G292R missense unknown ERBB2 (HER2) G292R lies within the extracellular domain of the Erbb2 protein (UniProt.org). G292R has been identified in the scientific literature (PMID: 24997986, PMID: 29338072), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
N857S missense gain of function ERBB2 (HER2) N857S lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). N857S results in constitutive phosphorylation of Erbb2 (Her2) and is transforming in cell culture (PMID: 22046346).
L755_E757delinsS insertion unknown ERBB2 (HER2) L755_E757delinsS results in the deletion of three amino acids from aa 755 to 757 within the protein kinase domain of the Erbb2 (Her2) protein, combined with the insertion of a serine (S) at the same site (UniProt.org). L755_E757delinsS has been identified in the scientific literature (PMID: 29420467), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
A751T missense unknown ERBB2 (HER2) A751T lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). A751T has not been biochemically characterized, but in one of two cell lines, A751T decreased cell proliferation and cell viability as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
N571K missense no effect - predicted ERBB2 (HER2) N571K lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). N571K has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
R683Q missense no effect - predicted ERBB2 (HER2) R683Q lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). R683Q has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
D1144Y missense no effect - predicted ERBB2 (HER2) D1144Y lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). D1144Y has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, is predicted to have no effect on Erbb2 (Her2) protein function.
P197S missense unknown ERBB2 (HER2) P197S lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). P197S has been identified in sequencing studies (PMID: 25589618), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Sep 2018).
K753M missense loss of function - predicted ERBB2 (HER2) K753M lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). K753M has been described as a kinase dead mutation and is predicted to confer a loss of function to the Erbb2 (Her2) protein as demonstrated by loss of Erbb2 phosphorylation (PMID: 16489002).
M774_A775insAYVM insertion gain of function ERBB2 (HER2) M774_A775insAYVM results in the insertion of four amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 774 and 775 (UniProt.org). M774_A775insAYVM results in constitutive phosphorylation of Erbb2 (Her2) and is transforming in cell culture (PMID: 17311002).
L755W missense unknown ERBB2 (HER2) L755W lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L755W has been identified in the scientific literature (PMID: 23220880 PMID: 27811364), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Sep 2018).
L755A missense unknown ERBB2 (HER2) L755A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L755A has been identified in the scientific literature (PMID: 28167203, PMID: 29989854), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Sep 2018).
positive unknown unknown ERBB2 (HER2) positive indicates the presence of the ERBB2 (HER2) gene, mRNA, and/or protein.
wild-type none no effect Wild-type ERBB2 (HER2) indicates that no mutation has been detected within the ERBB2 (HER2) gene.
P36S missense no effect - predicted ERBB2 (HER2) P36S lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). P36S has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
over exp none no effect ERBB2 (HER2) over exp indicates an over expression of the Erbb2 (Her2) protein and/or mRNA. However, the mechanism causing the over expression is unknown.
G776delinsVC indel gain of function ERBB2 (HER2) G776delinsVC results in a deletion of a glycine (G) at amino acid 776 within the protein kinase domain of the Erbb2 (Her2) protein, combined with the insertion of a valine (V) and a cystine (C) at the same site (UniProt.org). G776delinsVC leads to constitutive activation of Erbb2 (Her2), increased downstream signaling (PMID: 26545934), induces cell proliferation and cell viability in culture (PMID: 29533785), and is transforming in cell culture (PMID: 29967253).
D769Y missense gain of function ERBB2 (HER2) D769Y lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). D769Y results in constitutive phosphorylation of Erbb2 (Her2), increased downstream signaling, and is transforming in cell culture (PMID: 23220880, PMID: 29967253).
G778_S779insCPG insertion gain of function - predicted ERBB2 (HER2) G778_S779insCPG results in the insertion of three amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 778 and 779 (UniProt.org). G778_S779insCPG is transforming in culture (PMID: 28363995), and based on the effects of other ERBB2 (HER2) exon 20 insertions (PMID: 16843263, PMID: 17311002), is predicted to result in a gain of Erbb2 (Her2) function.
L915M missense unknown ERBB2 (HER2) L915M lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L915M confers Tykerb (lapatinib)-resistance in cell culture (PMID: 18413839), but has not been biochemically characterized and therefore its effect on Erbb2 (Her2) protein is unknown (PubMed, May 2018). Y
S1002R missense unknown ERBB2 (HER2) S1002R lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). S1002R confers Tykerb (lapatinib)-resistance in cell culture (PMID: 18413839), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2018). Y
E321G missense gain of function ERBB2 (HER2) E321G lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). E321G results in disulfide bond-mediated Erbb2 (Her2) dimerization and is transforming in cell culture (PMID: 22908275, PMID: 29533785).
G309E missense unknown ERBB2 (HER2) G309E lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). G309E results in disulfide bond-mediated Erbb2 (Her2) dimerization and is transforming in cell culture (PMID: 22908275), but in another study, G309E results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2), in two different cell lines (PMID: 29533785).
L663P missense no effect - predicted ERBB2 (HER2) L663P lies within the helical domain of the Erbb2 (Her2) protein (UniProt.org). L663P has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
L866M missense gain of function ERBB2 (HER2) L866M lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L866M results in constitutive phosphorylation of Erbb2 (Her2) and increased phosphorylation of Mapk in cell culture (PMID: 26243863).
D845A missense loss of function ERBB2 (HER2) D845A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). D845A results in loss of Erbb2 (Her2) phosphorylation and abolishes transformation potential in cell culture (PMID: 22908275).
E719G missense unknown ERBB2 (HER2) E719G lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). E719G is associated with resistance to Tykerb (lapatinib) in cell culture (PMID: 18413839), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2018). Y
L785F missense unknown ERBB2 (HER2) L785F lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L785F confers Tykerb (lapatinib)-resistance in cell culture (PMID: 18413839), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2018). Y
N319D missense no effect ERBB2 (HER2) N319D lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). N319D demonstrates phosphorylation level and transformation potential comparable to wild-type Erbb2 (Her2) protein in cell culture (PMID: 22908275).
V750E missense loss of function - predicted ERBB2 (HER2) V750E lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V750E is predicted to confer a loss of function to the Erbb2 (Her2) protein as demonstrated by decreased kinase activity (PMID: 22908275).
D769H missense unknown ERBB2 (HER2) D769H lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). D769H results in constitutive phosphorylation of Erbb2 (Her2), activation of downstream signaling, is transforming in cell culture (PMID: 29967253), and promotes tumor formation in xenograft models (PMID: 23220880), but in another study, D769H induced similar cell proliferation and cell viability as wild-type Erbb2 (Her2) in two different cell lines (PMID: 29533785).
E1021Q missense no effect - predicted ERBB2 (HER2) E1021Q lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). E1021Q has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, is predicted to have no effect on Erbb2 (Her2) protein function.
act mut unknown gain of function ERBB2 (HER2) act mut indicates that this variant results in a gain of function in the Erbb2 (Her2) protein. However, the specific amino acid change has not been identified.
A386D missense unknown ERBB2 (HER2) A386D lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). A386D has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
R897Q missense no effect - predicted ERBB2 (HER2) R897Q lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). R897Q has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, is predicted to have no effect on Erbb2 (Her2) protein function.
W906* nonsense loss of function - predicted ERBB2 (HER2) W906* results in a premature truncation of the Erbb2 (Her2) protein within the protein kinase domain of the Erbb2 (Her2) protein at amino acid 906 of 1255 (UniProt.org). Due to the disruption of the Erbb2 (Her2) kinase domain, W906* is predicted to lead to a loss of function.
I101S missense no effect - predicted ERBB2 (HER2) I101S lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). I101S has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
T798I missense no effect - predicted ERBB2 (HER2) T798I lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). T798I does not result in activation of Erbb2 (Her2) downstream signaling or transformation of cultured cells, but is associated with resistance to Erbb2 (Her2) inhibitors (PMID: 25238247, PMID: PMID: 28274957, PMID: 18413839) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function. Y
R647K missense no effect ERBB2 (HER2) R647K lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). R647K confers no effect to the Erbb2 (Her2) protein, resulting in kinase activity, phosphorylation, and cell morphology in culture similar to wild-type (PMID: 27697991).
E812K missense unknown ERBB2 (HER2) E812K lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). E812K confers Tykerb (lapatinib) resistance in cell culture (PMID: 18413839), but has not been biochemically characterized, and therefore its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2018). Y
I654V missense gain of function - predicted ERBB2 (HER2) I654V lies within the transmembrane domain of the Erbb2 (Her2) protein (UniProt.org). I654V is predicted to stabilize Erbb2 (Her2) dimerization, resulting in increased autophosphorylation and protein kinase activity (PMID: 15550452).
H878Y missense gain of function ERBB2 (HER2) H878Y lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). H878Y confers a gain of function to the Erbb2 (Her2) protein as demonstrated by increased Erbb2 (Her2) phosphorylation and transformation of cells in cell culture (PMID: 22046346).
S573L missense no effect - predicted ERBB2 (HER2) S573L lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). S573L has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
R784H missense unknown ERBB2 (HER2) R784H lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). R784H has been identified in the scientific literature (PMID: 24797764), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
T798M missense gain of function ERBB2 (HER2) T798M lies within the gatekeeper position in the ATP binding site of the Erbb2 (HER2) protein. T798M results in activation of the Erbb2 (Her2) protein in cell culture experiments (PMID: 22046346, PMID: 23948973) and demonstrates the ability to increase cell proliferation and cell viability in culture (PMID: 29533785).
R226S missense unknown ERBB2 (HER2) R226S lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). R226S has not been biochemically characterized, but demonstrated increased transformation ability in one of two different cell lines as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
G309A missense unknown ERBB2 (HER2) G309A lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). G309A does not result in increased Erbb2 (Her2) phosphorylation, but is transforming in cell culture and promotes tumor formation in xenograft models, and is predicted to enhance Erbb2 (Her2) dimerization (PMID: 23220880), yet in another study, G309A results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2), in two different cell lines (PMID: 29533785).
P885S missense unknown ERBB2 (HER2) P885S lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). P885S has not been biochemically characterized, but demonstrated decreased transformation ability in one of two different cell lines as compared to wild-type Erbb2 (Her2) (PMID: 29533785).
L786V missense unknown ERBB2 (HER2) L786V lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L786V has been identified in the scientific literature (PMID: 29420467), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2018).
V773M missense no effect - predicted ERBB2 (HER2) V773M lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V773M has not been biochemically characterized, but results in similar cell proliferation and viability levels as wild-type Erbb2 (Her2) (PMID: 29533785) and therefore, it is predicted to have no effect on Erbb2 (Her2) protein function.
V839G missense unknown ERBB2 (HER2) V839G lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V839G confers Tykerb (lapatinib)-resistance in cell culture (PMID: 18413839), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2018). Y
Molecular Profile Protein Effect Treatment Approaches
ERBB2 L720V unknown
ERBB2 E717K unknown
ERBB2 P122Q no effect - predicted
ERBB2 P230L unknown
ERBB2 L755P gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 M916I unknown
ERBB2 S305F no effect - predicted
ERBB2 P1170A no effect - predicted
ERBB2 R966C loss of function
ERBB2 L726F gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 D821N gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 G776delinsVV unknown
ERBB2 R678Q no effect
ERBB2 T733I no effect - predicted
ERBB2 E1244Q no effect - predicted
ERBB2 G660R gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 G660D gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 S310F ERBB2 G660D
ERBB2 A775_G776insSVMA gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 S250F unknown
ERBB2 V773A gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 D251N unknown
ERBB2 C311R gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 G776delinsLC gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 Y835F unknown
ERBB2 E930K no effect - predicted
ERBB2 L755S ERBB2 R1153* ERBB2 V777L
ERBB2 R1153* unknown
ERBB2 D582N no effect - predicted
ERBB2 exon 20 ins gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 D277Y no effect - predicted
ERBB2 I767M unknown
ERBB2 D277H ERBB2 S310F
ERBB2 D277H unknown
ERBB2 G778_S779insG gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 M953I no effect - predicted
ERBB2 P489L no effect - predicted
ERBB2 E280K no effect - predicted
ERBB2 R1053M no effect - predicted
ERBB2-TMEM98 unknown
ERBB2 R217C unknown
ERBB2 G778A unknown
ERBB2 R487W no effect - predicted
ERBB2 amp PTEN dec exp
ROS1 fusion ERBB2 amp FGFR3 amp RET amp
ERBB2 amp no effect HER inhibitor (Pan) HER2 (ERBB2) Antibody HER2 (ERBB2) Immune Cell Therapy HER2 (ERBB2) Vaccine HER2 Inhibitor
FGFR2 wild-type ERBB2 amp
ERBB2 amp TP53 R158H
ERBB2 amp ERBB2 over exp
ERBB2 amp PIK3CA N345K
ERBB2 amp PIK3CA E545K PIK3CA K567R
ERBB2 amp FGFR2 amp
ERBB2 amp ERBB2 L866M
ERBB2 amp PIK3CA mut
EGFR amp ERBB2 amp
ERBB2 amp PIK3CA C420R
ERBB2 amp PIK3CA H1047R
ERBB2 amp MET amp
ERBB2 amp ERBB2 L755S
ERBB2 amp PIK3CA wild-type
ERBB2 amp ERBB2 T798M
ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp
ERBB2 amp PIK3CA E545K
ERBB2 amp PIK3CA K111N
ERBB2 amp SRC E527K
ERBB2 P761del unknown
ERBB2 V777_G778insG gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 S760A no effect
ERBB2 R677L gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 C334S gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 Y772_A775dup ERBB2 C805S
ERBB2 M774delinsWLV ERBB2 C805S
ERBB2 C805S unknown
ERBB2 S310Y gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 G1015W no effect - predicted
ERBB2 K228N no effect - predicted
ERBB2 T182I no effect - predicted
ERBB2 G776V unknown
ERBB2 V697L unknown
ERBB2 W825* loss of function - predicted
CDH1 R63* ERBB2 L869Q
ERBB2 L869Q unknown
ERBB2 V842E unknown
ERBB2 S653C gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 K753E unknown Neratinib
ERBB2 G804S unknown
ERBB2 mutant unknown
ERBB2 K716Q unknown
ERBB2 H473N no effect - predicted
ERBB2 S974F unknown
ERBB2 V773L gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 G776_V777insYVMA gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 P489Q unknown
ERBB2 A1216D no effect - predicted
ERBB2 K831N unknown
ERBB2 G1041fs unknown
ERBB2 G776S gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 A293T no effect - predicted
ERBB2 A771_Y772insAYVM gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 A890V unknown
ERBB2 D1058A no effect - predicted
ERBB2 E1244D no effect - predicted
ERBB2 G222C unknown HER inhibitor (Pan) HER2 Inhibitor
ERBB2 R896C gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 P1234S no effect - predicted
ERBB2 V308M unknown
ERBB2 Y1248F loss of function - predicted
ERBB2 G804D unknown
ERBB2 D769N no effect - predicted
ERBB2 L755M no effect - predicted
ERBB2 E719K unknown
ERBB2 T862A gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 V777A loss of function
ERBB2 P416L no effect - predicted
ERBB2 G1015E unknown
ERBB2 D326G no effect
ERBB2 P1210S no effect - predicted
ERBB2 S974A unknown
ERBB2 E1229* unknown
ERBB2 C630Y unknown
ERBB2 R678L unknown
ERBB2 G778_P780dup gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 R868W loss of function
ERBB2 T496I unknown
ERBB2 P1207A unknown
ERBB2 G919W unknown
ERBB2 A775_G776insYVMA gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 A775_G776insYVMA PIK3CA R425L
ERBB2 T216S gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 L49H no effect
ERBB2 R1006C no effect - predicted
ERBB2 T306M no effect - predicted
ERBB2 G776C unknown
ERBB2 K716E unknown
ERBB2 K753A loss of function - predicted
ERBB2 P247S no effect - predicted
ERBB2 S779_P780insVGS gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 Q680R no effect
ERBB2 Y803N unknown
ERBB2 L755_E757del unknown
ERBB2 L869R ERBB2 T798I
ERBB2 L869R gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 A775_G776insIRDG no effect - predicted
ERBB2 G776_V777insVGC gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 V777M unknown
ERBB2 Q943* unknown
ERBB2 M774delinsWLV gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 D880N no effect - predicted
ERBB2 V842I unknown
ERBB2 S310F ERBB2 V842I
ERBB2 V777L ERBB2 V842I
ERBB2 I655V unknown
ERBB2 L768S gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 R970W unknown
ERBB2 Q711H no effect - predicted
ERBB2 V659E gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 E265K unknown
BRCA1 mut ERBB2 neg
ERBB2 neg no effect
ERBB2 neg ERBB2 pos
ERBB2 neg MET pos
BRCA2 mut ERBB2 neg
ERBB2 D769A loss of function - predicted
ERBB2 G383E no effect - predicted
ERBB2 T686M no effect - predicted
ERBB2 L726I unknown
ERBB2 C544F unknown
ERBB2 L755_T759del gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 R545* loss of function - predicted
ERBB2 A440T unknown HER inhibitor (Pan) HER2 Inhibitor
EGFR over exp ERBB2 dec exp
ERBB2 dec exp no effect
ERBB2 S783P unknown
ERBB2 L313V unknown
ERBB2 E971G unknown
ERBB2 L145F no effect - predicted
ERBB2 D277G unknown
ERBB2 D277G ERBB2 S310F
ERBB2 R138W no effect - predicted
ERBB2 R432W unknown
ERBB2 V782I no effect - predicted
ERBB2 G776_V777insVC gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 P551L unknown HER inhibitor (Pan) HER2 Inhibitor
ERBB2 K937R unknown
ERBB2 S656C gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 E757A unknown
ERBB2 L755S gain of function HER inhibitor (Pan) HER2 Inhibitor
APC Q1429fs BRAF N581S ERBB2 L755S
ERBB2 N1219S no effect - predicted
ERBB2 T652R no effect - predicted
ERBB2 Y772_A775dup gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 E930D no effect - predicted
ERBB2 P780L unknown
ERBB2 P780_Y781insGSP gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 F616L unknown
ERBB2 L841V gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 P391Q no effect - predicted
ERBB2 S310F gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 D417Y unknown
ERBB2 K676R no effect
ERBB2 Y803H no effect - predicted
ERBB2 E1064Q no effect - predicted
ERBB2 D742H no effect - predicted
ERBB2 V777L gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 G292R unknown
ERBB2 N857S gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 L755_E757delinsS unknown
ERBB2 A751T unknown
ERBB2 N571K no effect - predicted
ERBB2 R683Q no effect - predicted
ERBB2 D1144Y no effect - predicted
ERBB2 P197S unknown
ERBB2 K753M loss of function - predicted
ERBB2 M774_A775insAYVM gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 L755W unknown
ERBB2 L755A unknown
ERBB2 pos PIK3CA C420R
ERBB2 positive unknown HER inhibitor (Pan) HER2 Inhibitor
ERBB2 pos KRAS G13D
PIK3CA mutant ERBB2 pos
ERBB2 positive KRAS wild-type
ERBB2 pos PIK3CA K111N
ERBB2 pos PTEN loss PIK3CA act mut
ERBB2 pos PIK3CA H1047L
ERBB2 pos PTEN dec exp
ERBB2 pos PIK3CA E545K
ERBB2 pos PIK3CA H1047R
ERBB2 pos PIK3CA mut
ERBB2 pos PIK3CA I391M
ERBB2 pos PIK3CA act mut
ERBB2 pos PIK3CA wild-type
ERBB2 pos PTEN loss
ERBB2 pos PIK3CA N345T
ERBB2 pos MET amp
ERBB2 pos KRAS amp
ERBB2 pos PTEN mut
EGFR pos ERBB2 pos
EGFR amp ERBB2 pos
BRAF V600E ERBB2 pos KRAS A146V
ERBB2 pos KRAS amp MET N375S
EGFR exon 19 del ERBB2 wild-type
EGFR over exp + ERBB2 wild type
ERBB2 wild-type no effect
ERBB2 P36S no effect - predicted
ERBB2 over exp PIK3CA N345T
EGFR amp ERBB2 over exp
ERBB2 over exp MET amp MET R988C
EGFR T790M ERBB2 over exp
ERBB2 over exp PIK3CA H1047R
ERBB2 over exp PIK3CA mut
ERBB2 over exp no effect HER inhibitor (Pan) HER2 (ERBB2) Antibody HER2 (ERBB2) Immune Cell Therapy HER2 (ERBB2) Vaccine HER2 Inhibitor
ERBB2 over exp KRAS G13D
ERBB2 over exp MET amp
BRAF V600E ERBB2 over exp KRAS A146V
ERBB2 over exp PIK3CA H1047L
ERBB2 over exp PIK3CA H1047R SRC over exp
ERBB2 G776delinsVC gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 D769Y gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 G778_S779insCPG gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 L915M unknown
ERBB2 S1002R unknown
ERBB2 E321G gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 G309E unknown
ERBB2 L663P no effect - predicted
ERBB2 L866M gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 D845A loss of function
ERBB2 E719G unknown
ERBB2 L785F unknown
ERBB2 N319D no effect
ERBB2 V750E loss of function - predicted
ERBB2 D769H unknown
ERBB2 E1021Q no effect - predicted
ERBB2 act mut gain of function HER inhibitor (Pan) HER2 Inhibitor
PIK3CA act mut ERBB2 act mut
ERBB2 act mut STK11 loss
ERBB2 A386D unknown
ERBB2 R897Q no effect - predicted
ERBB2 W906* loss of function - predicted
ERBB2 I101S no effect - predicted
ERBB2 T798I no effect - predicted
ERBB2 R647K no effect
ERBB2 E812K unknown
ERBB2 I654V gain of function - predicted HER inhibitor (Pan) HER2 Inhibitor
ERBB2 H878Y gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 S573L no effect - predicted
ERBB2 R784H unknown
ERBB2 T798M gain of function HER inhibitor (Pan) HER2 Inhibitor
ERBB2 R226S unknown HER inhibitor (Pan) HER2 Inhibitor
ERBB2 G309A unknown
ERBB2 P885S unknown
ERBB2 L786V unknown
ERBB2 V773M no effect - predicted
ERBB2 V839G unknown
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 E717K Advanced Solid Tumor sensitive XL647 Preclinical Actionable In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E717K in culture (PMID: 18413839). 18413839
ERBB2 E717K Advanced Solid Tumor decreased response Lapatinib Preclinical Actionable In a preclinical study, transformed cells over expressing ERBB2 (HER2) E717K demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839). 18413839
ERBB2 L755P Advanced Solid Tumor resistant AEE788 Preclinical Actionable In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755P demonstrated resistance when treated with AEE788 in culture (PMID: 22046346). 22046346
ERBB2 L755P non-small cell lung carcinoma no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 14.8 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) L755P (PMID: 29420467; NCT01953926). 29420467
ERBB2 L755P Advanced Solid Tumor sensitive WZ4002 Preclinical Actionable In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755P in culture (PMID: 22046346). 22046346
ERBB2 L755P Advanced Solid Tumor resistant Lapatinib Preclinical Actionable In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755P demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346). 22046346
ERBB2 L755P Advanced Solid Tumor sensitive EKI-285 Preclinical Actionable In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755P in culture (PMID: 22046346). 22046346
ERBB2 L726F Advanced Solid Tumor decreased response Lapatinib Preclinical Actionable In a preclinical study, transformed cells over expressing ERBB2 (HER2) L726F demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839). 18413839
ERBB2 L726F breast cancer resistant Lapatinib Preclinical Actionable In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L726F demonstrated resistance to Tykerb (lapatinib) in both culture and xenograft models (PMID: 25435280). 25435280
ERBB2 L726F Advanced Solid Tumor sensitive XL647 Preclinical - Cell culture Actionable In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L726F in culture (PMID: 18413839). 18413839
ERBB2 D821N Advanced Solid Tumor sensitive XL647 Preclinical Actionable In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) D821N in culture (PMID: 18413839). 18413839
ERBB2 G776delinsVV Advanced Solid Tumor sensitive Poziotinib Preclinical - Cell culture Actionable In a preclinical study, Poziotinib (HM781-36B) inhibited growth of a transformed cell line expressing ERBB2 (HER2) G776delinsVV in culture (PMID: 29686424). 29686424
ERBB2 R678Q endometrial cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 5.5 months in a patient with endometrial cancer harboring ERBB2 (HER2) R678Q (PMID: 29420467; NCT01953926). 29420467
ERBB2 R678Q gastroesophageal junction adenocarcinoma predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with gastroesophageal cancer harboring ERBB2 (HER2) R678Q (PMID: 29420467; NCT01953926). 29420467
ERBB2 R678Q breast cancer sensitive Neratinib Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) R678Q demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880). 23220880
ERBB2 R678Q colorectal cancer predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.6 months in a patient with colorectal cancer harboring ERBB2 (HER2) R678Q (PMID: 29420467; NCT01953926). 29420467
ERBB2 R678Q breast cancer sensitive Lapatinib Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 R678Q demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880). 23220880
ERBB2 T733I biliary tract cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.7 months in a patient with biliary tract cancer harboring ERBB2 (HER2) T733I (PMID: 29420467; NCT01953926). 29420467
ERBB2 T733I Advanced Solid Tumor resistant Lapatinib Preclinical Actionable In a preclinical study, transformed cells expressing ERBB2 (HER2) T733I demonstrated resistance to treatment with Tykerb (lapatinib) (PMID: 18413839). 18413839
ERBB2 T733I Advanced Solid Tumor sensitive XL647 Preclinical Actionable In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) T733I in culture (PMID: 18413839). 18413839
ERBB2 G660D lung cancer sensitive Afatinib Clinical Study Actionable In a clinical case study, Gilotrif (afatinib) treatment resulted in partial response in the lung lesion and stable bone metastasis for over 16 months in a patient with familial lung cancer harboring germline ERBB2 G660D mutation (PMID: 29146616). 29146616
ERBB2 G660D lung cancer sensitive Afatinib Preclinical Actionable In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G660D in culture (PMID: 26545934). 26545934
ERBB2 G660D lung cancer no benefit Gefitinib Preclinical Actionable In a preclinical study, bronchial epithelial cells cells expressing ERBB2 (HER2) G660D did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934). 26545934
ERBB2 S310F ERBB2 G660D ampulla of Vater carcinoma predicted - sensitive Afatinib Clinical Study Actionable In a clinical case study, Gilotrif (afatinib) treatment resulted in stable disease with slight lymph node metastasis reduction in a patient with ampulla of Vater carcinoma harboring ERBB2 S310F and G660D, but the disease eventually progressed after 4 months (PMID: 29146616). 29146616
ERBB2 V773A Advanced Solid Tumor sensitive AEE788 Preclinical Actionable In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V773A in culture (PMID: 22046346). 22046346
ERBB2 V773A Advanced Solid Tumor decreased response Lapatinib Preclinical Actionable In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V773A in culture (PMID: 22046346). 22046346
ERBB2 G776delinsLC lung cancer sensitive Afatinib Preclinical Actionable In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsLC in culture (PMID: 26545934). 26545934
ERBB2 G776delinsLC lung cancer no benefit Gefitinib Preclinical Actionable In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsLC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934). 26545934
ERBB2 L755S ERBB2 R1153* ERBB2 V777L urinary bladder cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patients with bladder cancer harboring ERBB2 (HER2) L755S, R1153*, and V777L (PMID: 29420467; NCT01953926). 29420467
ERBB2 exon 20 ins lung adenocarcinoma predicted - sensitive Afatinib Clinical Study Actionable In a clinical study, treatment with pulse Gilotrif (afatinib) resulted in an objective response rate of 33.3% (1/3) in lung adenocarcinoma patients with ERBB2 (HER2) exon 20 insertion mutations (PMID: 26964772). 26964772
ERBB2 exon 20 ins non-small cell lung carcinoma predicted - sensitive Afatinib Clinical Study Actionable In a clinical study, targeted therapy with Gilotrif (afatinib) or Herceptin (trastuzumab) resulted in an objective response rate of 44% (4/9) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies, all four responders harbored ERBB2 (HER2) exon 20 insertions (PMID: 28167203). 28167203
ERBB2 exon 20 ins non-small cell lung carcinoma predicted - sensitive Trastuzumab Clinical Study Actionable In a clinical study, targeted therapy with Gilotrif (afatinib) or Herceptin (trastuzumab) resulted in an objective response rate of 44% (4/9) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies, all four responders harbored ERBB2 (HER2) exon 20 insertions (PMID: 28167203). 28167203
ERBB2 exon 20 ins non-small cell lung carcinoma no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 10 and progressive disease in 5 of the 15 patients with non-small cell lung cancer harboring ERBB2 (HER2) exon 20 insertion mutations (PMID: 29420467; NCT01953926). 29420467
ERBB2 exon 20 ins Advanced Solid Tumor sensitive AP32788 Preclinical - Pdx & cell culture Actionable In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing ERBB2 (HER2) exon 20 insertions in culture, and induced tumor regression in PDX models (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644). detail...
ERBB2 exon 20 ins Her2-receptor negative breast cancer predicted - sensitive Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response in 1, partial response in 1, and stable disease in 3 of the 5 patients with Erbb2 (Her2)-receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) exon 20 insertion mutations (PMID: 29420467; NCT01953926). 29420467
ERBB2 D277H ERBB2 S310F urinary bladder cancer decreased response Selumetinib Preclinical Actionable In a preclinical study, bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884). 24971884
ERBB2 D277H ERBB2 S310F urinary bladder cancer sensitive Lapatinib Preclinical Actionable In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F in culture (PMID: 24971884). 24971884
ERBB2 D277H ERBB2 S310F urinary bladder cancer sensitive Afatinib Preclinical Actionable In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F in culture (PMID: 24971884). 24971884
ERBB2 G778A colorectal cancer predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with colorectal cancer harboring ERBB2 (HER2) G778A (PMID: 29420467; NCT01953926). 29420467
ERBB2 amp PTEN dec exp Her2-receptor positive breast cancer decreased response CDX-3379 Preclinical Actionable In a preclinical study, knockdown of PTEN expression resulted in a decreased response to treatment with CDX-3379 (KTN3379) in ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 26880266). 26880266
ROS1 fusion ERBB2 amp FGFR3 amp RET amp non-small cell lung carcinoma predicted - resistant Crizotinib Clinical Study Actionable In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of ERBB2 (HER2), FGFR3, and RET (PMID: 29636358). 29636358
ERBB2 amp urinary bladder cancer sensitive Afatinib Phase II Actionable In a Phase II clinical trial, patients with ERBB2 (HER2) amplified urothelial carcinoma had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931). 27044931
ERBB2 amp lung squamous cell carcinoma resistant Gefitinib Preclinical Actionable In a preclinical study, a lung squamous cell carcinoma cell line with ERBB2 (HER2) amplification demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 26545934). 26545934
ERBB2 amp breast cancer sensitive Pertuzumab + Trastuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of Herceptin (trastuzumab) and Perjeta (pertuzumab), resulting in a delay of brain lesion growth and improved survival (PMID: 28539475). 28539475
ERBB2 amp gastric adenocarcinoma sensitive Trastuzumab FDA approved Actionable In a Phase III trial (ToGA) that supported FDA approval, patients with either gastric or gastroesophageal junction adenocarcinoma with ERBB2 (HER2) overexpression or ERBB2 (HER2) amplification had increased overall survival (13.8 mo vs 11.1 mo) when treated with Herceptin (trastuzumab) in combination with chemotherapy compared to chemotherapy alone (PMID: 20728210; NCT01041404). 20728210
ERBB2 amp Her2-receptor positive breast cancer sensitive Lapatinib + S63845 Preclinical - Cell culture Actionable In a preclinical study, the combination of Tykerb (lapatinib) and S63845 demonstrated synergy in an ERBB2 (HER2)-amplified breast cancer cell line in culture, resulting in decreased cell viability (PMID: 28768804). 28768804
ERBB2 amp Her2-receptor positive breast cancer sensitive S63845 + Trastuzumab Preclinical - Pdx & cell culture Actionable In a preclinical study, S63845 and Herceptin (trastuzumab) demonstrated synergy in ERBB2 (HER2)-amplified breast cancer cells in culture and in ERBB2 (HER2)-amplified breast cancer patient-derived xenograft (PDX) models, resulting in enhanced tumor growth inhibition and overall survival compared to either agent alone (PMID: 28768804). 28768804
ERBB2 amp non-small cell lung carcinoma sensitive Afatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Gilotrif (afatinib) inhibited proliferation and induced cell-cycle arrest and apoptosis of non-small cell lung cancer (NSCLC) cell lines with ERBB2 (HER2) amplification in culture, and inhibited tumor growth in ERBB2 (HER2)-amplified NSCLC cell line xenograft models (PMID: 26545934). 26545934
ERBB2 amp breast cancer sensitive Dacomitinib Preclinical Actionable In a preclinical study, Vizimpro (dacomitinib) was more effective in preventing proliferation in ERBB2 (HER2) amplified breast cancer cells than in wild-type ERBB2 (HER2) breast cancer cells (PMID: 22761403). 22761403
ERBB2 amp Her2-receptor positive breast cancer predicted - sensitive KRIBB11 + MK2206 Preclinical - Cell culture Actionable In a preclinical study, MK-2206 and KRIBB11 synergistically inhibited growth of ERBB2 (HER2)-amplified breast cancer cell lines in culture (PMID: 28598816). 28598816
ERBB2 amp stomach cancer sensitive BMS-690514 Preclinical Actionable In a preclinical study, BMS-690514 inhibited tumor growth in a gastric cancer xenograft model with ERBB2 (HER2) amplification and overexpression (PMID: 21531814). 21531814
ERBB2 amp stomach cancer sensitive Trastuzumab + Lapatinib Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) treatment induced tumor regression in ERBB2 (HER2)-amplified cell line xenograft models of gastric cancer (PMID: 26296355). 26296355
ERBB2 amp scrotum Paget's disease predicted - sensitive trastuzumab emtansine Phase II Actionable In a Phase II (MATCH) trial, Kadcyla (trastuzumab emtansine) treatment resulted in partial response in a patient with ERBB2 (HER2) amplified Paget’s disease of the scrotum (J Clin Oncol 36, 2018 (suppl; abstr 100); NCT02465060). detail...
ERBB2 amp stomach cancer sensitive Trastuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, Herceptin (trastuzumab) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification (PMID: 26296355). 26296355
ERBB2 amp uterine corpus serous adenocarcinoma sensitive SYD985 Preclinical Actionable In a preclinical study, SYD895 induced cell death in ERBB2 (HER2)-amplified primary uterine serous carcinoma (USC) cell lines in culture and inhibited tumor growth and improved survival in ERBB2 (HER2)-amplified USC primary cell line xenografts (PMID: 27256376). 27256376
ERBB2 amp gastric adenocarcinoma no benefit Lapatinib Phase III Actionable In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in gastric adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478). 26628478
ERBB2 amp uterine corpus serous adenocarcinoma sensitive Taselisib Preclinical - Cell culture Actionable In a preclinical study, a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification demonstrated sensitivity to treatment with Taselisib (GDC-0032) in culture, resulting in inhibition of cell growth (PMID: 26333383). 26333383
ERBB2 amp esophagus adenocarcinoma no benefit Lapatinib Phase III Actionable In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in esophagus adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478). 26628478
ERBB2 amp colorectal cancer sensitive Trastuzumab + Lapatinib Preclinical - Pdx Actionable In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) treatment induced tumor regression in patient-derived colorectal cancer tumorgraft models harboring ERBB2 (HER2) amplification (PMID: 26296355). 26296355
ERBB2 amp breast cancer sensitive LJM716 + Trastuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of Herceptin (trastuzumab) and LJM716, resulting in a delay of brain lesion growth and improved survival (PMID: 28539475). 28539475
ERBB2 amp breast cancer sensitive Buparlisib Preclinical - Cell line xenograft Actionable In a preclinical study, a breast cancer cell line xenograft model harboring ERBB2 (HER2) amplification demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475). 28539475
ERBB2 amp Advanced Solid Tumor predicted - sensitive trastuzumab emtansine Phase II Actionable In a Phase II (MATCH) trial, Kadcyla (trastuzumab emtansine) treatment resulted in partial response in 8.1% (3/37) and stable disease in 43% (16/37) of patients with ERBB2 (HER2) amplified non-breast, non-gastric advanced solid tumors, with a 6-month progression-free survival rate of 24.8% (J Clin Oncol 36, 2018 (suppl; abstr 100); NCT02465060). detail...
ERBB2 amp breast cancer predicted - sensitive Temsirolimus + Neratinib Phase I Actionable In a Phase I clinical trial, Nerlynx (neratinib) administered with Torisel (temsirolimus) was tolerable and demonstrated antitumor activity in ERBB2 (HER2)-amplified breast cancer resistant to (Herceptin) trastuzumab (PMID: 24323026). 24323026
ERBB2 amp Her2-receptor positive breast cancer sensitive CDX-3379 Preclinical Actionable In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-amplified breast cancer (PMID: 26880266). 26880266
ERBB2 amp breast cancer sensitive Neratinib + Pertuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of Perjeta (pertuzumab) and Nerlynx (neratinib), resulting in a delay of brain lesion growth and improved survival (PMID: 28539475). 28539475
ERBB2 amp colorectal cancer resistant Cetuximab Clinical Study Actionable In a clinical study, ERBB2 (HER2) amplification was associated with resistance to Erbitux (cetuximab) in colorectal cancer patients (PMID: 21900593). 21900593
ERBB2 amp gastric adenocarcinoma predicted - sensitive Lapatinib + Oxaliplatin + Capecitabine Phase II Actionable In a Phase II trial, Tykerb (lapatinib), Xeloda (capecitabine), and Eloxatin (oxaliplatin) combination treatment resulted in a disease control rate of 81.3% (26/32, 7 complete response, 15 partial response, 4 stable disease) in patients with Erbb2 (Her2)-positive (defined as IHC3+ or IHC 2+ with ERBB2 amplification) gastric adenocarcinoma (PMID: 29409051; NCT02015169). 29409051
ERBB2 amp breast cancer sensitive Torkinib Preclinical - Cell culture Actionable In a preclinical study, ERBB2 (HER2) amplified breast cancer cells treated with Torkinib (PP242) demonstrated some efficacy in culture including reduced phosphorylation of S6 and Akt, apoptosis, and decreased cell growth (PMID: 27197158). 27197158
ERBB2 amp acral lentiginous melanoma sensitive trastuzumab emtansine Clinical Study Actionable In a clinical case study, Kadcyla (trastuzumab emtansine) treatment resulted in complete radiographic response that lasted over 28 months in a patient with acral melanoma harboring ERBB2 (HER2) amplification (26-fold) that was resistant to check-point inhibition (PMID: 30093446). 30093446
ERBB2 amp breast cancer sensitive Afatinib Preclinical Actionable In a preclinical study, Gilotrif (afatinib) inhibited proliferation of breast cancer cell lines with ERBB2 (HER2) amplification in culture (PMID: 26545934). 26545934
ERBB2 amp gastrointestinal system cancer sensitive Dacomitinib Preclinical Actionable In a preclinical study, Vizimpro (dacomitinib) demonstrated significant growth-inhibitory effects in HER2- amplified gastric cancer cells (PMID: 18606718). 18606718
ERBB2 amp uterine corpus serous adenocarcinoma sensitive Neratinib + Taselisib Preclinical - Cell culture Actionable In a preclinical study, the combination of Taselisib (GDC-0032) and Nerlynx (neratinib) resulted in a synergistic effect, demonstrating greater cell growth inhibitory activity in uterine serous carcinoma cells harboring ERBB2 (HER2) amplification compared to either agent alone (PMID: 26333383). 26333383
ERBB2 amp breast cancer sensitive CH5132799 Preclinical Actionable In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells with ERBB2 (HER2) amplification in culture (PMID: 21558396). 21558396
ERBB2 amp colorectal cancer sensitive Lapatinib + Pertuzumab Preclinical - Pdx Actionable In a preclinical study, the combination of Perjeta (pertuzumab) and Tykerb (lapatinib) induced tumor regression in patient-derived xenograft (PDX) models of colorectal cancer with ERBB2 (HER2) amplification (PMID: 22586653). 22586653
ERBB2 amp Her2-receptor positive breast cancer sensitive Palbociclib + Trastuzumab Preclinical Actionable In a preclinical study, the combination of Ibrance (palbociclib) and Herceptin (trastuzumab) worked synergistically to inhibit growth of ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 19874578). 19874578
ERBB2 amp duodenum adenocarcinoma sensitive Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin Clinical Study Actionable In a clinical case study, a patient with duodenal adenocarcinoma harboring ERBB2 (HER2) amplification demonstrated a complete pathologic response after treatment with a combination of Herceptin (trastuzumab), Adrucil (fluorouracil), Wellcovorin (leucovorin), and Eloxatin (oxaliplatin) (PMID: 28784859). 28784859
ERBB2 amp breast cancer sensitive LJM716 + Neratinib Preclinical - Cell line xenograft Actionable In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of LJM716 and Nerlynx (neratinib), resulting in a delay of brain lesion growth and improved survival (PMID: 28539475). 28539475
ERBB2 amp vulva squamous cell carcinoma sensitive Depatuxizumab mafodotin Preclinical - Cell line xenograft Actionable In a preclinical study, ABT-414 demonstrated cytoxicity against a EGFR-amplified vulvar epidermoid carcinoma cell line in culture and induced tumor regression in EGFR-amplified vulvar epidermoid carcinoma cell line xenograft models (PMID: 26846818). 26846818
ERBB2 amp colorectal cancer sensitive Cetuximab + Lapatinib Preclinical - Pdx Actionable In a preclinical study, the combination of Erbitux (cetuximab) and Tykerb (lapatinib) induced tumor regression in patient-derived xenograft (PDX) models of colorectal cancer with ERBB2 (HER2) amplification (PMID: 22586653). 22586653
ERBB2 amp colorectal adenocarcinoma sensitive trastuzumab emtansine Clinical Study Actionable In a clinical case study, a patient with metastatic colorectal adenocarcinoma harboring ERBB2 (HER2) amplification demonstrated clinical benefit with stable disease in the primary tumor for 7 months following treatment with Kadcyla (trastuzumab emtansine) (PMID: 28040715). 28040715
ERBB2 amp colorectal cancer decreased response Lapatinib Preclinical - Pdx Actionable In a preclinical study, treatment with Tykerb (lapatinib) resulted in initial disease stabilization with subsequent progression, in patient-derived colorectal cancer tumorgraft models with ERBB2 (HER2) amplification (PMID: 26296355). 26296355
ERBB2 amp colorectal cancer resistant Trastuzumab Preclinical Actionable In a preclinical study, colorectal cancer tumorgrafts with ERBB2 (HER2) amplification demonstrated resistance to Herceptin (trastuzumab) treatment in animal models (PMID: 26296355). 26296355
ERBB2 amp esophageal cancer sensitive Ibrutinib Preclinical - Cell culture Actionable In a preclinical study, esophageal cancer cells with ERBB2 (HER2) amplification demonstrated sensitivity to Imbruvica (ibrutinib), resulting in decreased survival in culture (PMID: 28830912). 28830912
ERBB2 amp colorectal cancer no benefit Pertuzumab Preclinical - Pdx Actionable In a preclinical study, Perjeta (pertuzumab) did not inhibit tumor growth in patient-derived xenograft (PDX) models of ERBB2 (HER2)-amplified colorectal cancer (PMID: 22586653). 22586653
ERBB2 amp breast cancer sensitive Lapatinib + Torkinib Preclinical - Cell culture Actionable In a preclinical study, the combination therapy of Tykerb (lapatinib) and Torkinib (PP242) in ERBB2 (HER2) amplified breast cancer cells in culture blocked cell growth, inhibited phosphorylation of Akt and S6, and led to greater caspase activity when compared to each agent alone (PMID: 27197158). 27197158
ERBB2 amp Her2-receptor positive breast cancer sensitive CDX-3379 + Trastuzumab Preclinical Actionable In a preclinical study, the combination of Herceptin (trastuzumab) and CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-amplified breast cancer, with increased efficacy compared to KTN3379 alone (PMID: 26880266). 26880266
ERBB2 amp stomach cancer sensitive Lapatinib Preclinical Actionable In preclinical studies, Tykerb (lapatinib) demonstrated antiproliferative activity in HER2-amplified gastric cancer in cell assays and in xenograft models (PMID: 20179222). 20179222
ERBB2 amp breast cancer sensitive Lapatinib + S63845 Preclinical - Cell culture Actionable In a preclinical study, the combination of S63845 and Tykerb (lapatinib) resulted in potent cytotoxic effects in ERBB2 (HER2)-amplified breast cancer cells in culture compared to the cytostatic effect of Tykerb (lapatinib) alone (PMID: 27760111). 27760111
ERBB2 amp stomach carcinoma no benefit FF-284 Preclinical - Cell line xenograft Actionable In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of ERBB2 (HER2) amplified gastric carcinoma (PMID: 26438159). 26438159
ERBB2 amp Her2-receptor positive breast cancer sensitive trastuzumab emtansine FDA approved Actionable In a Phase III trial (EMILIA) that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) improved median progression free survival (9.6 mo vs 6.4 mo) and overall survival (30.9 mo vs 25.1 mo) compared to Tykerb (lapatinib) combined with Xeloda (capecitabine) in patients with metastatic ERBB2 (HER2)-positive breast cancer (PMID: 24879797, PMID: 23020162; NCT00829166). 24879797 23020162
ERBB2 amp stomach cancer sensitive Poziotinib Preclinical Actionable In a preclinical study, Poziotinib suppressed cell growth, decreased phosphorylation of downstream signaling molecules, and induced apoptosis of human gastric cancer cells harboring ERBB2 (HER2) amplification (PMID: 21306821). 21306821
ERBB2 amp uterine corpus serous adenocarcinoma sensitive Neratinib Preclinical - Cell culture Actionable In a preclinical study, a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification demonstrated sensitivity to treatment with Nerlynx (neratinib) in culture, resulting in inhibition of cell growth (PMID: 26333383). 26333383
ERBB2 amp Her2-receptor positive breast cancer sensitive Trastuzumab Clinical Study Actionable In a meta-analysis, breast cancer patients with >12 copies of ERBB2 (HER2) had a better response to Herceptin (trastuzumab) than patients with 6-12 copies of ERBB2 (HER2) (PMID: 24691421). 24691421
ERBB2 amp breast cancer decreased response Lapatinib Preclinical - Cell culture Actionable In a preclinical study, ERBB2 (HER2) amplified breast cancer cells treated with Tykerb (lapatinib) demonstrated decreased phosphorylation of Erbb2 (her2) and Akt, however, after 4-8 hours, Akt-driven Rictor showed upregulation, thereby resulting in a decreased treatment response (PMID: 27197158). 27197158
ERBB2 amp Her2-receptor positive breast cancer predicted - sensitive BGB-283 Preclinical - Cell culture Actionable In a preclinical study, BGB-283 inhibited proliferation of ERBB2 (HER2) amplified breast cancer cells in culture (PMID: 26208524). 26208524
ERBB2 amp Advanced Solid Tumor sensitive Afatinib Phase II Actionable In a Phase II trial, Gilotrif (afatinib), demonstrated safety and efficacy in various advanced solid tumor patients with ERBB2 (HER2) amplification (PMID: 23775486). 23775486
ERBB2 amp gastroesophageal junction adenocarcinoma no benefit Lapatinib Phase III Actionable In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in gastroesophageal junction adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478). 26628478
ERBB2 amp parotid gland cancer predicted - sensitive trastuzumab emtansine Phase II Actionable In a Phase II (MATCH) trial, Kadcyla (trastuzumab emtansine) treatment resulted in partial response in a patient with ERBB2 (HER2) amplified salivary duct carcinoma of the parotid gland and a patient with ERBB2 (HER2) amplified squamous cell carcinoma of the parotid gland (J Clin Oncol 36, 2018 (suppl; abstr 100); NCT02465060). detail...
ERBB2 amp gastroesophageal junction adenocarcinoma sensitive Trastuzumab FDA approved Actionable In a Phase III trial (ToGA) that supported FDA approval, patients with either gastric cancer or gastroesophageal junction adenocarcinoma with ERBB2 (HER2) overexpression or ERBB2 (HER2) amplification had increased overall survival (13.8 mo vs 11.1 mo) when treated with Herceptin (trastuzumab) in combination with chemotherapy compared to chemotherapy alone (PMID: 20728210; NCT01041404). 20728210
FGFR2 wild-type ERBB2 amp stomach cancer resistant AZD4547 Preclinical Actionable In a preclinical study, gastric cancer cells with wild-type FGFR2 and ERBB2 (HER2) amplification were resistant to treatment with AZD4547 in culture (PMID: 22869148). 22869148
ERBB2 amp TP53 R158H gastric adenocarcinoma predicted - resistant AMG 337 Clinical Study Actionable In a clinical case study, a patient with gastric adenocarcinoma containing amplification of ERBB2 (HER2) and a TP53 R158H mutation progressed and developed metastases while being treated with AMG 337 (PMID: 26432108). 26432108
ERBB2 amp ERBB2 over exp stomach cancer sensitive Afatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Gilotrif (afatinib) induced tumor regression in a gastric cancer cell line xenograft model with HER2 (ERBB2) amplification and over expression (PMID: 23578997). 23578997
ERBB2 amp ERBB2 over exp stomach cancer sensitive trastuzumab emtansine Preclinical - Cell line xenograft Actionable In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification and over expression (PMID: 21458915). 21458915
ERBB2 amp PIK3CA N345K breast cancer sensitive CH5132799 Preclinical Actionable In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA N345K and ERBB2 (HER2) amplification in culture (PMID: 21558396). 21558396
ERBB2 amp PIK3CA E545K PIK3CA K567R Her2-receptor positive breast cancer sensitive Gedatolisib Preclinical - Cell line xenograft Actionable In a preclinical study, Gedatolisib (PKI-587) inhibited PI3K signaling, cell growth and induced apoptosis in human breast cancer cells harboring ERBB2 (HER2) amplification, PIK3CA E545K, and PIK3CA K567R in culture and in cell line xenografts (PMID: 21325073, PMID: 17314276). 17314276 21325073
ERBB2 amp FGFR2 amp esophagus adenocarcinoma sensitive AZD4547 + Lapatinib Preclinical - Cell culture Actionable In a preclinical study, the combination of AZD-4547 and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and FGFR2 amplification in culture (PMID: 27595477). 27595477
ERBB2 amp ERBB2 L866M colorectal cancer resistant Trastuzumab Preclinical Actionable In a preclinical study, Herceptin (trastuzumab) had no effect on tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863). 26243863
ERBB2 amp ERBB2 L866M colorectal cancer resistant Cetuximab Preclinical Actionable In a preclinical study, xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification were resistant to Erbitux (cetuximab) (PMID: 26243863). 26243863
ERBB2 amp ERBB2 L866M colorectal cancer sensitive Neratinib Preclinical Actionable In a preclinical study, Nerlynx (neratinib) treatment resulted in stable tumor size in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863). 26243863
ERBB2 amp ERBB2 L866M colorectal cancer sensitive Neratinib + Trastuzumab Preclinical Actionable In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in sustained tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863). 26243863
ERBB2 amp PIK3CA mut Her2-receptor positive breast cancer sensitive Copanlisib Preclinical - Cell line xenograft Actionable In a preclinical study, Aliqopa (copanlisib) promoted tumor regression in xenograft models of a human ERBB2 (HER2)-amplified breast cancer cell line harboring a PIK3CA activating mutation (PMID: 24170767). 24170767
ERBB2 amp PIK3CA mut breast cancer sensitive CUDC-907 Preclinical Actionable In a preclinical study, CUDC-907 inhibited downstream signaling and growth of PIK3CA-mutant breast cancer cells with ERBB2 amplification in culture (PMID: 22693356). 22693356
ERBB2 amp PIK3CA mut uterine corpus serous adenocarcinoma sensitive Neratinib + Taselisib Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of Nerlynx (neratinib) and Taselisib (GDC-0032), compared to either agent alone, resulted in greater inhibition of cell cycle activity in a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification and a PIK3CA mutation in culture, and in xenograft models, showed increased tumor growth inhibition and tumor regression (PMID: 26333383). 26333383
ERBB2 amp PIK3CA mut Her2-receptor positive breast cancer sensitive Ipatasertib Preclinical - Cell line xenograft Actionable In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cell line xenograft models harboring amplification of ERBB2 (HER2) and a PIK3CA mutation demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624). 24141624
EGFR amp ERBB2 amp urinary bladder cancer sensitive Afatinib Phase II Actionable In a Phase II clinical trial, two urothelial carcinoma patients with ERBB2 (HER2) and EGFR co-amplification had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931). 27044931
ERBB2 amp PIK3CA C420R breast cancer sensitive CH5132799 Preclinical Actionable In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA C420R and ERBB2 (HER2) amplification (PMID: 21558396). 21558396
ERBB2 amp PIK3CA H1047R breast cancer sensitive CH5132799 + Trastuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of CH5132799 and Herceptin (trastuzumab) inhibited tumor growth and overcame Herceptin (trastuzumab) insensitivity in xenograft models of a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification (PMID: 21558396). 21558396
ERBB2 amp PIK3CA H1047R ovarian cancer sensitive CH5132799 Preclinical - Cell line xenograft Actionable In a preclinical study, CH5132799 inhibited cell growth in a human ovarian cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396). 21558396
ERBB2 amp PIK3CA H1047R breast cancer sensitive Gedatolisib Preclinical Actionable In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring ERBB2 (HER2) amplification and PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276). 17314276 21325073
ERBB2 amp PIK3CA H1047R breast cancer sensitive CH5132799 Preclinical - Cell line xenograft Actionable In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396). 21558396
ERBB2 amp MET amp esophageal carcinoma resistant Lapatinib Preclinical Actionable In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Tykerb (lapatinib) in culture (PMID: 26432108). 26432108
ERBB2 amp MET amp gastric adenocarcinoma resistant AMG 337 Clinical Study Actionable In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to AMG 337 therapy (PMID: 26432108). 26432108
ERBB2 amp MET amp esophageal carcinoma resistant Crizotinib Preclinical - Cell culture Actionable In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was resistant to Xalkori (crizotinib) in culture (PMID: 26432108). 26432108
ERBB2 amp MET amp gastric adenocarcinoma resistant Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin Clinical Study Actionable In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to treatment with Herceptin (trastuzumab) and FOLFOX (PMID: 26432108). 26432108
ERBB2 amp MET amp esophagus adenocarcinoma sensitive Crizotinib + Lapatinib Preclinical - Cell culture Actionable In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and MET amplification in culture (PMID: 27595477). 27595477
ERBB2 amp MET amp esophageal carcinoma sensitive Crizotinib + Lapatinib Preclinical - Cell culture Actionable In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was sensitive to inhibition by Tykerb (lapatinib) and Xalkori (crizotinib) in culture (PMID: 26432108). 26432108
ERBB2 amp MET amp gastroesophageal junction adenocarcinoma sensitive Crizotinib + Lapatinib Preclinical - Cell culture Actionable In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) inhibited the growth of gastroesophageal adenocarcinoma cells with ERBB2 (HER2) and MET amplification in culture (PMID: 25350844). 25350844
ERBB2 amp MET amp gastric adenocarcinoma resistant Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab Clinical Study Actionable In a clinical case study, a patient with ERBB2 (HER2) amplified gastric adenocarcinoma progressed rapidly when treated with Herceptin (trastuzumab) with Xeloda (capecitabine), Eloxatin (oxaliplatin), and Avastin (bevacizumab), and reprofiling of the tumor revealed co-amplification of MET (PMID: 26432108). 26432108
ERBB2 amp MET amp gastric adenocarcinoma sensitive Crizotinib + Trastuzumab + Paclitaxel Clinical Study Actionable In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma had near complete regression of the disease after 2 months of treatment with Herceptin (trastuzumab), Xalkori (crizotinib) and weekly Taxol (paclitaxel) (PMID: 26432108). 26432108
ERBB2 amp ERBB2 L755S Her2-receptor positive breast cancer sensitive Neratinib Preclinical - Cell culture Actionable In a preclinical study, Nerlynx (neratinib) inhibited growth of ESR1-positive/ERBB2 (HER2)-positive breast cancer cell lines with ERBB2 amplification and harboring ERBB2 L755S in culture (PMID: 28487443). 28487443
ERBB2 amp ERBB2 L755S Her2-receptor positive breast cancer resistant Lapatinib Preclinical - Cell line xenograft Actionable In a preclinical study, ERBB2 (HER2) L755S was associated with reactivation of ERBB2 (HER2) signaling and acquired resistance to Tykerb (lapatinib) in ESR1-positive/ERBB2 (HER2)-positive breast cancer cell lines with ERBB2 amplification in culture and in xenograft models (PMID: 28487443). 28487443
ERBB2 amp ERBB2 L755S Her2-receptor positive breast cancer sensitive Afatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Gilotrif (afatinib) inhibited growth of ESR1-positive/ERBB2 (HER2)-positive breast cancer cell lines with ERBB2 amplification and harboring ERBB2 L755S in culture, and inhibited tumor growth in xenograft models (PMID: 28487443). 28487443
ERBB2 amp ERBB2 L755S Her2-receptor positive breast cancer resistant Pertuzumab + Trastuzumab Preclinical - Cell culture Actionable In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Perjeta (pertuzumab) plus Herceptin (trastuzumab) combination therapy in ESR1-positive/ERBB2 (HER2)-positive breast cancer cells with ERBB2 amplification in culture (PMID: 28487443). 28487443
ERBB2 amp ERBB2 L755S Her2-receptor positive breast cancer resistant Trastuzumab + Lapatinib Preclinical - Cell culture Actionable In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Tykerb (lapatinib) plus Herceptin (trastuzumab) combination therapy in ESR1-positive/ERBB2 (HER2)-positive breast cancer cells with ERBB2 amplification in culture (PMID: 28487443). 28487443
ERBB2 amp ERBB2 L755S Her2-receptor positive breast cancer decreased response trastuzumab emtansine Preclinical - Cell culture Actionable In a preclinical study, expression of ERBB2 (HER2) L755S resulted in decreased sensitivity to treatment with Kadcyla (trastuzumab emtansine) in ESR1-positive/ERBB2 (HER2)-positive breast cancer cells with ERBB2 amplification in culture (PMID: 28487443). 28487443
ERBB2 amp PIK3CA wild-type uterine corpus serous adenocarcinoma sensitive Neratinib + Taselisib Preclinical - Cell culture Actionable In a preclinical study, the combination of Taselisib (GDC-0032) and Nerlynx (neratinib) delayed cell cycle activity in a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture (PMID: 26333383). 26333383
ERBB2 amp PIK3CA wild-type uterine corpus serous adenocarcinoma sensitive Taselisib Preclinical - Cell line xenograft Actionable In a preclinical study, Taselisib (GDC-0032) did not result in delay of cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, however, did result in tumor growth inhibition in xenograft models (PMID: 26333383). 26333383
ERBB2 amp PIK3CA wild-type uterine corpus serous adenocarcinoma sensitive Neratinib Preclinical - Cell line xenograft Actionable In a preclinical study, Nerlynx (neratinib) delayed cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, and inhibited tumor growth in xenograft models (PMID: 26333383). 26333383
ERBB2 amp ERBB2 T798M breast cancer resistant Trastuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, a human ERBB2-amplified breast cancer cell line expressing ERBB2 (HER2) T798M was resistant to Herceptin (trastuzumab) in culture and in xenograft models (PMID: 23948973). 23948973
ROS1 fusion ERBB2 amp NOTCH1 amp SRC amp STK11 amp non-small cell lung carcinoma predicted - resistant Crizotinib Clinical Study Actionable In a clinical study, a non-small cell lung carcinoma patient harboring a ROS1 fusion treated with Xalkori (crizotinib) responded, but eventually progressed, and was subsequently found to harbor presumed resistance alterations, including amplification of SRC, ERBB2 (HER2), STK11, and NOTCH1 (PMID: 29636358). 29636358
ERBB2 amp PIK3CA E545K breast cancer sensitive Buparlisib Preclinical - Cell line xenograft Actionable In a preclinical study, a breast cancer cell line xenograft model co-harboring ERBB2 (HER2) amplification and PIK3CA E545K demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475). 28539475
ERBB2 amp PIK3CA E545K breast cancer sensitive CH5132799 Preclinical Actionable In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K and ERBB2 (HER2) amplification in culture (PMID: 21558396). 21558396
ERBB2 amp PIK3CA K111N breast cancer sensitive CH5132799 Preclinical - Cell line xenograft Actionable In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA K111N and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396). 21558396
ERBB2 amp SRC E527K gastroesophageal junction adenocarcinoma resistant Lapatinib Preclinical - Cell culture Actionable In a preclinical study, an ERBB2 (HER2)-amplified gastroesophageal cancer cell line initially sensitive to treatment with Tykerb (lapatinib) in culture developed resistance and was subsequently found to have acquired a secondary drug resistant mutation, SRC E527K (PMID: 25350844). 25350844
ERBB2 amp SRC E527K gastroesophageal junction adenocarcinoma sensitive Lapatinib + Saracatinib Preclinical - Cell culture Actionable In a preclinical study, the combination of Tykerb (lapatinib) and Saracatinib (AZD0530) inhibited growth of ERBB2 (HER2)-amplified gastroesophageal adenocarcinoma cells harboring SRC E527K in culture (PMID: 25350844). 25350844
ERBB2 P761del endometrial cancer predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with endometrial cancer harboring ERBB2 (HER2) P761del (PMID: 29420467; NCT01953926). 29420467
ERBB2 Y772_A775dup ERBB2 C805S Advanced Solid Tumor resistant Dacomitinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells co-expressing ERBB2 (HER2) C805S and ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) demonstrated resistance to Vizimpro (dacomitinib) in culture (PMID: 28363995). 28363995
ERBB2 Y772_A775dup ERBB2 C805S Advanced Solid Tumor resistant Afatinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells co-expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) and ERBB2 (HER2) C805S demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995). 28363995
ERBB2 Y772_A775dup ERBB2 C805S Advanced Solid Tumor resistant Neratinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells co-expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) and ERBB2 (HER2) C805S demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 28363995). 28363995
ERBB2 M774delinsWLV ERBB2 C805S Advanced Solid Tumor resistant Dacomitinib Preclinical - Cell culture Actionable In a preclinical study, acquisition of ERBB2 (HER2) C805S in transformed cells expressing ERBB2 (HER2) M774delinsWLV conferred resistance to Vizimpro (dacomitinib) in culture (PMID: 28363995). 28363995
ERBB2 M774delinsWLV ERBB2 C805S Advanced Solid Tumor resistant Afatinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells co-expressing ERBB2 (HER2) M774delinsWLV and ERBB2 (HER2) C805S demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995). 28363995
ERBB2 M774delinsWLV ERBB2 C805S Advanced Solid Tumor resistant Neratinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells co-expressing ERBB2 (HER2) M774delinsWLV and ERBB2 (HER2) C805S demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 28363995). 28363995
ERBB2 S310Y cervical cancer predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 0.5 month in a patient with cervical cancer harboring ERBB2 (HER2) S310Y (PMID: 29420467; NCT01953926). 29420467
ERBB2 S310Y urinary bladder cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 2 patients and progressive disease in 2 patients with bladder cancer harboring ERBB2 (HER2) S310Y (PMID: 29420467; NCT01953926). 29420467
ERBB2 S310Y colorectal cancer sensitive Neratinib + Trastuzumab Preclinical Actionable In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863). 26243863
ERBB2 S310Y colorectal cancer sensitive Lapatinib Preclinical Actionable In a preclinical study, Tykerb (lapatinib) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863). 26243863
ERBB2 S310Y endometrial cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 9.6 months in a patient with endometrial cancer harboring ERBB2 (HER2) S310Y (PMID: 29420467; NCT01953926). 29420467
ERBB2 S310Y colorectal cancer resistant Cetuximab Preclinical Actionable In a preclinical study, xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y were resistant to Erbitux (cetuximab) (PMID: 26243863). 26243863
ERBB2 S310Y gastroesophageal junction adenocarcinoma predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 0.8 month in a patient with gastroesophageal cancer harboring ERBB2 (HER2) S310Y (PMID: 29420467; NCT01953926). 29420467
ERBB2 S310Y colorectal cancer sensitive Trastuzumab + Lapatinib Preclinical Actionable In a preclinical study, Herceptin (trastuzumab) and Tykerb (lapatinib) combination treatment resulted in tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863). 26243863
ERBB2 S310Y colorectal cancer sensitive Neratinib Preclinical Actionable In a preclinical study, Nerlynx (neratinib) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863). 26243863
ERBB2 S310Y colorectal cancer sensitive Trastuzumab Preclinical Actionable In a preclinical study, Herceptin (trastuzumab) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863). 26243863
ERBB2 G776V Advanced Solid Tumor sensitive AP32788 Preclinical - Cell culture Actionable In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing ERBB2 (HER2) G776V in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644). detail...
ERBB2 V697L endometrial cancer predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.6 months in a patient with endometrial cancer harboring ERBB2 (HER2) V697L (PMID: 29420467; NCT01953926). 29420467
ERBB2 V697L Advanced Solid Tumor predicted - sensitive Neratinib Phase II Actionable In a Phase II trial, a patient with cancer of unknown primary involving the head and neck that harbored ERBB2 (HER2) V697L demonstrated a response to treatment with Nerlynx (neratinib) that lasted 13 months (PMID: 29247016). 29247016
ERBB2 V697L triple-receptor negative breast cancer sensitive Neratinib Phase II Actionable In a Phase II trial, a triple-negative breast cancer patient harboring ERBB2 V697L demonstrated a response to treatment with Nerlynx (neratinib) (PMID: 29247016). 29247016
CDH1 R63* ERBB2 L869Q breast cancer sensitive Lapatinib + Capecitabine Clinical Study Actionable In a clinical case study, treatment with the combination of Tykerb (lapatinib) and Xeloda (capecitabine) resulted in prolonged response and reduction in liver metastasis in a metastatic breast cancer patient harboring ERBB2 L869Q and CDH1 R63* mutations (PMID: 26487584). 26487584
ERBB2 S653C urinary bladder cancer sensitive Lapatinib Preclinical Actionable In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S653C in culture (PMID: 24971884). 24971884
ERBB2 S653C urinary bladder cancer decreased response Selumetinib Preclinical Actionable In a preclinical study, bladder cancer cells over expressing ERBB2 (HER2) S653C demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884). 24971884
ERBB2 S653C urinary bladder cancer sensitive Afatinib Preclinical Actionable In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S653C in culture (PMID: 24971884). 24971884
ERBB2 K753E breast cancer sensitive Neratinib Preclinical - Cell culture Actionable In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753 were sensitive to Nerlynx (neratinib) in culture, resulting in decreased colony formation (PMID: 27697991). 27697991
ERBB2 K753E breast cancer resistant Trastuzumab Preclinical - Cell culture Actionable In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753E were resistant to Herceptin (trastuzumab) in culture (PMID: 27697991). 27697991
ERBB2 K753E breast cancer resistant Lapatinib Preclinical - Cell culture Actionable In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753E were resistant to Tykerb (lapatinib) in culture (PMID: 27697991). 27697991
ERBB2 mutant non-small cell lung carcinoma predicted - sensitive Afatinib Clinical Study Actionable In a clinical study, treatment with Gilotrif (afatinib) resulted in an objective response rate of 33% (2/6) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies (PMID: 28167203). 28167203
ERBB2 mutant Her2-receptor negative breast cancer sensitive Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in an object response rate of 24% (6/25), a clinical benefit rate of 40% (10/25), and a median progression-free survival of 3.5 months in patients with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926). 29420467
ERBB2 mutant Her2-receptor positive breast cancer sensitive Neratinib Phase II Actionable In a Phase II trial, Nerlynx (neratinib) treatment resulted in complete response in 12.5% (3/24) and partial response in 20.8% (5/24) of ERBB2 (HER2) mutant but not amplified breast cancer patients (Cancer Res 2017;77(4 Suppl):Abstract nr PD2-08). detail...
ERBB2 mutant ovarian cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, no clinical benefit, and a median progression-free survival of 2.1 months in patients with ovarian cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926). 29420467
ERBB2 mutant non-small cell lung carcinoma sensitive Pyrotinib Phase II Actionable In a Phase II trial, Pyrotinib treatment in non-small cell lung cancer patients harboring an ERBB2 (HER2) mutation resulted in a partial response in 54.5% (6/11) of patients and stable disease in 27.3% (3/11) of patients, and a PFS of 6.2 months (Journal of Thoracic Oncology, Vol. 12, Issue 1, S359). detail...
ERBB2 mutant urinary bladder cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, a clinical benefit rate of 18.8% (3/16), and a median progression-free survival of 1.8 months in patients with bladder cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926). 29420467
ERBB2 mutant biliary tract cancer predicted - sensitive Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in an objective response rate at 8 weeks of 22.2% (2/9), a clinical benefit rate of 33.3% (3/9), and a median progression-free survival of 2.8 months in patients with biliary tract cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926). 29420467
ERBB2 mutant non-small cell lung carcinoma predicted - sensitive Trastuzumab Clinical Study Actionable In a clinical study, treatment with Herceptin (trastuzumab) in combination with chemotherapy resulted in an objective response rate of 67% (4/6) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies (PMID: 28167203). 28167203
ERBB2 mutant lung cancer sensitive Neratinib Phase I Actionable In a Phase I clinical trial, Nerlynx (neratinib) administered with Torisel (temsirolimus) was tolerable and demonstrated antitumor activity in ERBB2 (HER2)-mutant non-small-cell lung cancer (PMID: 24323026). 24323026
ERBB2 mutant gastroesophageal junction adenocarcinoma no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, a clinical benefit rate of 20% (1/5), and a median progression-free survival of 1.7 months in patients with gastroesophageal cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926). 29420467
ERBB2 mutant non-small cell lung carcinoma sensitive Neratinib Phase I Actionable In a Phase I study, Nerlynx (neratinib) administered with temsirolimus was tolerable and demonstrated antitumor activity in ERBB2-mutant non-small-cell lung cancer (PMID: 24323026). 24323026
ERBB2 mutant non-small cell lung carcinoma sensitive Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in an objective response rate of 3.8% (1/26), a clinical benefit rate of 42.3% (11/26), and a median progression-free survival of 5.5 months in patients with non-small cell lung cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926). 29420467
ERBB2 mutant non-small cell lung carcinoma sensitive AV-412 Preclinical Actionable In a preclinical study, non-small cell lung cancer cells harboring an ERBB2 (HER2) mutation demonstrated sensitivity to AV-412, resulting in decreased phosphorylation of Erbb2, Akt, and Erk (PMID: 19459856). 19459856
ERBB2 mutant invasive bladder transitional cell carcinoma predicted - sensitive Cisplatin + Gemcitabine + Sorafenib Phase II Actionable In a Phase II trial, ERBB2 (HER2) mutations were only detected in patients with muscle-invasive urothelial bladder cancer that responded to Nexavar (sorafenib), Platinol (cisplatin) and Gemzar (gemcitabine) combination therapy (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)). detail...
ERBB2 mutant non-small cell lung carcinoma sensitive trastuzumab emtansine Guideline Actionable Kadcyla (trastuzumab emtansine) is included in guidelines for non-small cell lung cancer patients with ERBB2 (HER2) mutations (NCCN.org). detail...
ERBB2 mutant lung adenocarcinoma sensitive Afatinib Phase II Actionable In a Phase II trial, treatment with Gilotrif (afatinib) resulted in objective response in 3 lung adenocarcinoma patients harboring ERBB2 (HER2) mutations (PMID: 22325357). 22325357
ERBB2 mutant breast cancer predicted - sensitive Neratinib Phase II Actionable In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, with treatment resulting in a clinical benefit rate of 31% (5/16; 1 complete response, 1 partial response, and 3 patients achieving stable disease for 24 weeks or more) and a median progression-free survival of 16 weeks (PMID: 28679771). 28679771
ERBB2 mutant cervical cancer predicted - sensitive Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in an objective response rate of 20% (1/5), a clinical benefit rate of 60% (3/5), and a median progression-free survival of 20.1 months in patients with cervical cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926). 29420467
ERBB2 mutant lung squamous cell carcinoma predicted - sensitive Afatinib Phase III Actionable In a Phase III trial (LUX-Lung 8), secondary analysis demonstrated favorable outcomes with Gilotrif (afatinib) treatment compared to Tarceva (erlotinib) in lung squamous cell carcinoma patients with ERBB (HER) family mutations, and ERBB2 (HER2) mutations predicted an OS (HR=0.06, p=0.02) and PFS (HR=0.06, p=0.02) benefit for Gilotrif (afatinib) over Tarceva (erlotinib) treatment (PMID: 29902295; NCT01523587). 29902295
ERBB2 mutant endometrial cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, a clinical benefit rate of 28.6% (2/7), and a median progression-free survival of 2.6 months in patients with endometrial cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926). 29420467
ERBB2 mutant colorectal cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in no objective response, a clinical benefit rate of 8.3% (1/12), and a median progression-free survival of 1.8 months in patients with colorectal cancer harboring ERBB2 (HER2) mutations (PMID: 29420467; NCT01953926). 29420467
ERBB2 V773L breast cancer sensitive Neratinib Preclinical - Cell culture Actionable In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Nerlynx (nerlatinib) in culture, resulting in decreased colony formation (PMID: 27697991). 27697991
ERBB2 V773L breast cancer sensitive Trastuzumab Preclinical - Cell culture Actionable In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Herceptin (trastuzumab) in culture, resulting in decreased colony formation (PMID: 27697991). 27697991
ERBB2 V773L breast cancer sensitive Lapatinib Preclinical - Cell culture Actionable In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Tykerb (lapatinib) in culture, resulting in decreased colony formation (PMID: 27697991). 27697991
ERBB2 G776_V777insYVMA Advanced Solid Tumor sensitive Canertinib Preclinical Actionable In a preclinical study, Canertinib inhibited Erbb2 (Her2) phosphorylation and cell growth in transformed human cell lines expressing ERBB2 (HER2) G776_V777insYVMA (PMID: 16843263). 16843263
ERBB2 K831N colorectal cancer predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with colorectal cancer harboring ERBB2 (HER2) K831N (PMID: 29420467; NCT01953926). 29420467
ERBB2 R896C breast cancer sensitive Neratinib Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) R896C reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880). 23220880
ERBB2 R896C breast cancer sensitive Trastuzumab Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 R896C reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880). 23220880
ERBB2 R896C breast cancer sensitive Lapatinib Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 R896C reverted to normal morphology in culture upon Tykerb (lapatinib) treatment (PMID: 23220880). 23220880
ERBB2 D769N cervical cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.5 months in a patient with cervical cancer harboring ERBB2 (HER2) D769N (PMID: 29420467; NCT01953926). 29420467
ERBB2 T862A Advanced Solid Tumor sensitive AEE788 Preclinical Actionable In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T862A in culture (PMID: 22046346). 22046346
ERBB2 T862A Advanced Solid Tumor decreased response Lapatinib Preclinical Actionable In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) N862A in culture (PMID: 22046346). 22046346
ERBB2 G778_P780dup Her2-receptor negative breast cancer predicted - sensitive Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 3.5 months in one patient, and stable disease with a progression-free survival of 20.0 months in another patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) G778_P780dup (PMID: 29420467; NCT01953926). 29420467
ERBB2 G778_P780dup Advanced Solid Tumor sensitive Poziotinib Preclinical - Cell culture Actionable In a preclinical study, Poziotinib (HM781-36B) inhibited growth of a transformed cell line expressing ERBB2 (HER2) G778_P780dup (reported P780insGSP) in culture (PMID: 29686424). 29686424
ERBB2 G778_P780dup Advanced Solid Tumor sensitive Dacomitinib Preclinical - Cell culture Actionable In a preclinical study, Vizimpro (dacomitinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 28363995). 28363995
ERBB2 G778_P780dup Advanced Solid Tumor sensitive Neratinib Preclinical - Cell culture Actionable In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 28363995). 28363995
ERBB2 G778_P780dup lung adenocarcinoma sensitive Dacomitinib Phase II Actionable In a Phase II trial, two lung adenocarcinoma patients harboring ERBB2 (HER2) P780_Y781insGSP (also referred to as G778_780dup) demonstrated partial response to treatment with Vizimpro (dacomitinib) (PMID: 25899785). 25899785
ERBB2 G778_P780dup non-small cell lung carcinoma no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival over 17 months in 2 patient with non-small cell lung cancer harboring ERBB2 (HER2) G778_P780dup (PMID: 29420467; NCT01953926). 29420467
ERBB2 G778_P780dup breast cancer resistant Lapatinib Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 P780_Y781insGSP demonstrated resistance when treated with Tykerb (lapatinib) (PMID: 23220880). 23220880
ERBB2 G778_P780dup breast cancer sensitive Neratinib Phase II Actionable In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), which included patients with ERBB2 G778_P780dup (1 complete response (referred to as V777_G778insGSP) and 1 patient with stable disease for more than 24 weeks (referred to as P780_Y781insGSP) (PMID: 28679771). 28679771
ERBB2 G778_P780dup breast cancer sensitive Neratinib Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) P780_Y781insGSP reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880). 23220880
ERBB2 G778_P780dup lung adenocarcinoma predicted - sensitive Afatinib Clinical Study Actionable In a clinical study, a patient with metastatic lung adenocarcinoma harboring ERBB2 (HER2) G778_P780dup (also referred to as V777_G778insGSP) demonstrated tumor shrinkage and clinical response for 7 months following treatment with Gilotrif (afatinib) (PMID: 28363995). 28363995
ERBB2 G778_P780dup lung adenocarcinoma predicted - sensitive Afatinib Clinical Study Actionable In a clinical study, a lung adenocarcinoma patient harboring ERBB2 (HER2) G778_P780dup (also referred to as V747_G748insGSP and G748_P750dup), demonstrated a 13% regression of target lesions and stable disease for 11 months following treatment with pulse Gilotrif (afatinib) (PMID: 26964772). 26964772
ERBB2 G778_P780dup lung cancer no benefit Gefitinib Preclinical Actionable In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934). 26545934
ERBB2 G778_P780dup breast cancer resistant Trastuzumab Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 P780_Y781insGSP demonstrated resistance when treated with Herceptin (trastuzumab) (PMID: 23220880). 23220880
ERBB2 G778_P780dup lung cancer sensitive Afatinib Preclinical Actionable In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 26545934). 26545934
ERBB2 A775_G776insYVMA Advanced Solid Tumor sensitive JQ1 + Osimertinib Preclinical Actionable In a preclinical study, transgenic mouse models expressing ERBB2 (HER2) A775_G776insYVMA demonstrated greater tumor regression when treated with the combination of JQ1 and Tagrisso (osimertinib) compared to treatment with either agent alone, which resulted in little to no regression (PMID: 29298799). 29298799
ERBB2 A775_G776insYVMA PIK3CA R425L non-small cell lung carcinoma predicted - resistant Trastuzumab Clinical Study Actionable In a clinical study, the PIK3CA R425L mutation was identified as a potential resistance mechanism in a non-small cell lung carcinoma patient harboring ERBB2 (HER2) A775_G776insYVMA, that progressed during Herceptin (trastuzumab) treatment (PMID: 28167203). 28167203
ERBB2 Y803N Advanced Solid Tumor decreased response Lapatinib Preclinical Actionable In a preclinical study, transformed cells over expressing ERBB2 (HER2) Y803N demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839). 18413839
ERBB2 Y803N Advanced Solid Tumor sensitive XL647 Preclinical Actionable In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) Y803N in culture (PMID: 18413839). 18413839
ERBB2 L869R breast cancer resistant Erlotinib Preclinical - Cell culture Actionable In a preclinical study, transformed breast cancer cells over expressing ERBB2 (HER2) L869R were resistant to Tarceva (erlotinib) in culture (PMID: 27900369). 27900369
ERBB2 L869R lung adenocarcinoma resistant Erlotinib Clinical Study Actionable In a clinical study, ERBB2 (HER2) L869R conferred resistant to ERBB2 (HER2)-directed therapy including Tarceva (erlotinib) and Tykerb (lapatinib) in a patient with lung adenocarcinoma (PMID: 27900369). 27900369
ERBB2 L869R Her2-receptor negative breast cancer predicted - sensitive Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 3.6 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L869R (PMID: 29420467; NCT01953926). 29420467
ERBB2 L869R breast cancer resistant Lapatinib Preclinical - Cell line xenograft Actionable In a preclinical study, transformed breast cancer cells over expressing ERBB2 (HER2) L869R were resistant to Tykerb (lapatinib) in culture, formed tumors and metastasized readily in xenograft animal models (PMID: 27900369). 27900369
ERBB2 L869R breast cancer sensitive Neratinib Phase II Actionable In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response, and 3 patients achieving stable disease for 24 weeks or more, which included a patient harboring ERBB2 (HER2) L869R (PMID: 28679771). 28679771
ERBB2 L869R breast cancer sensitive Neratinib Preclinical - Cell culture Actionable In a preclinical study, Nerlynx (neratinib) inhibited ERBB2 (HER2) phosphorylation and growth of transformed breast epithelial cells expressing ERBB2 (HER2) L869R in culture (PMID: 28274957). 28274957
ERBB2 L869R breast cancer sensitive Afatinib Preclinical - Cell culture Actionable In a preclinical study, Gilotrif (afatinib) inhibited ERBB2 (HER2) phosphorylation and growth of transformed breast epithelial cells expressing ERBB2 (HER2) L869R in culture (PMID: 28274957). 28274957
ERBB2 L869R lung adenocarcinoma resistant Lapatinib Clinical Study Actionable In a clinical study, ERBB2 (HER2) L869R conferred resistant to ERBB2 (HER2)-directed therapy including Tarceva (erlotinib) and Tykerb (lapatinib) in a patient with lung adenocarcinoma (PMID: 27900369). 27900369
ERBB2 G776_V777insVGC non-small cell lung carcinoma predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 1 patient and progressive disease in 2 patients with non-small cell lung cancer harboring ERBB2 (HER2) G776_V777insVGC (PMID: 29420467; NCT01953926). 29420467
ERBB2 M774delinsWLV Advanced Solid Tumor sensitive Dacomitinib Preclinical - Cell culture Actionable In a preclinical study, Vizimpro (dacomitinib) inhibited growth of transformed cells expressing ERBB2 (HER2) M774delinsWLV in culture (PMID: 28363995). 28363995
ERBB2 M774delinsWLV lung adenocarcinoma sensitive Dacomitinib Phase II Actionable In a Phase II trial, a lung adenocarcinoma patient harboring ERBB2 (HER2) M774delinsWLV demonstrated a partial response to treatment with Vizimpro (dacomitinib) (PMID: 25899785). 25899785
ERBB2 V842I colorectal cancer sensitive Afatinib Preclinical Actionable In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cell lines over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863). 26243863
ERBB2 V842I breast cancer sensitive Neratinib Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) V842I demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880). 23220880
ERBB2 V842I colorectal cancer conflicting Neratinib Preclinical Actionable In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cell lines over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863). 26243863
ERBB2 V842I colorectal cancer conflicting Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 2 patients and progressive disease in 1 patient with colorectal cancer harboring ERBB2 (HER2) V842I (PMID: 29420467; NCT01953926). 29420467
ERBB2 V842I breast cancer sensitive Trastuzumab Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 V842I reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880). 23220880
ERBB2 V842I endometrial cancer predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.8 months in a patient with endometrial cancer harboring ERBB2 (HER2) V842I (PMID: 29420467; NCT01953926). 29420467
ERBB2 V842I breast cancer sensitive Lapatinib Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 V842I demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880). 23220880
ERBB2 V842I colon cancer resistant Trastuzumab Preclinical Actionable In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V842I were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863). 26243863
ERBB2 V842I colon cancer sensitive Neratinib Preclinical Actionable In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863). 26243863
ERBB2 V842I colorectal cancer resistant Cetuximab Preclinical Actionable In a preclinical study, colorectal cancer cell lines over expressing ERBB2 (HER2) V842I were resistant to Erbitux (cetuximab) in culture (PMID: 26243863). 26243863
ERBB2 V842I colorectal cancer resistant Panitumumab Preclinical Actionable In a preclinical study, colorectal cancer cell lines over expressing ERBB2 (HER2) V842I were resistant to Vectibix (panitumumab) in culture (PMID: 26243863). 26243863
ERBB2 S310F ERBB2 V842I breast cancer predicted - sensitive Neratinib Phase II Actionable In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response, and 3 patients achieving stable disease for 24 weeks or more, which included a patient harboring ERBB2 (HER2) S310F and V842I (PMID: 28679771). 28679771
ERBB2 V777L ERBB2 V842I colorectal cancer predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.8 months in a patient with colorectal cancer harboring ERBB2 (HER2) V777L and V842I (PMID: 29420467; NCT01953926). 29420467
ERBB2 L768S breast cancer sensitive Lapatinib Preclinical - Cell culture Actionable In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Tykerb (lapatinib) in culture, resulting in decreased colony formation (PMID: 27697991). 27697991
ERBB2 L768S breast cancer sensitive Neratinib Preclinical - Cell culture Actionable In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Nerlynx (neratinib) in culture, resulting in decreased colony formation (PMID: 27697991). 27697991
ERBB2 L768S breast cancer sensitive Trastuzumab Preclinical - Cell culture Actionable In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Herceptin (trastuzumab) in culture, resulting in decreased colony formation (PMID: 27697991). 27697991
ERBB2 V659E lung cancer no benefit Gefitinib Preclinical Actionable In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) V659E did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934). 26545934
ERBB2 V659E lung cancer sensitive Afatinib Preclinical Actionable In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) V659E in culture (PMID: 26545934). 26545934
ERBB2 V659E non-small cell lung carcinoma no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in two patients with non-small cell lung cancer harboring ERBB2 (HER2) V659E (PMID: 29420467; NCT01953926). 29420467
ERBB2 V659E breast cancer sensitive 23814 + Tivozanib Preclinical Actionable In a preclinical study, the combination of 23814 and Tivozanib (AV-951) inhibited tumor growth in several transgenic mouse models of breast cancer expressing ERBB2 (HER2) V659E, including those with resistance to VEGFR inhibitors (PMID: 25995436). 25995436
ERBB2 V659E biliary tract cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 11.1 months in a patient with biliary tract cancer harboring ERBB2 (HER2) V659E (PMID: 29420467; NCT01953926). 29420467
ERBB2 neg Her2-receptor negative breast cancer predicted - sensitive Sorafenib + Vinorelbine Phase Ib/II Actionable In a Phase I/II trial, combination of Navelbine (vinorelbine) and Nexavar (sorafenib) resulted in a response rate of 30% (8/27), median progression free survival of 5.7 months, and a clinical benefit rate (absence of disease progression at 6 months) of 48% (13/27) in patients with ERBB2 (HER2)-negative metastatic breast cancer (PMID: 27992451). 27992451
ERBB2 neg Her2-receptor negative breast cancer no benefit Ramucirumab + Docetaxel Phase III Actionable In a Phase III trial, Cyramze (ramucirumab) in combination with Taxotere (docetaxel) did not improve clinical outcomes in ERBB2 (HER2)-negative breast cancer patients (PMID: 25185099). 25185099
ERBB2 neg Her2-receptor negative breast cancer predicted - sensitive Exemestane + Seribantumab Phase II Actionable In a Phase II trial, Seribantumab (MM-12) and Aromasin (exemestane) combination treatment resulted in a 74% decrease in risk of progression (HR 0.26) and a a 59% decrease in risk of death (HR 0.436) compared to exemestane alone in ERBB2-negative, hormone receptor positive breast cancer patients (AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer, May 2016, Abstract # A14). detail...
ERBB2 neg ERBB2 pos Her2-receptor negative breast cancer sensitive RO4929097 + Paclitaxel Preclinical Actionable In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of RO4929097 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone (PMID: 27556950). 27556950
ERBB2 neg ERBB2 pos Her2-receptor negative breast cancer sensitive LY411575 + Paclitaxel Preclinical Actionable In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of LY411575 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone (PMID: 27556950). 27556950
ERBB2 neg MET pos gastric adenocarcinoma no benefit Onartuzumab Phase III Actionable In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)). detail...
ERBB2 neg MET pos gastroesophageal junction adenocarcinoma no benefit AMG102 Phase III Actionable In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)). detail...
ERBB2 neg MET pos gastric adenocarcinoma no benefit Onartuzumab + mFOLFOX6 Phase III Actionable In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764). 27918764
ERBB2 neg MET pos gastroesophageal junction adenocarcinoma no benefit Onartuzumab Phase III Actionable In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)). detail...
ERBB2 neg MET pos gastric adenocarcinoma no benefit AMG102 Phase III Actionable In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)). detail...
ERBB2 neg MET pos esophagus adenocarcinoma no benefit Onartuzumab + mFOLFOX6 Phase III Actionable In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764). 27918764
ERBB2 L726I breast cancer resistant Gefitinib Preclinical Actionable In a preclinical study, an ERBB2 (HER2) L726I mutation was detected in a murine breast cancer cell line that acquired resistance to Iressa (gefitinib) in culture (PMID: 17638894). 17638894
ERBB2 L755_T759del breast cancer resistant Lapatinib Preclinical Actionable In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were resistant to treatment with Tykerb (lapatinib), resulting in decreased growth inhibition (PMID: 23220880). 23220880
ERBB2 L755_T759del breast cancer sensitive Gefitinib Preclinical Actionable In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were sensitive to treatment with Iressa (gefitinib) (PMID: 23220880). 23220880
ERBB2 L755_T759del breast cancer sensitive Neratinib Preclinical Actionable In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were sensitive to treatment with Nerlynx (neratinib) (PMID: 23220880). 23220880
EGFR over exp ERBB2 dec exp inflammatory breast carcinoma sensitive Sapitinib Preclinical - Pdx & cell culture Actionable In a preclinical study, Sapitinib (AZD8931) demonstrated antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erb2 (Her2) protein in culture and in xenograft models (PMID: 24886365). 24886365
EGFR over exp ERBB2 dec exp inflammatory breast carcinoma sensitive Sapitinib + Paclitaxel Preclinical - Pdx & cell culture Actionable In a preclinical study, combination of Sapatinib (AZD8931) and Taxol (paclitaxel) demonstrated enhanced antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erbb2 (Her2) protein in culture and in xenograft models (PMID: 24886365). 24886365
ERBB2 S783P Advanced Solid Tumor sensitive XL647 Preclinical Actionable In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) S783P in culture (PMID: 18413839). 18413839
ERBB2 S783P Advanced Solid Tumor resistant Lapatinib Preclinical Actionable In a preclinical study, transformed cells over expressing ERBB2 (HER2) S783P were resistant to Tykerb (lapatinib) in culture (PMID: 18413839). 18413839
ERBB2 D277G ERBB2 S310F urinary bladder cancer predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with bladder cancer harboring both ERBB2 (HER2) D277G and S310F (PMID: 29420467; NCT01953926). 29420467
ERBB2 L755S colorectal cancer sensitive Afatinib Preclinical Actionable In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863). 26243863
ERBB2 L755S colorectal cancer resistant Cetuximab Preclinical Actionable In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Erbitux (cetuximab) in culture (PMID: 26243863). 26243863
ERBB2 L755S colon cancer sensitive Neratinib Phase II Actionable In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response in a patient with ERBB2 (HER2) L755S, and 3 patients achieving stable disease for 24 weeks or more (PMID: 28679771). 28679771
ERBB2 L755S colon cancer sensitive Neratinib Preclinical Actionable In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863). 26243863
ERBB2 L755S Advanced Solid Tumor resistant Lapatinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing ERBB2 L755S demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346). 23220880 22046346
ERBB2 L755S biliary tract cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease in one and stable disease in another patient with biliary tract cancer harboring ERBB2 (HER2) L755S (PMID: 29420467; NCT01953926). 29420467
ERBB2 L755S breast cancer sensitive Neratinib Preclinical - Cell culture Actionable In a preclinical study, treatment with Nerlynx (neratinib) resulted in growth inhibition in transformed human breast cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 23220880). 23220880
ERBB2 L755S Advanced Solid Tumor resistant AEE788 Preclinical Actionable In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755S demonstrated resistance to AEE788 in culture, except at very high doses (PMID: 22046346). 22046346
ERBB2 L755S Her2-receptor positive breast cancer resistant Lapatinib Preclinical - Cell culture Actionable In a preclinical study, expression of ERBB2 (HER2) L755S conferred resistance to Tykerb (lapatinib) in ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 28487443). 28487443
ERBB2 L755S Her2-receptor negative breast cancer predicted - sensitive Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response in 1 patient, partial response in 1 patient, stable disease in 2 patients, and progressive disease in 4 patients with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L755S (PMID: 29420467; NCT01953926). 29420467
ERBB2 L755S colorectal cancer resistant Panitumumab Preclinical Actionable In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Vectibix (panitumumab) in culture (PMID: 26243863). 26243863
ERBB2 L755S Advanced Solid Tumor sensitive WZ4002 Preclinical Actionable In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 22046346). 22046346
ERBB2 L755S Advanced Solid Tumor sensitive XL647 Preclinical Actionable In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L755S in culture (PMID: 18413839). 18413839
ERBB2 L755S non-small cell lung carcinoma predicted - sensitive Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 12.7 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) L755S (PMID: 29420467; NCT01953926). 29420467
ERBB2 L755S Advanced Solid Tumor sensitive EKI-285 Preclinical Actionable In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 22046346). 22046346
ERBB2 L755S colon cancer sensitive Trastuzumab Preclinical Actionable In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863). 26243863
ERBB2 L755S colorectal cancer sensitive Neratinib Preclinical Actionable In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863). 26243863
APC Q1429fs BRAF N581S ERBB2 L755S rectum adenocarcinoma no benefit Fluorouracil + Leucovorin + Trastuzumab Clinical Study Actionable In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067). 27626067
ERBB2 Y772_A775dup non-small cell lung carcinoma predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 5 patients and progressive disease in 4 patients with non-small cell lung cancer harboring ERBB2 (HER2) Y772_A775dup (PMID: 29420467; NCT01953926). 29420467
ERBB2 Y772_A775dup lung adenocarcinoma conflicting Afatinib Clinical Study Actionable In a clinical study, a lung adenocarcinoma patient harboring ERBB2 Y772_A775dup (also referred to as A775_G776insYVMA and E740_A741insAYVM) achieved a partial response for 5 months following treatment with pulse Gilotrif (afatinib), however, a second patient harboring ERBB2 Y772_A775dup treated with pulse Gilotrif (afatinib) demonstrated progressive disease (PMID: 26964772). 26964772
ERBB2 Y772_A775dup lung cancer no benefit Gefitinib Preclinical Actionable In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934). 26545934
ERBB2 Y772_A775dup urinary bladder cancer predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patients with bladder cancer harboring ERBB2 (HER2) Y722_A775dup (PMID: 29420467; NCT01953926). 29420467
ERBB2 Y772_A775dup Her2-receptor negative breast cancer predicted - sensitive Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response in one patient, and stable disease in 2 patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) Y772_A775dup (PMID: 29420467; NCT01953926). 29420467
ERBB2 Y772_A775dup Advanced Solid Tumor sensitive Neratinib Preclinical - Cell culture Actionable In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as ERBB2 A775_G776insYVMA) in culture (PMID: 28363995). 28363995
ERBB2 Y772_A775dup Advanced Solid Tumor sensitive Poziotinib Preclinical - Cell culture Actionable In a preclinical study, Poziotinib (HM781-36B) inhibited ERBB2 (HER2) phosphorylation and growth of a transformed cell line expressing (HER2) Y772_A775dup (reported as A775_G776insYVMA) in culture (PMID: 29686424). 29686424
ERBB2 Y772_A775dup lung cancer sensitive Afatinib Preclinical Actionable In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) in culture (PMID: 26545934). 26545934
ERBB2 Y772_A775dup lung cancer sensitive Poziotinib Preclinical Actionable In a preclinical study, Poziotinib (HM781-36B) induced regression of lung tumors in mouse models harboring ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA), with no signs of progression at 12 weeks (PMID: 29686424). 29686424
ERBB2 P780L Advanced Solid Tumor resistant Lapatinib Preclinical Actionable In a preclinical study, transformed cells expressing ERBB2 (HER2) P780L demonstrated resistance to treatment with Tykerb (lapatinib) (PMID: 18413839). 18413839
ERBB2 P780L Advanced Solid Tumor sensitive XL647 Preclinical Actionable In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) P780L in culture (PMID: 18413839). 18413839
ERBB2 L841V colorectal cancer predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.8 months in a patient with colorectal cancer harboring ERBB2 (HER2) L841V (PMID: 29420467; NCT01953926). 29420467
ERBB2 L841V Her2-receptor negative breast cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 2.8 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L841V (PMID: 29420467; NCT01953926). 29420467
ERBB2 S310F endometrial cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 2.6 months in a patient with endometrial cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926). 29420467
ERBB2 S310F colorectal cancer sensitive Afatinib Preclinical Actionable In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863). 26243863
ERBB2 S310F urinary bladder cancer sensitive Afatinib Preclinical Actionable In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 24971884). 24971884
ERBB2 S310F colorectal cancer resistant Cetuximab Preclinical Actionable In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) S310F were resistant to Erbitux (cetuximab) in culture (PMID: 26243863). 26243863
ERBB2 S310F biliary tract cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response in one and progressive disease in another patient with biliary tract cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926). 29420467
ERBB2 S310F urinary bladder cancer sensitive Lapatinib Preclinical Actionable In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 24971884). 24971884
ERBB2 S310F cervical cancer predicted - sensitive Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response in 1 patient, stable disease in 1 patient, and progressive disease in 1 patient with cervical cancer harboring ERBB2 (HER2) D769N (PMID: 29420467; NCT01953926). 29420467
ERBB2 S310F Advanced Solid Tumor sensitive Lapatinib Preclinical Actionable In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cells expressing ERBB2 S310F in culture (PMID: 22908275). 22908275
ERBB2 S310F Her2-receptor negative breast cancer predicted - sensitive Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response with a progression-free survival of 14.6 months in one patient, and stable disease with a progression-free survival of 3.7 months in another patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926). 29420467
ERBB2 S310F gastroesophageal junction adenocarcinoma no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.9 months in a patient with gastroesophageal cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926). 29420467
ERBB2 S310F Advanced Solid Tumor sensitive Neratinib Preclinical Actionable In a preclinical study, Nerlynx (neratinib) decreased cell survival of transformed human cells expressing ERBB2 (HER2) S310F (PMID: 22908275). 22908275
ERBB2 S310F colon cancer sensitive Neratinib Preclinical Actionable In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863). 26243863
ERBB2 S310F colorectal cancer conflicting Neratinib Preclinical Actionable In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863). 26243863
ERBB2 S310F colorectal cancer conflicting Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with colorectal cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926). 29420467
ERBB2 S310F urinary bladder cancer decreased response Selumetinib Preclinical Actionable In a preclinical study, bladder cancer cells over expressing ERBB2 (HER2) S310F demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884). 24971884
ERBB2 S310F urinary bladder cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 4 patients and progressive disease in 1 patient with bladder cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926). 29420467
ERBB2 S310F colorectal cancer resistant Panitumumab Preclinical Actionable In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) S310F were resistant to Vectibix (panitumumab) in culture (PMID: 26243863). 26243863
ERBB2 S310F non-small cell lung carcinoma predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) S310F (PMID: 29420467; NCT01953926). 29420467
ERBB2 S310F colon cancer sensitive Trastuzumab Preclinical Actionable In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863). 26243863
ERBB2 V777L breast cancer sensitive Lapatinib Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880). 23220880
ERBB2 V777L colorectal cancer sensitive Afatinib Preclinical Actionable In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture (PMID: 26243863). 26243863
ERBB2 V777L endometrial cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 6.9 months in a patient with endometrial cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926). 29420467
ERBB2 V777L colorectal cancer resistant Panitumumab Preclinical Actionable In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Vectibix (panitumumab) in culture (PMID: 26243863). 26243863
ERBB2 V777L Advanced Solid Tumor sensitive Lapatinib Preclinical Actionable In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V777L in culture (PMID: 22046346). 22046346
ERBB2 V777L colorectal cancer conflicting Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.4 months in a patient with colorectal cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926). 29420467
ERBB2 V777L colorectal cancer conflicting Neratinib Preclinical - Cell line xenograft Actionable In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture and suppressed tumor growth in cell line xenograft models (PMID: 26243863). 26243863
ERBB2 V777L urinary bladder cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 6.9 months in a patients with bladder cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926). 29420467
ERBB2 V777L colorectal cancer sensitive Neratinib + Trastuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture and suppressed tumor growth in cell line xenograft models (PMID: 26243863). 26243863
ERBB2 V777L Advanced Solid Tumor sensitive AEE788 Preclinical Actionable In a preclinical study, transformed cell lines expressing ERBB2 (HER2) V777L demonstrated growth inhibition when treated with AEE788 in culture (PMID: 22046346). 22046346
ERBB2 V777L biliary tract cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 3.6 months in one patient, and progressive disease with a progression-free survival of 0.8 months in another patient with biliary tract cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926). 29420467
ERBB2 V777L breast cancer sensitive Neratinib Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) V777L demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880). 23220880
ERBB2 V777L breast cancer sensitive Trastuzumab Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880). 23220880
ERBB2 V777L colon cancer sensitive Neratinib Preclinical Actionable In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L in culture (PMID: 26243863). 26243863
ERBB2 V777L gastroesophageal junction adenocarcinoma predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.1 months in a patient with gastroesophageal cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926). 29420467
ERBB2 V777L colorectal cancer resistant Cetuximab Preclinical - Pdx Actionable In a preclinical study, human colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Erbitux (cetuximab) in culture and in patient-derived xenograft models (PMID: 26243863). 26243863
ERBB2 V777L Her2-receptor negative breast cancer predicted - sensitive Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response in one patient, and progressive disease in 4 patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) V777L (PMID: 29420467; NCT01953926). 29420467
ERBB2 V777L colon cancer resistant Trastuzumab Preclinical Actionable In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863). 26243863
ERBB2 G292R urinary bladder cancer predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patient with bladder cancer harboring both ERBB2 (HER2) G292R (PMID: 29420467; NCT01953926). 29420467
ERBB2 N857S Advanced Solid Tumor sensitive AEE788 Preclinical Actionable In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2(HER2) N857S in culture (PMID: 22046346). 22046346
ERBB2 N857S Advanced Solid Tumor decreased response Lapatinib Preclinical Actionable In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) N857S in culture (PMID: 22046346). 22046346
ERBB2 L755_E757delinsS Her2-receptor negative breast cancer predicted - sensitive Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in partial response with a progression-free survival of 9.0 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) L755_E757delinsS (PMID: 29420467; NCT01953926). 29420467
ERBB2 L755A non-small cell lung carcinoma no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.6 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) L755A (PMID: 29420467; NCT01953926). 29420467
ERBB2 pos PIK3CA C420R Her2-receptor positive breast cancer sensitive trastuzumab emtansine Preclinical - Cell culture Actionable In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA C420R in culture (PMID: 26920887). 26920887
ERBB2 positive breast carcinoma sensitive SYD985 Preclinical - Pdx & cell culture Actionable In a preclinical study, SYD985 decreased survival of ERBB2 (HER2)-positive breast carcinoma cell lines in culture, and inhibited tumor growth and induced tumor remission in cell line and patient-derived xenograft models of ERBB2 (HER2)-positive breast carcinoma, including models with low ERBB2 (HER2) expression (PMID: 25589493). 25589493
ERBB2 positive Her2-receptor positive breast cancer sensitive BKM120 + Trastuzumab Phase I Actionable In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated in patients with ERBB2 (HER2)-positive advanced or metastatic breast cancer that had progressed on Herceptin (trastuzumab) (PMID: 24470511). 24470511
ERBB2 positive breast cancer sensitive MI130004 Preclinical - Cell line xenograft Actionable In a preclinical study, MI130004 inhibited proliferation of ERBB2 (HER2)-receptor positive breast cancer cells in culture, and led to decreased tumor volume and improved survival in cell line xenograft models (PMID: 29440297). 29440297
ERBB2 positive Her2-receptor positive breast cancer sensitive MYL-1401O + Paclitaxel Phase III Actionable In a Phase III trial, MYL-1401O demonstrated safety and efficacy comparable to Herceptin (trastuzumab) when given in combination with Taxol (paclitaxel), resulted in an objective response rate of 69.6% in ERBB2 (HER2)-positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr LBA503)). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Capecitabine + Neratinib Phase II Actionable In a Phase II trial, Nerlynx (neratinib) and Xeloda (capecitabine) combination therapy resulted in an overall 12-month survival rate of 63% (23/37) in patients with Erbb2 (Her2)-positive breast cancer brain metastases (J Clin Oncol 35, 2017 (suppl; abstr 1005)). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Entinostat + Lapatinib + Trastuzumab Phase I Actionable In a Phase I trial, combination treatment consisted of Entinostat, Tykerb (lapatinib) and Herceptin (trastuzumab) resulted in complete response in 9% (2/22), partial response in 14% (3/22), and stable disease in 27% (6/22) of ERBB2 (HER2) positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 609)). detail...
ERBB2 positive Advanced Solid Tumor predicted - sensitive S-222611 Phase I Actionable In a Phase I clinical trial, S-222611 demonstrated safety and some efficacy in patients with advanced solid tumors expressing EGFR or ERBB2 (HER2), with an overall clinical benefit rate of 27% (7/33) (PMID: 25434923). detail... 25434923
ERBB2 positive breast cancer predicted - sensitive SYD985 Phase I Actionable In a Phase I trial, SYD985 treatment resulted in an overall response of 33% (33/99) and a median progression-free survival of 9.4 months in patients with ERBB2 (HER2)-positive (50) or ERBB2 (HER2)-low (49) metastatic breast cancer (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 1014-1014; NCT02277717). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive CT-P6 Phase III Actionable In a Phase III trial, CT-P6 demonstrated equivalence to reference Herceptin (trastuzumab) in patients with ERBB2 (HER2)-positive breast cancer, with 46.8% (116/248) of patients treated with CT-P6 achieving pathologic complete response compared to 50.4% (129/256) with Herceptin (trastuzumab) treatment (PMID: 28592386). 28592386
ERBB2 positive Her2-receptor positive breast cancer sensitive CDX-3379 Preclinical Actionable In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-positive breast cancer (PMID: 26880266). 26880266
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive Capecitabine + Trastuzumab + Tucatinib Phase Ib/II Actionable In a Phase Ib trial, the combination of Tucatinib (ARRY-380), Herceptin (trastuzumab), and Capecitabine demonstrated clinical activity in CNS metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 50% (1/2) of evaluable patients achieving CNS partial response and 50% (1/2) achieving CNS stable disease (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19). detail...
ERBB2 positive stomach carcinoma sensitive Tucatinib Preclinical - Cell culture Actionable In a preclinical study, Tucatinib (ARRY-380) inhibited tumor growth in a ERBB2 (HER2)-positive gastric carcinoma cell line xenograft model (Cancer Res April 15, 2012 72:852). detail...
ERBB2 positive inflammatory breast carcinoma predicted - sensitive Afatinib Phase II Actionable In a Phase II clinical trial, treatment with Gilotrif (afatinib) resulted in a clinical benefit rate of 35% (9/26) in patients with ERBB2 (HER2)-positive inflammatory breast cancer, with 8 confirmed partial responses and 1 patient achieving stable disease for greater than 6 months (PMID: 27923043). 27923043
ERBB2 positive glioblastoma multiforme sensitive HER2 CAR-T cells Phase I Actionable In a Phase I trial, glioblastoma patients positive for ERBB2 (HER2) demonstrated antitumor activity when treated with ERBB2 (HER2)-CAR-T cell therapy including one patient with a partial response and seven patients with stable disease ranging from 8 weeks to 29 months (PMID: 28426845). 28426845
ERBB2 positive Advanced Solid Tumor predicted - sensitive ZW25 Phase I Actionable In a Phase I trial, ZW25 treatment resulted in partial response in 14% (2/14) and stable disease in 21% (3/14) of patients with ERBB2 (HER2)-positive tumors, including breast, gastric, esophageal, colorectal, and adnexal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123). detail...
ERBB2 positive ovarian cancer sensitive PRS-343 Preclinical - Cell line xenograft Actionable In a preclinical study, PRS-343 induced localized immune activation in cell line xenograft models of Erbb2 (Her2)-positive ovarian cancer, resulted in significant tumor growth inhibition (Eur J Cancer, Dec 2016, 69 (Suppl. 1): S99, abstract 301). detail...
ERBB2 positive breast cancer sensitive Tucatinib + Trastuzumab emtansine Phase Ib/II Actionable In a Phase Ib/II trial, ERBB2 (HER2)-positive breast cancer patients demonstrated an objective response rate of 47% (16/34), including one complete response and fifteen partial responses, and a progression-free survival of 8.2 months when treated with a combination of Tucatinib (ARRY-380) and Kadcyla (trastuzumab emtansine) compared to 6.5 months with Herceptin (trastuzumab) and Perjeta (pertuzumab) treatment (PMID: 29955792; NCT01983501). 29955792
ERBB2 positive breast adenocarcinoma sensitive DS-8201a Preclinical - Cell culture Actionable In a preclinical study, DS-8201 inhibited growth of an ERBB2 (HER2)-positive breast adenocarcinoma cell line in culture (PMID: 27026201). 27026201
ERBB2 positive stomach cancer sensitive Lapatinib + Paclitaxel Phase III Actionable In a Phase III trial, second-line treatment using Tykerb (lapatinib) with paclitaxel demonstrated some efficacy in patients with HER2-positive advanced gastric cancer (PMID: 24868024). 24868024
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive ZW25 Phase I Actionable In a Phase I trial, ZW25 treatment resulted in partial response in 28.6% (2/7) and stable disease in 28.6% (2/7) of patients with ERBB2 (HER2)-positive breast cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123). detail...
ERBB2 positive stomach cancer sensitive MI130004 Preclinical - Cell line xenograft Actionable In a preclinical study, MI130004 inhibited proliferation of ERBB2 (HER2)-positive gastric cancer cells in culture, and led to decreased tumor volume and improved survival in cell line xenograft models (PMID: 29440297). 29440297
ERBB2 positive ductal carcinoma in situ predicted - sensitive HER2-pulsed DC1 vaccine Phase Ib/II Actionable In a Phase I/Ib clinical trial, vaccination with a HER2-peptide pulsed dendritic cell vaccine was well-tolerated and resulted in immune response in patients with ERBB2 (HER2)-positive ductal carcinoma in situ (DCIS), and resulted in pathologic complete response rate of 28% (12/42), compared to 8.3% (1/12) in patients with invasive breast cancer (PMID: 27965306). 27965306
ERBB2 positive pancreatic cancer sensitive DS-8201a Preclinical - Cell line xenograft Actionable In a preclinical study, DS-8201a inhibited tumor growth in a pancreatic cancer cell line xenograft model with low ERBB2 (HER2) expression (PMID: 27026201). 27026201
ERBB2 positive Her2-receptor positive breast cancer sensitive Pertuzumab + Trastuzumab Phase III Actionable In a Phase III trial, adjuvant Herceptin (trastuzumab), Perjeta (pertuzumab), plus chemotherapy resulted in improved invasive disease-free survival compared to Herceptin (trastuzumab) plus chemotherapy in patients with Erbb2 (Her2)-positive breast cancer (J Clin Oncol 35, 2017 (suppl; abstr LBA500)). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Trastuzumab + Docetaxel + Carboplatin Guideline Actionable Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) therapy is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer (NCCN.org). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Trastuzumab + Oxaliplatin Preclinical Actionable In a preclinical study, the combination of Herceptin (trastuzumab) and Eloxatin (oxaliplatin) resulted in growth inhibition of ERBB2 (HER2)-positive breast cancer cells in culture (PMID: 24300914). 24300914
ERBB2 positive salivary gland cancer predicted - sensitive DS-8201a Phase I Actionable In a Phase I trial, treatment with DS-8201a resulted in a partial response in 50% (2/4) of evaluable patients with salivary gland cancer and ERBB2 (HER2) expression (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 409P; NCT02564900). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive HER2 BATs Preclinical - Cell culture Actionable In a preclinical study, HER2 BATs demonstrated enhanced toxicity comparing to unarmed T-cells against Erbb2 (Her2)-positive breast cancer cells in culture (PMID: 11359672). 11359672
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive MGAH22 Phase I Actionable In a Phase I trial, Margetuximab (MGAH22) treatment resulted in tumor reduction in 78% (18/23) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 28119295). 28119295
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive HER2 Vaccine Phase II Actionable In Phase II clinical trials, ERBB2 (HER2) vaccines demonstrated safety and some efficacy in the adjuvant setting in ERBB2 (HER2)-positive breast cancer patients (PMID: 23585514). 23585514
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive Ibrutinib Preclinical - Cell line xenograft Actionable In a preclinical study, Imbruvica (ibrutinib) inhibited Her family receptor signaling, resulted in apoptosis and growth inhibition in ERBB2 (HER2)-positive breast cancer cell lines in culture and in cell line xenograft models (PMID: 27256378). 27256378
ERBB2 positive Advanced Solid Tumor predicted - sensitive DS-8201a Phase I Actionable In a Phase I trial, treatment with DS-8201a was well-tolerated and resulted in an overall response rate (ORR) of 38% (19/50) and disease control rate (DCR) of 90% (45/50) in patients with ERBB2 (HER2)-expressing solid tumors, and an ORR of 29% (4/14) and DCR of 93% (13/14) in patients with low ERBB2 (HER2) expression (J Clin Oncol 35, 2017 (suppl; abstr 108)). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive MM-302 Phase I Actionable In a Phase I study, MM-302 demonstrated safety in patients with ERBB2 (HER2) positive breast cancer (Cancer Res 2012;72(24 Suppl):Abstract nr P5-18-09) detail...
ERBB2 positive breast cancer sensitive ADCT-502 Preclinical - Pdx Actionable In a preclinical study, ADCT-502 demonstrated anti-tumor activity in ERBB2 (HER2)-expressing breast cancer cell line and patient-derived xenograft (PDX) models, including PDX models expressing low levels of ERBB2 (HER2) (Eur J Cancer, 2016, Vol. 69, Supp1, S28). detail...
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive ABP 980 Phase III Actionable In a Phase III trial, ABP 980 treatment demonstrated safety and efficacy similar to Herceptin (trastuzumab), with pathologic complete response rates of 48% and 40.5%, respectively, in patients with Erbb2 (Her2)-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 151PD; NCT01901146). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Neratinib Phase II Actionable In a Phase II clinical trial, Nerlynx (neratinib) demonstrated safety and efficacy as a monotherapy in patients with ERBB2 (HER2)-positive breast cancer (PMID: 23953056). 23953056
ERBB2 positive Her2-receptor positive breast cancer sensitive Neratinib FDA approved Actionable In a Phase III trial that supported FDA approval, ERBB2 (HER2)-positive breast cancer patients previously treated with Herceptin (trastuzumab) demonstrated a significantly greater two year invasive disease-free survival rate (93.9%) when treated with Nerlynx (neratinib) compared to the rate (91.6%) in those patients treated with placebo (PMID: 26874901; NCT00878709). 26874901
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive Trastuzumab + Tucatinib Phase Ib/II Actionable In a Phase Ib clinical trial, the combination of Tucatinib (ARRY-380) and Herceptin (trastuzumab) demonstrated clinical activity in central nervous system (CNS) metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 100% (3/3) patients achieving CNS stable disease as best response (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19). detail...
ERBB2 positive esophageal cancer predicted - sensitive ZW25 Phase I Actionable In a Phase I trial, ZW25 treatment resulted in stable disease in 20% (1/5) of patients with ERBB2 (HER2)-positive gastric or esophageal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #255P; NCT02892123). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Oxaliplatin + Trastuzumab + TS-1 Phase II Actionable In a Phase II clinical trial, the combination of TS-1 (S-1) and Herceptin (trastuzumab) demonstrated safety and efficacy in patients with ERBB2 (HER2)-positive metastatic breast cancer, with an overall response rate of 53.6% (15/28), and a clinical benefit rate of 75.0% (21/28) (PMID: 24982373). 24982373
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive Capecitabine + Tucatinib Phase Ib/II Actionable In a Phase Ib trial, the combination of Tucatinib (ARRY-380) with other agents demonstrated clinical activity in central nervous system (CNS) metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 1/1 evaluable patient treated with Tucatinib (ARRY-380) and Capecitabine achieving CNS partial response (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19). detail...
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive SB3 Phase III Actionable In a Phase III trial, SB3 treatment demonstrated safety, immunogenicity, and survival result similar to Herceptin (trastuzumab), resulted in event-free-survival rates of 92.2% and 91.6%, respectively, in patients with Erbb2 (Her2)-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 153PD; NCT02149524). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Trastuzumab + Lapatinib Clinical Study Actionable In a meta-analysis of six randomized clinical trials, Tykerb (lapatinib) and Herceptin (trastuzumab) combination treatment resulted in 13% absolute improvement in pathologic complete response rate in ERBB2 (HER2)-positive breast cancer patients compared to Herceptin (trastuzumab) single treatment (PMID: 27140927). 27140927
ERBB2 positive Her2-receptor positive breast cancer sensitive Trastuzumab + Lapatinib Phase II Actionable In a Phase II trial, Tykerb (lapatinib) and Herceptin (trastuzumab) combination treatment resulted in complete response in the breast in 10.6% (7/66) and minimal residual disease in 16.7% (11/66) of ERBB2-positive breast cancer patients 11 days after receiving the treatment (European Breast Cancer Conference; Mar 2016; Abstract #6LBA). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Docetaxel + T-DM1 + Pertuzumab Phase Ib/II Actionable In a Phase Ib/II trial, Kadcyla (trastuzumab emtansine), Taxotere (docetaxel) and Perjeta (pertuzumab) combination treatment resulted in pathologic complete response in 60.3% (44/73) of patients with ERBB2 (HER2)-positive locally advanced breast cancer (PMID: 27052654). 27052654
ERBB2 positive Her2-receptor positive breast cancer sensitive Lapatinib + Palbociclib Preclinical Actionable In a preclinical study, the combination of Tykerb (lapatinib) and Ibrance (palbociclib) worked additively to suppress growth of ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 25221644). 25221644
ERBB2 positive ovarian carcinoma sensitive SYD985 Preclinical - Cell culture Actionable In a preclinical study, SYD985 decreased survival of a ERBB2 (HER2)-positive ovarian carcinoma cell line in culture (PMID: 25589493). 25589493
ERBB2 positive stomach carcinoma sensitive SYD985 Preclinical - Cell culture Actionable In a preclinical study, SYD985 decreased survival of a ERBB2 (HER2)-positive gastric carcinoma cell line in culture (PMID: 25589493). 25589493
ERBB2 positive Her2-receptor positive breast cancer sensitive Neratinib + Paclitaxel Phase II Actionable In a Phase II trial, Nerlynx (neratinib) plus Taxol (paclitaxel) demonstrated similar efficacy to Herceptin (trastuzumab) plus Taxol (paclitaxel), with an median progression-free survival of 12.9 months, however, potentially decreased CNS metastasis risk, with an incidence of 8.3% (20/242) compared to 17.3% (41/237) in the Herceptin (trastuzumab) plus Taxol (paclitaxel) group (PMID: 27078022). 27078022
ERBB2 positive stomach cancer sensitive HER2 Vaccine Preclinical - Patient cell culture Actionable In a preclinical study, ERBB2 (HER2)-specific cytotoxic T-cell lines generated from gastric cancer patients demonstrated activity against autologous ERBB2 (HER2)-expressing gastric cancer cells in culture (PMID: 9754653). 9754653
ERBB2 positive Her2-receptor positive breast cancer sensitive Docetaxel + T-DM1 Phase Ib/II Actionable In a Phase Ib/II trial, Kadcyla (trastuzumab emtansine) and Taxotere (docetaxel) combination treatment resulted in median progression-free survival of 13.8 months and objective response in 80.0% (20/25) of patients with ERBB2 (HER2)-positive metastatic breast cancer (PMID: 27052654). 27052654
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive MEDI4276 Phase I Actionable In a Phase I trial, MEDI4276 treatment resulted in complete response in 1 patient with breast cancer, partial response in 1 patient with breast cancer, and stable disease in 12 patients with Erbb2 (Her2)-positive breast or gastric cancer (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 470; NCT02576548). detail...
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive Metformin Phase III Actionable In a Phase III trial, ERBB2 (HER2) positive breast cancer patients with diabetes demonstrated a greater disease free survival and overall survival when treated with Glucophage (metformin) compared to ERBB2 (HER2) positive breast cancer patients with diabetes not treated with Glucophage (metformin) (PMID: 28375706). 28375706
ERBB2 positive Advanced Solid Tumor predicted - sensitive AC480 Phase I Actionable In a Phase I clinical trial, AC480 (BMS-599626) treatment demonstrated preliminary clinical activity, resulting in stable disease as best response in 25% (11/44) of patients with advanced solid tumors, including patients expressing EGFR and/or ERBB2, with 2 patients achieving stable disease for greater than 6 months (PMID: 21576284). 21576284
ERBB2 positive gastroesophageal junction adenocarcinoma no benefit trastuzumab emtansine Phase III Actionable In a Phase III trial, Kadcyla (trastuzumab emtansine) did not demonstrated efficacy benefit over Taxol (paclitaxel) on median overall survival (7.9 vs 8.6 months) in patients with previously treated ERBB2 (HER2)-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (J Clin Oncol 34, 2016 (suppl 4S; abstr 5)). detail...
ERBB2 positive ovarian cancer sensitive MI130004 Preclinical - Cell line xenograft Actionable In a preclinical study, MI130004 inhibited proliferation of ERBB2 (HER2)-positive ovarian cancer cells in culture, and led to decreased tumor volume, reduced ERBB2 (HER2) expression, and improved survival in cell line xenograft models (PMID: 29440297). 29440297
ERBB2 positive Her2-receptor positive breast cancer sensitive Afatinib + Trastuzumab Phase I Actionable In a Phase I clinical trial, ERBB2 (HER2)-positive breast cancer patients treated with Gilotrif (afatinib), in combination with Herceptin (trastuzumab), demonstrated an overall objective response rate of 11% (2/18) while 28% (5/18) attained a best response of stable disease (PMID: 25370464). 25370464
ERBB2 positive Her2-receptor positive breast cancer sensitive Pertuzumab + Trastuzumab + Carboplatin + Docetaxel Guideline Actionable Taxotere (docetaxel), Paraplatin (carboplatin), and Herceptin (trastuzumab) plus Perjeta (pertuzumab) therapy, is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org). detail...
ERBB2 positive stomach cancer predicted - sensitive MEDI4276 Phase I Actionable In a Phase I trial, MEDI4276 treatment resulted in complete response in 1 patient with breast cancer, partial response in 1 patient with breast cancer, and stable disease in 12 patients with Erbb2 (Her2)-positive breast or gastric cancer (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 470; NCT02576548). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Copanlisib Preclinical Actionable In a preclinical study, breast cancer cell lines with a PIK3CA activating mutation and/or ERBB2 (HER2)-over expression demonstrated increased sensitivity to inhibition of proliferation by Aliqopa (copanlisib) in culture, compared to ERBB2 (HER2)-negative and wild-type PIK3CA cell lines (PMID: 24170767). 24170767
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive trastuzumab emtansine Phase III Actionable In a Phase III trial, Kadclya (trastuzumab emtansine) demonstrated improved median progression free survival and overall survival compared to Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment in patients with ERBB2 (HER2) positive breast cancer, regardless of the expression level of Erbb2 (Her2), Egfr, and Her3, or PIK3CA mutation status (PMID: 26920887). 26920887
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive trastuzumab emtansine FDA approved Actionable In a Phase III trial (EMILIA) that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) improved median progression free survival (9.6 mo vs 6.4 mo) and overall survival (30.9 mo vs 25.1 mo) compared to Tykerb (lapatinib) combined with Xeloda (capecitabine) in patients with metastatic ERBB2 (HER2)-positive breast cancer (PMID: 24879797, PMID: 23020162; NCT00829166). 23020162 24879797
ERBB2 positive stomach cancer predicted - sensitive MGAH22 Phase I Actionable In a Phase I trial, Margetuximab (MGAH22) treatment resulted in partial responses in 12% (7/60) and stable disease in 50% (30/60) of patients with ERBB2 (HER2)-positive breast or gastric cancer, or other carcinomas that overexpress Erbb2 (Her2) (PMID: 28119295). 28119295
ERBB2 positive Her2-receptor positive breast cancer sensitive Lapatinib + MK2206 Phase I Actionable In a Phase I trial, Tykerb (lapatinib) and MK2206 combination treatment resulted in stable disease for more than 6 months in 40% (2/5) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 27026198). 27026198
ERBB2 positive Her2-receptor positive breast cancer sensitive Pertuzumab + Trastuzumab + Paclitaxel Guideline Actionable Perjeta (pertuzumab), Herceptin (trastuzumab), and Taxol (paclitaxel) therapy is included in the guidelines as systemic therapy for patients with recurrent or metastatic hormone receptor-negative, ERBB2 (HER2) receptor-positive breast cancer (NCCN.org). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Entinostat + Lapatinib Phase I Actionable In a Phase I trial, Entinostat and Tykerb (lapatinib) combination treatment resulted in complete response in 7% (1/15) and stable disease in 27% (4/15) of ERBB2 (HER2) positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 609)). detail...
ERBB2 positive breast cancer sensitive Withacnistin Preclinical Actionable In a preclinical study, withacnistin induced tumor regression in transgenic mouse models of Erbb2 (Her2)-driven breast cancer (PMID: 24983364). 24983364
ERBB2 positive Her2-receptor positive breast cancer sensitive Hertuzumab-vc-MMAE Preclinical - Cell culture Actionable In a preclinical study, Hertuzumab-vc-MMAE decreased viability of ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 27509865). 27509865
ERBB2 positive colorectal cancer no benefit ZW25 Phase I Actionable In a Phase I trial, ZW25 treatment resulted in disease progression in a patient with ERBB2 (HER2)-positive colorectal cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123). detail...
ERBB2 positive stomach cancer sensitive ARX-788 Preclinical - Cell line xenograft Actionable In a preclinical study, ERBB2 (HER2)-positive ovarian xenograft model was sensitive to treatment with ARX-788, resulting in tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639). detail...
ERBB2 positive stomach cancer predicted - sensitive ZW25 Phase I Actionable In a Phase I trial, ZW25 treatment resulted in stable disease in 20% (1/5) of patients with ERBB2 (HER2)-positive gastric or esophageal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #255P; NCT02892123). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Capecitabine + Trastuzumab Phase II Actionable In Phase II clinical trials, the combination of Xeloda (capecitabine) and Herceptin (trastuzumab) demonstrated efficacy with a manageable toxicity profile in heavily pretreated patients with ERBB2 (HER2)-positive advanced breast cancer and earlier Herceptin (trastuzumab) exposure (PMID: 17679724). 17679724
ERBB2 positive Her2-receptor positive breast cancer sensitive Pertuzumab + Trastuzumab + Docetaxel FDA approved Actionable In a Phase III trial (CLEOPATRA) that supported FDA approval, treatment with Perjeta (pertuzumab), combined with Herceptin (trastuzumab) and Taxotere (docetaxel), improved median progression free survival to 18.5 months compared to 12.4 months with placebo plus Herceptin (trastuzumab) and Taxotere (docetaxel) in patients with ERBB2 (HER2)-positive metastatic breast cancer (PMID: 23801166). 23801166
ERBB2 positive stomach cancer sensitive Trastuzumab + Oxaliplatin Preclinical Actionable In a preclinical study, the combination of Herceptin (trastuzumab) and Eloxatin (oxaliplatin) resulted in growth inhibition of ERBB2 (HER2)-positive gastric cancer cells in culture (PMID: 24300914). 24300914
ERBB2 positive gastric adenosquamous carcinoma no benefit trastuzumab emtansine Phase III Actionable In a Phase III trial, Kadcyla (trastuzumab emtansine) did not demonstrated efficacy benefit over Taxol (paclitaxel) on median overall survival (7.9 vs 8.6 months) in patients with previously treated ERBB2 (HER2)-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (J Clin Oncol 34, 2016 (suppl 4S; abstr 5)). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Sunitinib + Trastuzumab Phase II Actionable In a Phase II trial, Sutent (sunitinib), in combination with Herceptin (trastuzumab), demonstrated safety and efficacy in ERBB2 (HER2) positive advanced breast cancer patients (PMID: 24606768). 24606768
ERBB2 positive breast cancer sensitive XMT-1522 Preclinical - Pdx & cell culture Actionable In a preclinical study, XMT-1522 inhibited growth of Erbb2 (Her2)-positive breast cancer cells in culter, resulted in tumor regression in both cell line and patient-derived xenograft models (Cancer Res 2016;76(4 Suppl): Abstract nr P4-14-28). detail...
ERBB2 positive breast cancer sensitive DS-8201a Preclinical - Pdx & cell culture Actionable In a preclinical study, DS-8201 inhibited growth of ERBB2 (HER2)-positive breast cancer cell lines in culture and xenograft models, and demonstrated antitumor activity in patient-derived xenograft (PDX) models of ERBB2 (HER2)-positive breast cancer, including models with low ERBB2 (HER2) expression (PMID: 27026201). 27026201
ERBB2 positive sarcoma predicted - sensitive HER2 CAR-T cells Phase Ib/II Actionable In a Phase I/II trial, treatment with ERBB2 (HER2)-specific CAR-T cells resulted in stable disease for 12 weeks to 14 months in 4/17 evaluable patients with ERBB2 (HER2)-positive sarcomas and a median overall survival of 10.3 months (PMID: 25800760; NCT00902044). 25800760
ERBB2 positive ovarian cancer sensitive ARX-788 Preclinical - Cell line xenograft Actionable In a preclinical study, an ERBB2 (HER2)-positive ovarian cancer xenograft model was sensitive to treatment with ARX-788, resulting in tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Trastuzumab + Everolimus + Vinorelbine Phase III Actionable In a Phase III trial (BOLERO-3), the combination of Afinitor (everolimus), Herceptin (trastuzumab), and Navelbine (vinorelbine) increased progression-free survival in patients with Herceptin (trastuzumab)-resistant, ERBB2 (HER2)-positive, advanced breast cancer who had prior taxane treatment (PMID: 24742739; NCT01007942). 24742739
ERBB2 positive gastroesophageal junction adenocarcinoma no benefit Paclitaxel + Trastuzumab + MM-111 Phase II Actionable In a Phase II trial, Taxol (paclitaxel) and Herceptin (trastuzumab) treatment in combination with MM-111 did not improve progression free survival (9.6 weeks) and median overall survival (32.1 weeks) compared to without MM-111 (23.3 weeks, 56.1 weeks) in ERBB2 positive gastroesophageal junction cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 4043)). detail...
ERBB2 positive uterine corpus serous adenocarcinoma sensitive SYD985 Preclinical - Cell line xenograft Actionable In a preclinical study, SYD895 induced cell death in ERBB2 (HER2)-expressing primary uterine serous carcinoma (USC) cell lines in culture, including cell lines with both high and low levels of ERBB2 (HER2) expression, and inhibited tumor growth and improved survival in ERBB2 (HER2)-expressing USC primary cell line xenografts (PMID: 27256376). 27256376
ERBB2 positive stomach cancer sensitive DS-8201a Preclinical - Pdx & cell culture Actionable In a preclinical study, DS-8201 inhibited growth of a ERBB2 (HER2)-positive gastric carcinoma cell line in culture and in xenograft models, and induced tumor regression in a patient-derived xenograft (PDX) model of ERBB2 (HER2)-positive gastric cancer (PMID: 27026201). 27026201
ERBB2 positive Her2-receptor positive breast cancer sensitive Tucatinib Phase I Actionable In a Phase I trial, treatment with Tucatinib (ARRY-380) resulted in a response rate of 14% (3/22; all partial responses (PR)) and a clinical benefit rate (PR plus stable disease for greater than or equal to 24 weeks) of 27% (6/22) in Erbb2 (Her2)-positive breast cancer patients (PMID: 28053022). 28053022
ERBB2 positive transitional cell carcinoma no benefit lapuleucel-T Phase II Actionable In a Phase II trial, Neuvenge (lapuleucel-T) treatment did not result in statistically significant improvement of overall survival (37.0 vs 22.2 months, HR = 0.96) or disease recurrence-free survival (11.9 vs 10.1 months, HR = 0.99) compared to standard of care in ERBB2 (HER2) positive urothelial cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 4513)). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Cyclophosphamide + Doxorubicin + Paclitaxel + Pertuzumab + Trastuzumab Guideline Actionable Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab) and Perjeta (pertuzumab), is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer who are node positive (NCCN.org). detail...
ERBB2 positive ovarian cancer sensitive Hertuzumab-vc-MMAE Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with Hertuzumab-vc-MMAE decreased viability of ERBB2 (HER2)-positive ovarian cancer cell lines in culture and inhibited tumor growth in ERBB2 (HER2)-positive ovarian cancer cell line xenograft models (PMID: 27509865). 27509865
ERBB2 positive Her2-receptor positive breast cancer sensitive Pyrotinib Phase I Actionable In a Phase I trial, Pyrotinib treatment resulted in an objective response rate of 50% (18/36, all partial responses), and a clinical benefit rate of 61.1% (22/36), and a median progression-free survival of 35.4 weeks in patients with ERBB2 (HER2)-positive breast cancer (PMID: 28498781, NCT01937689). detail... 28498781
ERBB2 positive breast cancer sensitive ARX-788 Preclinical - Cell line xenograft Actionable In a preclinical study, an ERBB2 (HER2)-positive breast cancer xenograft model was sensitive to treatment with ARX-788, resulting in tumor regression (Cancer Res 2015;75(15 Suppl):Abstract nr 639). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Trodusquemine Preclinical - Cell line xenograft Actionable In a preclinical study, Trodusquemine (MSI-1436) inhibited tumor growth and metastasis in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model (PMID: 24845231). 24845231
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive Poziotinib Phase II Actionable In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in a median progression-free survival of 4.04 months, and a disease control rate of 75.49% (77/102; 20 partial responses) in heavily-treated Erbb2 (Her2)-positive breast cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 237O; NCT02418689). detail...
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive Tucatinib + Trastuzumab emtansine Phase Ib/II Actionable In a Phase Ib clinical trial, treatment with the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) resulted in partial response in 33% (11/33) and stable disease in 48% (16/33) and a clinical benefit rate of 58% (19/33) in patients with ERBB2 (HER2)-positive metastatic breast cancer (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-20). detail...
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive Tucatinib + Trastuzumab emtansine Phase Ib/II Actionable In a Phase Ib clinical trial, treatment with the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) resulted in an overall response rate of 47% (15/52) and median progression-free survival of 6.5 months in patients with ERBB2 (HER2)-positive metastatic breast cancer, including patients with CNS metastasis (J Clin Oncol 34, 2016 (suppl; abstr 513)). detail...
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive Tucatinib + Trastuzumab emtansine Phase Ib/II Actionable In a Phase Ib trial, the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) demonstrated clinical activity in CNS metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 12.5% (1/8) evaluable patients achieving CNS complete response, 25% (2/8) partial CNS response, and 62.5% (5/8) CNS stable disease (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive varlitinib Phase I Actionable In a Phase I expansion trial, 36% (5/14) of metastatic breast cancer patients positive for ERBB2 (HER2) demonstrated stable disease for up to 16 weeks when treated with Varlitinib (ARRY-334543) (Cancer Res May 1, 2009 69; 3603). detail...
ERBB2 positive colorectal cancer predicted - sensitive DS-8201a Phase I Actionable In a Phase I trial, treatment with DS-8201a resulted in an objective response rate of 25% (3/12) and disease control rate of 83.3% (10/12) in evaluable patients with Erbbe (Her2)-expressing colorectal cancer (Annals of Oncology (2018) 29 (suppl_8): viii150-viii204; NCT02564900). detail...
ERBB2 positive Her2-receptor positive breast cancer sensitive Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide Guideline Actionable Sequential therapy, Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide), followed by Taxol (paclitaxel) plus Herceptin (trastuzumab), is included in the guidelines as adjuvant therapy for patients with hormone receptor-negative (ER and PR), ERBB2 (HER2)-positive breast cancer (NCCN.org). detail...
PIK3CA mutant ERBB2 pos Her2-receptor positive breast cancer decreased response Trastuzumab + Lapatinib Phase II Actionable In a Phase II trial, ERBB2-positive breast cancer patients harboring PIK3CA mutations demonstrated lower pathologic complete remission rate (12.5%) compared to those with wild-type PIK3CA (48.4%) after Herceptin (trastuzumab) and Tykerb (lapatinib) combination therapy (PMID: 26245675). 26245675
PIK3CA mutant ERBB2 pos Her2-receptor positive breast cancer decreased response Trastuzumab + Lapatinib Clinical Study Actionable In a clinical study, a retrospective analysis of the combined treatment, Herceptin (trastuzumab) and Tykerb (lapatinib), in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302). 27687302
ERBB2 positive KRAS wild-type colorectal cancer sensitive Trastuzumab + Lapatinib Phase II Actionable In a Phase II clinical trial, 30% (8/27) of patients with ERBB2 (HER2)-positive KRAS wild-type colorectal cancer achieved an objective response and 44% (12/27) of patients had stable disease when treated with the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 27108243). 27108243
ERBB2 pos PIK3CA K111N Her2-receptor positive breast cancer sensitive trastuzumab emtansine Preclinical - Cell line xenograft Actionable In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887). 26920887
ERBB2 pos PTEN dec exp Her2-receptor positive breast cancer decreased response Trastuzumab Clinical Study Actionable In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563). 17936563
ERBB2 pos PIK3CA E545K Her2-receptor positive breast cancer sensitive trastuzumab emtansine Preclinical - Cell line xenograft Actionable In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA E545K in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887). 26920887
ERBB2 pos PIK3CA H1047R Her2-receptor positive breast cancer sensitive trastuzumab emtansine Preclinical - Cell line xenograft Actionable In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA H1047R in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887). 26920887
ERBB2 pos PIK3CA mut Her2-receptor positive breast cancer decreased response Trastuzumab Clinical Study Actionable In a clinical study, a retrospective analysis of Herceptin (trastuzumab) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302). 27687302
ERBB2 pos PIK3CA mut Her2-receptor positive breast cancer decreased response Lapatinib Clinical Study Actionable In a clinical study, a retrospective analysis of Tykerb (lapatinib) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302). 27687302
ERBB2 pos PIK3CA mut Her2-receptor positive breast cancer sensitive AT13148 Preclinical - Cell line xenograft Actionable In a preclinical study, AT13148 inhibited tumor growth in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model harboring mutant PIK3CA (PMID: 22781553). 22781553
ERBB2 pos PIK3CA mut Her2-receptor positive breast cancer decreased response Lapatinib + Capecitabine Phase III Actionable In a Phase III trial, Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment resulted in decreased median progression free survival (4.3 vs. 6.4 months), median overall survival (17.3 vs. 27.8 months), and overall response rate(17.1% vs. 39.7%) in ERBB2 (HER2) positive breast cancer patients harboring PIK3CA mutations compared to PIK3CA wild type patients (PMID: 26920887). 26920887
ERBB2 pos PIK3CA I391M Her2-receptor positive breast cancer sensitive trastuzumab emtansine Preclinical - Cell culture Actionable In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture (PMID: 26920887). 26920887
ERBB2 pos PIK3CA act mut uterine cancer sensitive Taselisib Preclinical Actionable In a preclinical study, Taselisib (GDC-0032) inhibited growth of HER2 positive uterine cancer cell lines with PIK3CA mutations (PMID: 25172762). 25172762
ERBB2 pos PIK3CA act mut Her2-receptor positive breast cancer decreased response Trastuzumab Clinical Study Actionable In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563). 17936563
ERBB2 pos PIK3CA act mut Her2-receptor positive breast cancer decreased response Trastuzumab Clinical Study Actionable In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation due to PTEN loss and/or PIK3CA activating mutation demonstrated a decreased median progression-free survival of 4.5 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217). 21676217
ERBB2 pos PIK3CA act mut Her2-receptor positive breast cancer sensitive Palbociclib + Pictilisib Preclinical Actionable In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit survival of ERBB2 (HER2)-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857). 27020857
ERBB2 pos PIK3CA act mut Her2-receptor positive breast cancer predicted - sensitive BKM120 + Trastuzumab Phase I Actionable In a Phase I trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on trastuzumab-based therapy (PMID: 24470511). 24470511
ERBB2 pos PTEN loss Her2-receptor positive breast cancer no benefit Palbociclib + Pictilisib Preclinical Actionable In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in ERBB2 (HER2)-positive breast cancer cell lines harboring PTEN loss in culture (PMID: 27020857). 27020857
ERBB2 pos PTEN loss Her2-receptor positive breast cancer decreased response Trastuzumab Phase I Actionable In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PTEN loss demonstrated a decreased median progression-free survival of 6.0 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217). 21676217
ERBB2 pos PTEN mut Her2-receptor positive breast cancer predicted - sensitive BKM120 + Trastuzumab Phase I Actionable In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on Herceptin (trastuzumab)-based therapy (PMID: 24470511). 24470511
EGFR pos ERBB2 pos breast cancer sensitive S-222611 Preclinical - Cell line xenograft Actionable In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human breast cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). 24837299
EGFR pos ERBB2 pos stomach cancer sensitive S-222611 Preclinical - Cell line xenograft Actionable In a preclinical study, S-222611 inhibited cell growth, decreased phosphorylation of Egfr and Erbb2, and resulted in anti-tumor activity of human gastric cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). 24837299
EGFR pos ERBB2 pos urinary bladder cancer predicted - sensitive Afatinib + Radiotherapy Preclinical - Cell line xenograft Actionable In a preclinical study, Gilotrif (afatinib) pre-treatment inhibited radiotherapy-induced activation of EGFR and ERBB2 (HER2) and downstream AKT and radiosensitized bladder cancer cell lines in culture, and Gilotrif (afatinib) in combination with radiotherapy led to improved tumor growth inhibition in bladder cancer cell line xenograft models compared to radiotherapy alone (PMID: 25589492). 25589492
EGFR pos ERBB2 pos colon cancer sensitive S-222611 Preclinical - Cell line xenograft Actionable In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human colon cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). 24837299
EGFR pos ERBB2 pos colorectal cancer sensitive Afatinib Preclinical Actionable In a preclinical study, colorectal cancer cells positive for EGFR and ERBB2 (HER2) had decreased growth upon Gilotrif (afatinib) treatment (PMID: 21617858). 21617858
EGFR pos ERBB2 pos lung cancer sensitive S-222611 Preclinical - Cell line xenograft Actionable In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human lung cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). 24837299
EGFR exon 19 del ERBB2 wild-type Advanced Solid Tumor sensitive Osimertinib Preclinical Actionable In a preclinical study, transgenic mouse models with ERBB2 (HER2)-wild-type cells expressing EGFR exon 19 deletion demonstrated tumor growth inhibition and an improved progression-free survival when treated with Tagrisso (osimertinib) compared to treatment with Tarceva (erlotinib) (PMID: 29298799). 29298799
ERBB2 wild-type Advanced Solid Tumor sensitive Lapatinib Preclinical Actionable In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing wild-type ERBB2 (HER2) in culture (PMID: 22046346). 22046346
ERBB2 wild-type Advanced Solid Tumor sensitive AEE788 Preclinical Actionable In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing wild-type ERBB2 (HER2) in culture (PMID: 22046346). 22046346
ERBB2 wild-type Advanced Solid Tumor sensitive Osimertinib Preclinical Actionable In a preclinical study, Tagrisso (osimertinib) treatment resulted in antitumor efficacy in cells overexpressing wild-type ERBB2 (HER2), demonstrating inhibition of ERBB2 (HER2) phosphorylation and cell growth in culture and tumor regression in mouse models overexpressing wild-type ERBB2, with an 80% reduction in tumor volume (PMID: 29298799). 29298799
ERBB2 over exp PIK3CA N345T stomach cancer predicted - resistant Trastuzumab Clinical Study Actionable In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA N345T (PMID: 29208673). 29208673
EGFR amp ERBB2 over exp stomach cancer predicted - resistant Trastuzumab Clinical Study Actionable In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified EGFR amplification in 2 patients demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673). 29208673
ERBB2 over exp MET amp MET R988C stomach cancer predicted - resistant Trastuzumab Clinical Study Actionable In a clinical study, assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) gastric or gastroesophageal cancer patients identified MET R988C and amplification of MET in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673). 29208673
EGFR T790M ERBB2 over exp lung adenocarcinoma resistant Osimertinib Preclinical Actionable In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Tagrisso (osimertinib) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416). 27252416
EGFR T790M ERBB2 over exp lung adenocarcinoma resistant CO1686 Preclinical Actionable In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Rociletinib (CO-1686) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416). 27252416
ERBB2 over exp PIK3CA H1047R Her2-receptor positive breast cancer sensitive BKM120 + Bevacizumab Preclinical Actionable In a preclinical study, treatment with Buparlisib (BKM120) resulted in decreased tumor growth, but not tumor regression, in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R (PMID: 23940356). 23940356
ERBB2 over exp PIK3CA H1047R Her2-receptor positive breast cancer sensitive BKM120 + Trastuzumab Preclinical Actionable In a preclinical study, the combination of Herceptin (trastuzumab) and Buparlisib (BKM120) inhibited tumor growth in mouse ERBB2 (HER2)-over expressing breast cancer models expressing PIK3CA H1047R, with moderate efficacy over Buparlisib (BKM120) alone (PMID: 23940356). 23940356
ERBB2 over exp PIK3CA H1047R Her2-receptor positive breast cancer sensitive BKM120 + Trastuzumab + Pertuzumab Preclinical Actionable In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Perjeta (pertuzumab) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, with improved efficacy over Buparlisib (BKM120) alone (PMID: 23940356). 23940356
ERBB2 over exp PIK3CA H1047R Her2-receptor positive breast cancer resistant Pertuzumab + Trastuzumab Preclinical Actionable In a preclinical study, a mouse breast cancer model with ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Heceptin (trastuzumab) and Perjeta (pertuzumab) (PMID: 23940356). 23940356
ERBB2 over exp PIK3CA H1047R Her2-receptor positive breast cancer no benefit BKM120 + Trastuzumab + Lapatinib Preclinical Actionable In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Tykerb (lapatinib) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, but efficacy was not significantly improved over Buparlisib (BKM120) alone (PMID: 23940356). 23940356
ERBB2 over exp PIK3CA H1047R stomach cancer predicted - resistant Trastuzumab Clinical Study Actionable In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047R (PMID: 29208673). 29208673
ERBB2 over exp PIK3CA H1047R Her2-receptor positive breast cancer resistant Trastuzumab Preclinical Actionable In a preclinical study, mouse breast cancer models over expressing ERBB2 (HER2) and expressing PIK3CA H1047R were resistant to Herceptin (trastuzumab) (PMID: 23940356). 23940356
ERBB2 over exp PIK3CA H1047R Her2-receptor positive breast cancer resistant Trastuzumab + Lapatinib Preclinical Actionable In a preclinical study, a mouse breast cancer model with mammary ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23940356). 23940356
ERBB2 over exp PIK3CA mut Her2-receptor positive breast cancer sensitive PKI-179 Preclinical - Cell line xenograft Actionable In a preclinical study, PKI-179 inhibited growth of breast cancer cells harboring PIK3CA mutations and ERBB2 (HER2) over expression in culture and cell line xenograft models (PMID: 20797855). 20797855
ERBB2 over exp PIK3CA mut breast cancer sensitive ARQ092 + Paclitaxel Preclinical - Cell line xenograft Actionable In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of ARQ092 and Taxol (paclitaxel), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692). 26469692
ERBB2 over exp PIK3CA mut breast cancer sensitive ARQ092 + Trastuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of ARQ092 and Herceptin (trastuzumab), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692). 26469692
ERBB2 over exp stomach cancer sensitive S-222611 Phase I Actionable In a Phase I trial, S-222611 resulted in a complete response in a gastric-esophageal junction cancer patient overexpressing ERBB2 (HER2) and a partial response in a gastric cancer patient also overexpressing ERBB2 (HER2) (J Clin Oncol 33, 2015 (suppl; abstr 2511)). detail...
ERBB2 over exp stomach cancer sensitive CDX-3379 Preclinical Actionable In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth by 43% in N87 gastric cancer xenograft model, which has been demonstrated to have ERBB2 (HER2) amplification and overexpression (AACR; 2015. Abstract nr 1558, PMID: 18441328). detail... 18441328
ERBB2 over exp Her2-receptor positive breast cancer sensitive TAK-285 Preclinical - Cell line xenograft Actionable In a preclinical study, TAK-285 inhibited growth of breast cancer cell line harboring ERBB2 (HER2) over expression in culture and in cell line xenograft models (PMID: 23983820). 23983820
ERBB2 over exp stomach cancer predicted - sensitive MM-302 Preclinical Actionable In a preclinical study, ERBB2 (HER2) over expressing gastric cancer xenograft models demonstrated anti-tumor activity when treated with MM-302 (Cancer Res December 15, 2010 70; P3-14-09). detail...
ERBB2 over exp stomach cancer sensitive Paclitaxel + Trastuzumab + MM-111 Preclinical - Cell line xenograft Actionable In a preclinical study, MM-111, in combination with Herceptin (trastuzumab) and Taxol (paclitaxel), resulted in a synergistic effect thereby inhibiting ErbB2 in ERBB2 (HER2) over expressing gastric cancer cell line xenograft models (J Clin Oncol 31, 2013 (suppl 4; abstr 48)). detail...
ERBB2 over exp stomach cancer sensitive Tucatinib Preclinical - Cell culture Actionable In a preclinical study, Tucatinib (ARRY-380) inhibited proliferation of an ERBB2 (HER2) over expressing gastric cancer cell line in culture (Cancer Res April 15, 2010 70:3610). detail...
ERBB2 over exp Her2-receptor positive breast cancer sensitive PF-05280014 Preclinical Actionable In a preclinical study, PF-05280014 inhibited growth of ERBB2 (HER2)-over expressing breast cancer cells with activity comparable to Herceptin (trastuzumab) in culture (PMID: 25001079). 25001079
ERBB2 over exp pancreatic carcinoma predicted - sensitive HER2 CAR-T cells Phase I Actionable In a Phase I trial, treatment with ERBB2 (HER2)-specific CAR-T cells demonstrated safety and preliminary activity in patients with biliary tract or pancreatic carcinoma with ERBB2 (HER2) over expression, resulting in partial response in one of 11 patients and stable disease in 5, and a median progression free survival of 4.8 months (PMID: 28710747; NCT01935843). 28710747
ERBB2 over exp stomach cancer sensitive Lapatinib Preclinical Actionable In a preclinical study, Tykerb (lapatinib) inhibited growth of HER2-amplified and HER2-over expressing gastric cancer cell lines in culture (PMID: 18774637). 18774637
ERBB2 over exp breast cancer sensitive AV-412 Preclinical - Cell line xenograft Actionable In a preclinical study, AV-412 inhibited growth of ERBB2 (HER2)-over expressing breast cancer cell lines in culture, and inhibited tumor growth in a ERBB2 (HER2)-over expressing breast cancer cell line xenograft model (PMID: 17888033). 17888033
ERBB2 over exp stomach cancer sensitive HER2 CAR-T cells Preclinical - Cell line xenograft Actionable In a preclinical study, ERBB2 (HER2)-specific CAR-T cells induced cell death in ERBB2 (HER2)-over expressing gastric cancer cell lines in culture, and inhibited tumor growth and improved survival in a ERBB2 (HER2)-over expressing gastric cancer cell line xenograft model (PMID: 28284008). 28284008
ERBB2 over exp gastric adenocarcinoma sensitive Trastuzumab Guideline Actionable Herceptin (trastuzumab), in combination with fluoropyrimidine and cisplatin, or other chemotherapy agents, but not anthracyclines, is included in guidelines as first-line therapy for Erbb2 (Her2)-overexpressing metastatic gastric adenocarcinoma patients (NCCN.org) detail...
ERBB2 over exp gastric adenocarcinoma sensitive VS-5584 Preclinical - Cell line xenograft Actionable In a preclinical study, VS-5584 inhibited tumor growth in human gastric cancer cell line xenograft models overexpressing ERBB2 (HER2) (PMID: 23270925). 23270925
ERBB2 over exp Her2-receptor positive breast cancer predicted - sensitive MGAH22 Phase Ib/II Actionable In Phase I clinical trial, Margetuximab (MGAH22) displayed safety and had initial efficacy in patients with ERBB2 (HER2) positive breast cancer (J Clin Oncol 31, 2013 (suppl; abstr 3004)). detail...
ERBB2 over exp colorectal cancer resistant Cetuximab Preclinical - Cell line xenograft Actionable In a preclinical study, ERBB2 (HER2) over expression was associated with resistance to Erbitux (cetuximab) treatment in a human cell line xenograft model of colorectal cancer (PMID: 26296355). 26296355
ERBB2 over exp carcinoma predicted - sensitive MGAH22 Phase I Actionable In a Phase I trial, Margetuximab (MGAH22) treatment resulted in partial responses in 12% (7/60) and stable disease in 50% (30/60) of patients with ERBB2 (HER2)-positive breast or gastric cancer, or other carcinomas that overexpress Erbb2 (Her2) (PMID: 28119295). 28119295
ERBB2 over exp stomach cancer sensitive trastuzumab emtansine Preclinical - Cell line xenograft Actionable In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification and over expression (PMID: 21458915). 21458915
ERBB2 over exp Her2-receptor positive breast cancer sensitive CUDC-101 Phase I Actionable In a Phase I clinical trial, a breast cancer patient with ERBB2 (HER2) over expression that had progressed on Herceptin (trastuzumab) demonstrated stable disease for more than 12 weeks following treatment with CUDC-101 (PMID: 25107918). 25107918
ERBB2 over exp stomach cancer sensitive trastuzumab + varlitinib Preclinical - Cell line xenograft Actionable In a preclinical study, Varlitinib (ARRY-334543), in combination with Herceptin (trastuzumab), resulted in a 91% tumor growth inhibition and tumor regression in human cell line xenograft models of gastric cancer overexpressing ERBB2 (HER2) (Cancer Res January 15, 2009 69; 2150). detail...
ERBB2 over exp Her2-receptor positive breast cancer sensitive NAX014 Preclinical Actionable In a preclinical study, NAX014 induced cellular senescence, prevented tumor growth, and decreased tumor volume in a Her2 positive breast cancer mouse model (PMID: 26168818). 26168818
ERBB2 over exp esophagus adenocarcinoma sensitive Trastuzumab Guideline Actionable Herceptin (trastuzumab), in combination with fluoropyrimidine and cisplatin, or other chemotherapy agents, but not anthracyclines, is included in guidelines for Erbb2 (Her2)-overexpressing metastatic esophageal adenocarcinoma patients (NCCN.org) detail...
ERBB2 over exp biliary tract cancer predicted - sensitive HER2 CAR-T cells Phase I Actionable In a Phase I trial, treatment with ERBB2 (HER2)-specific CAR-T cells demonstrated safety and preliminary activity in patients with biliary tract or pancreatic carcinoma with ERBB2 (HER2) over expression, resulting in partial response in one of 11 patients and stable disease in 5, and a median progression free survival of 4.8 months (PMID: 28710747; NCT01935843). 28710747
ERBB2 over exp stomach cancer sensitive varlitinib Preclinical - Cell line xenograft Actionable In a preclinical study, Varlitinib (ARRY-334543) resulted in a 74% tumor growth inhibition and tumor regression in 88% (7/8) of human cell line xenograft models of gastric cancer overexpressing ERBB2 (HER2) (Cancer Res January 15, 2009 69; 2150). detail...
ERBB2 over exp gastric adenocarcinoma predicted - sensitive Lapatinib + Oxaliplatin + Capecitabine Phase II Actionable In a Phase II trial, Tykerb (lapatinib), Xeloda (capecitabine), and Eloxatin (oxaliplatin) combination treatment resulted in a disease control rate of 81.3% (26/32, 7 complete response, 15 partial response, 4 stable disease) in patients with Erbb2 (Her2)-positive (defined as IHC3+ or IHC 2+ with ERBB2 amplification) gastric adenocarcinoma (PMID: 29409051; NCT02015169). 29409051
ERBB2 over exp stomach cancer sensitive Dacomitinib Preclinical Actionable In a preclinical study, ERBB2 (HER2) over expressing gastric cancer cells were sensitive to Vizimpro (dacomitinib), resulting in inhibition of ERBB2 (HER2)/ERBB3 (HER3) heterodimers (PMID: 22135232). 22135232
ERBB2 over exp stomach cancer sensitive Dacomitinib Phase II Actionable In a Phase II trial, Vizimpro (dacomitinib) resulted in a 7.4% (2/27) response rate and 40.7% (11/27) disease control rate when treating advanced gastric cancer patients with ERBB2 (HER2) over expression (J Clin Oncol 30, 2012 (suppl 4; abstr 54)). detail...
ERBB2 over exp stomach cancer sensitive MM-302 + Trastuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, combination of MM-302 and Herceptin (trastuzumab) resulted in improved tumor growth inhibition in cell line xenograft models of Erbb2 (Her2)-over expressing gastric cancer (PMID: 26759238). 26759238
ERBB2 over exp stomach cancer sensitive TAK-285 Preclinical - Cell line xenograft Actionable In a preclinical study, TAK-285 inhibited tumor growth in gastric cancer cell line xenograft models over expressing ERBB2 (HER2) (PMID: 23983820). 23983820
ERBB2 over exp stomach cancer sensitive TAK-285 Preclinical Actionable In a preclinical study, the N87 gastric cancer cell line, which has been demonstrated to have ERBB2 (HER2) amplification and over expression, was sensitive to TAK-285, inhibiting phosphorylation of ERBB2 (HER2) and ERBB3 (HER3) (PMID: 25594012, PMID: 18441328). 18441328 25594012
ERBB2 over exp stomach cancer sensitive BMS-690514 Preclinical Actionable In a preclinical study, BMS-690514 inhibited tumor growth in a gastric cancer xenograft model with ERBB2 (HER2) amplification and overexpression (PMID: 21531814). 21531814
ERBB2 over exp breast cancer sensitive KU004 Preclinical Actionable In a preclinical study, KU004 inhibited growth and induced apoptosis in breast cancer cell lines over expressing ERBB2 in culture (PMID: 26437915). 26437915
ERBB2 over exp gastroesophageal junction adenocarcinoma sensitive S-222611 Phase I Actionable In a Phase I trial, S-222611 resulted in a complete response in a gastric-esophageal junction cancer patient over expressing ERBB2 (HER2) and a partial response in a gastric cancer patient also over expressing ERBB2 (HER2) (J Clin Oncol 33, 2015 (suppl; abstr 2511)). detail...
ERBB2 over exp breast cancer sensitive MM-302 + Trastuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, combination of MM-302 and Herceptin (trastuzumab) synergistically inhibited tumor growth in cell line xenograft models of Erbb2 (Her2)-over expressing breast cancer (PMID: 26759238). 26759238
ERBB2 over exp gastroesophageal junction adenocarcinoma sensitive Trastuzumab Guideline Actionable Herceptin (trastuzumab), in combination with fluoropyrimidine and cisplatin, or other chemotherapy agents, but not anthracyclines, is included in guidelines for Erbb2 (Her2)-overexpressing metastatic esophagogastric junction adenocarcinoma patients (NCCN.org) detail...
ERBB2 over exp stomach cancer sensitive KU004 Preclinical Actionable In a preclinical study, KU004 inhibited growth and induced apoptosis in gastric cancer cell lines over expressing ERBB2 in culture and suppressed growth in a dose dependent manner in xenograft models (PMID: 26437915). 26437915
ERBB2 over exp Her2-receptor positive breast cancer sensitive ADXS31-164 Preclinical Actionable In a preclinical study, ADXS31-164 prevented development of spontaneous mammary tumors in Erbb2 (Her2)-over expressing transgenic animal models (PMID: 20725099). 20725099
ERBB2 over exp cholangiocarcinoma predicted - sensitive HER2 CAR-T cells Phase I Actionable In a Phase I trial, a patient with perihilar cholangiocarcinoma over expressing ERBB2 achieved a partial response and progression-free survival for 4.5 months following treatment with ERBB2 (HER2)-specific CAR-T cells (PMID: 28710747, NCT01935843). 28710747
ERBB2 over exp Her2-receptor positive breast cancer sensitive trastuzumab emtansine FDA approved Actionable In a Phase III trial (EMILIA) that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) improved median progression free survival (9.6 mo vs 6.4 mo) and overall survival (30.9 mo vs 25.1 mo) compared to Tykerb (lapatinib) combined with Xeloda (capecitabine) in patients with metastatic ERBB2 (HER2)-positive breast cancer (PMID: 24879797, PMID: 23020162; NCT00829166). 24879797 23020162
ERBB2 over exp Her2-receptor positive breast cancer sensitive Lapatinib Preclinical - Cell culture Actionable In a preclinical study, Tykerb (lapatinib) inhibited growth of HER2-over expressing breast carcinoma cell lines in culture (PMID: 27450453). 27450453
ERBB2 over exp KRAS G13D stomach cancer predicted - resistant Trastuzumab Clinical Study Actionable In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified KRAS G13D in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673). 29208673
ERBB2 over exp MET amp stomach cancer predicted - resistant Trastuzumab Clinical Study Actionable In a clinical study (AMNESIA-1), assessment of pre-treatment tissue from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified MET amplification in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673). 29208673
BRAF V600E ERBB2 over exp KRAS A146V stomach cancer predicted - resistant Trastuzumab Clinical Study Actionable In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified KRAS A146V and BRAF V600E in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673). 29208673
ERBB2 over exp PIK3CA H1047L stomach cancer predicted - resistant Trastuzumab Clinical Study Actionable In a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified PIK3CA mutations in 15% (3/20) of patients demonstrating primary resistance to Herceptin (trastuzumab), including 1 patient harboring PIK3CA H1047L (PMID: 29208673). 29208673
ERBB2 over exp PIK3CA H1047R SRC over exp urinary bladder cancer no benefit Lapatinib Preclinical - Pdx Actionable In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481). 26270481
ERBB2 over exp PIK3CA H1047R SRC over exp urinary bladder cancer no benefit Ponatinib Preclinical - Pdx Actionable In a preclinical study, treatment with Iclusig (ponatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft (PDX) model of bladder cancer with SRC over expression, which also over expressed ERBB2 (HER2) and harbored PIK3CA H1047R (PMID: 26270481). 26270481
ERBB2 G776delinsVC Advanced Solid Tumor sensitive Poziotinib Preclinical - Cell culture Actionable In a preclinical study, Poziotinib (HM781-36B) inhibited growth of a transformed cell line expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 29686424). 29686424
ERBB2 G776delinsVC non-small cell lung carcinoma no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 8.5 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) G776delinsVC (PMID: 29420467; NCT01953926). 29420467
ERBB2 G776delinsVC non-small cell lung carcinoma sensitive Afatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Gilotrif (afatinib) inhibited proliferation and induced cell-cycle arrest and apoptosis of a non-small cell lung cancer (NSCLC) cell line harboring ERBB2 (HER2) G776delinsVC in culture and inhibited tumor growth in NSCLC cell line xenografts carrying ERBB2 (HER2) G776delinsVC (PMID: 26545934). 26545934
ERBB2 G776delinsVC lung cancer no benefit Gefitinib Preclinical Actionable In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934). 26545934
ERBB2 G776delinsVC lung cancer sensitive Afatinib Preclinical Actionable In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 26545934). 26545934
ERBB2 G776delinsVC non-small cell lung carcinoma resistant Gefitinib Preclinical Actionable In a preclinical study, non-small cell lung cancer cells harboring ERBB2 (HER2) G776delinsVC demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 26545934). 26545934
ERBB2 D769Y breast cancer sensitive Neratinib Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) D769Y reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880). 23220880
ERBB2 D769Y breast cancer sensitive Trastuzumab Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880). 23220880
ERBB2 D769Y urinary bladder cancer predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.4 months in a patient with bladder cancer harboring both ERBB2 (HER2) D769Y (PMID: 29420467; NCT01953926). 29420467
ERBB2 D769Y breast cancer sensitive Lapatinib Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Tykerb (lapatinib) treatment (PMID: 23220880). 23220880
ERBB2 D769Y gastroesophageal junction adenocarcinoma predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with gastroesophageal cancer harboring ERBB2 (HER2) D769Y (PMID: 29420467; NCT01953926). 29420467
ERBB2 G778_S779insCPG Advanced Solid Tumor sensitive Dacomitinib Preclinical - Cell culture Actionable In a preclinical study, Vizimpro (dacomitinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G778_S779insCPG in culture (PMID: 28363995). 28363995
ERBB2 L915M Advanced Solid Tumor sensitive XL647 Preclinical - Cell culture Actionable In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L915M in culture (PMID: 18413839). 18413839
ERBB2 L866M colorectal cancer sensitive Neratinib Preclinical Actionable In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863). 26243863
ERBB2 L866M colorectal cancer resistant Cetuximab Preclinical Actionable In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L866M were resistant to Erbitux (cetuximab) in culture (PMID: 26243863). 26243863
ERBB2 L866M colon cancer sensitive Neratinib Preclinical Actionable In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863). 26243863
ERBB2 L866M colon cancer sensitive Trastuzumab Preclinical Actionable In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863). 26243863
ERBB2 L866M colorectal cancer sensitive Afatinib Preclinical Actionable In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863). 26243863
ERBB2 L866M colorectal cancer resistant Panitumumab Preclinical Actionable In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L866M were resistant to Vectibix (panitumumab) in culture (PMID: 26243863). 26243863
ERBB2 E719G Advanced Solid Tumor decreased response Lapatinib Preclinical Actionable In a preclinical study, transformed cells over expressing ERBB2 (HER2) E719G demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839). 18413839
ERBB2 E719G Advanced Solid Tumor sensitive XL647 Preclinical Actionable In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E719G in culture (PMID: 18413839). 18413839
ERBB2 L785F Advanced Solid Tumor sensitive XL647 Preclinical Actionable In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L785F in culture (PMID: 18413839). 18413839
ERBB2 L785F Advanced Solid Tumor decreased response Lapatinib Preclinical Actionable In a preclinical study, transformed cells over expressing ERBB2 (HER2) L785F demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839). 18413839
ERBB2 D769H breast cancer sensitive Lapatinib Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 D769H demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880). 23220880
ERBB2 D769H Her2-receptor negative breast cancer no benefit Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 3.5 months in a patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) D769H (PMID: 29420467; NCT01953926). 29420467
ERBB2 D769H breast cancer sensitive Trastuzumab Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 D769H reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880). 23220880
ERBB2 D769H colorectal cancer predicted - resistant Neratinib Phase II Actionable In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.9 months in a patient with colorectal cancer harboring ERBB2 (HER2) D769H (PMID: 29420467; NCT01953926). 29420467
ERBB2 D769H breast cancer sensitive Neratinib Preclinical Actionable In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) D769H demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880). 23220880
ERBB2 act mut Advanced Solid Tumor sensitive AEE788 Preclinical Actionable In a preclinical study, transformed cells expressing ERBB2 (HER2) activation loop mutations demonstrated sensitivity to AEE788 in culture (PMID: 22046346). 22046346
ERBB2 act mut breast cancer sensitive Neratinib Phase II Actionable In a Phase II clinical trial, Nerlynx (neratinib) treatment resulted in clinical benefit in 36% (5/14) of metastatic breast cancer patients harboring ERBB2 (HER2) activating mutations, with 1 complete response, 1 partial response, and 2 patients achieving stable disease for greater than 6 months, and a median progression-free survival of 5 months (J Clin Oncol 34, 2016 (suppl; abstr 516)). detail...
ERBB2 act mut estrogen-receptor positive breast cancer predicted - sensitive Vistusertib Phase I Actionable In a Phase I trial, Vistusertib (AZD2014) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a patient with ER-positive breast cancer harboring an ERBB2 activating mutation (PMID: 25805799). 25805799
PIK3CA act mut ERBB2 act mut breast cancer sensitive VS-5584 Preclinical Actionable In a preclinical study, breast cancer cells with mutations in both ERBB2 (HER2) and PIK3CA were more sensitive to VS-5584 (PMID: 23270925). 23270925
ERBB2 act mut STK11 loss breast cancer sensitive AZD8055 Preclinical Actionable In a preclinical study, AZD8055 inhibited tumor growth in a mouse model of spontaneous breast cancer harboring an ERBB2 (HER2) activating mutation and loss of STK11 (LKB1), which was enhanced by the addition of 2-DG (2-deoxyglucose) (PMID: 25436981). 25436981
ERBB2 T798I Advanced Solid Tumor resistant Lapatinib Preclinical Actionable In a preclinical study, transformed cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247). 25238247
ERBB2 T798I lung cancer resistant Lapatinib Preclinical Actionable In a preclinical study, transformed lung cancer cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247). 25238247
ERBB2 T798I Advanced Solid Tumor sensitive XL647 Preclinical Actionable In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) T798I in culture (PMID: 18413839). 18413839
ERBB2 E812K Advanced Solid Tumor decreased response Lapatinib Preclinical Actionable In a preclinical study, transformed cells over expressing ERBB2 (HER2) E812K demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839). 18413839
ERBB2 E812K Advanced Solid Tumor sensitive XL647 Preclinical Actionable In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E812K in culture (PMID: 18413839). 18413839
ERBB2 H878Y Advanced Solid Tumor sensitive AEE788 Preclinical Actionable In a preclinical study, transformed cell lines expressing ERBB2 (HER2) H878Y demonstrated growth inhibition when treated with AEE788 in culture (PMID: 22046346). 22046346
ERBB2 H878Y Advanced Solid Tumor sensitive Lapatinib Preclinical Actionable In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) H878Y in culture (PMID: 22046346). 22046346
ERBB2 T798M Advanced Solid Tumor resistant Lapatinib Preclinical Actionable In a preclinical study, transformed cell lines expressing ERBB2 (HER2) T798M demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346). 22046346
ERBB2 T798M breast cancer sensitive Trastuzumab + XL147 Preclinical Actionable In a preclinical study, breast cancer cells expressing ERBB2 (HER2) T798M were sensitive to the combination of Herceptin (trastuzumab) and XL147 (PMID: 23948973). 23948973
ERBB2 T798M Advanced Solid Tumor sensitive EKI-285 Preclinical Actionable In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T798M in culture (PMID: 22046346). 22046346
ERBB2 T798M breast cancer sensitive Cetuximab + Lapatinib Preclinical - Cell line xenograft Actionable In preclinical studies, the combination of Erbitux (cetuximab) and Tykerb (lapatinib) inhibited cell growth of a human breast cancer cell line harboring ERBB2 T798M and synergized to inhibit tumor growth in xenograft models (PMID: 23948973). 23948973
ERBB2 T798M breast cancer resistant CI-1040 Preclinical Actionable In a preclinical study, breast cancer cells expressing ERBB2 T798M demonstrated resistance to CI-1040 (PMID: 23948973). 23948973
ERBB2 T798M Her2-receptor positive breast cancer resistant Lapatinib Preclinical Actionable In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cells expressing ERBB2 (HER2) T798M were resistant to Tykerb (lapatinib) in both culture and xenograft models (PMID: 23948973). 23948973
ERBB2 T798M breast cancer sensitive XL147 Preclinical Actionable In a preclinical study, breast cancer cell lines expressing ERBB2 (HER2) T798M demonstrated sensitivity to XL147 (SAR245408) in cell culture (PMID: 23948973). 23948973
ERBB2 T798M Advanced Solid Tumor resistant AEE788 Preclinical Actionable In a preclinical study, transformed cell lines expressing ERBB2 (HER2) T798M demonstrated resistance when treated with AEE788 in culture (PMID: 22046346). 22046346
ERBB2 T798M breast cancer sensitive Trastuzumab + Lapatinib Preclinical - Cell line xenograft Actionable In a preclinical study, human breast cancer cell lines and cell line xenografts expressing ERBB2 T798M demonstrated sensitivity to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23948973). 23948973
ERBB2 T798M breast cancer sensitive Afatinib Preclinical Actionable In a preclinical study, breast cancer cells expressing ERBB2(HER2) T798M were sensitive to Gilotrif (afatinib) (PMID: 23948973). 23948973
ERBB2 T798M breast cancer resistant Cetuximab Preclinical Actionable In a preclinical study, breast cancer cells expressing the ERBB2 (HER2) T798M mutant were resistant to Erbitux (cetuximab)(PMID: 23948973). 23948973
ERBB2 T798M breast cancer sensitive Buparlisib Preclinical Actionable In a preclinical study, human breast cancer cells expressing the ERBB2 (HER2) T798M mutation demonstrated sensitivity to BKM120 (PMID: 23948973). 23948973
ERBB2 T798M Advanced Solid Tumor sensitive WZ4002 Preclinical Actionable In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T798M in culture (PMID: 22046346). 22046346
ERBB2 G309A breast cancer